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Summary 
Hepatitis C virus (HCV) has a positive-strand RNA genome and is grouped into the family of 
Flaviviridae. Similar to other positive-stranded RNA viruses, HCV RNA replication takes 
place in the cytoplasm. The sites of viral replication are designated “membranous web” and 
represented by an accumulation of vesicular structures, which are induced by the viral non-
structural proteins and probably originate from membranes of the Endoplasmic Reticulum. 
The aim of this work was to purify and characterize these viral replication complexes (RCs) in 
vitro and to identify potential host factors of viral replication.  
First a purification strategy for enzymatically active viral replication complexes was 
developed to determine associated cellular proteins by proteomics. Thereby, several 
potential host factors of viral replication were identified and the most reproducible, Annexin II 
(ANXA2) was further characterized.  
In immunofluorescence analyses, ANXA2 strongly colocalized to the sites of viral replication 
in all applicable cell lines supporting HCV replication, in HCV-transfected as well as in 
infected cells. In contrast, we found no obvious colocalization of HCV proteins with Annexin I, 
IV or V or with p11 (also denoted S100A10), a common cellular ligand of Annexin II. 
Specificity of the ANXA2-HCV interaction was further indicated by the lack of colocalization 
with replication sites of other positive-strand RNA viruses, namely Dengue virus and Semliki-
Forest-Virus. By individual expression of the viral non-structural (NS) proteins we found that 
NS5A colocalized with Annexin II, indicating that NS5A might be involved in the recruitment 
of ANXA2. SiRNA-mediated silencing clearly reduced Annexin II levels but failed to block 
HCV replication. However, FACS analyses revealed a strong correlation of intracellular HCV 
and ANXA2 levels even in presence of ANXA2 siRNA, suggesting that Annexin II expression 
was induced by HCV, thereby counteracting siRNA-mediated knockdown. Still, ANXA2 
silencing moderately reduced the number of HCV positive cells. Interestingly, the presence of 
replicating HCV sequences in HepG2 cells, harboring very little endogenous ANXA2, clearly 
induced Annexin II expression to detectable levels perfectly colocalizing with the viral NS 
proteins. However, the role and function of ANXA2 in the HCV life cycle has yet to be 
defined. 
In a second line of investigations, a detailed stoichiometric analysis of HCV RCs was 
performed. Thus, the ratio of non-structural proteins to RNA that is required for HCV RNA 
replication could be determined. Almost the entire negative- and positive-strand RNA but 
<5% of the non-structural proteins present in HCV-harboring cells were protected against 
nuclease and protease treatments. Nevertheless, this protease-resistant portion of NS 
proteins accounted for the full in vitro replicase activity. Therefore, only a minor fraction of the 
HCV non-structural proteins was actively involved in RNA synthesis. However, due to the 
high amounts present in replicon cells, this still represented a huge excess compared to the 
viral RNA. Based on the comparison of nuclease-resistant viral RNA to protease-resistant 
viral proteins, an active HCV replication complex probably consists of one negative-strand 
RNA, two to ten positive-strand RNAs, and several hundred non-structural protein copies. 
These might be required as structural components of the vesicular compartments that are 
the site of HCV replication. 
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Zusammenfassung 
Das Hepatitis C Virus (HCV) besitzt ein Plusstrang-RNA-Genom und gehört zur Familie der 
Flaviviridae. Die HCV RNA-Replikation findet, ähnlich wie bei anderen Plusstrang-RNA-Viren, im 
Zytoplasma statt. Die Stätten der viralen Replikation werden als „membranous web“ bezeichnet und 
repräsentieren eine Anhäufung vesikulärer Strukturen, die durch die viralen Nichtstruktur-Proteine 
induziert werden und wahrscheinlich den Membranen des Endoplasmatischen Retikulums 
entstammen. Das Ziel dieser Arbeit war sowohl die Reinigung und Charakterisierung dieser viralen 
Replikations-Komplexe (RC) in vitro als auch die Identifikation möglicher Wirtsfaktoren der viralen 
Replikation. 
Als Erstes wurde eine Reinigungsstrategie für enzymatisch aktive virale Replikations-Komplexe 
entwickelt, um assoziierte zelluläre Proteine durch Proteom-Analysen zu ermitteln. Einige potentielle 
Wirtsfaktoren der viralen Replikation konnten dadurch identifiziert werden, und der am häufigsten 
reproduzierbare, Annexin II (ANXA2), wurde eingehend charakterisiert. Immunfluoreszenz-Studien 
zeigten, dass in allen geeigneten, HCV-Replikation unterstützenden Zelllinien, in HCV-transfizierten 
sowie infizierten Zellen, ANXA2 deutlich mit den Stätten der viralen Replikation kolokalisiert. Im 
Gegensatz dazu fanden wir weder eine ersichtliche Kolokalisation von HCV-Proteinen mit Annexin I, 
IV, oder V, noch mit p11 (auch S100A10 genannt), einem häufigen zellulären Liganden von  
Annexin II. Die Spezifität der ANXA2-HCV Interaktion wurde noch betont durch die fehlende 
Kolokalisation mit Replikations-Stätten anderer Positiv-Strang-RNA-Viren wie Dengue Virus und 
Semliki-Forest-Virus. Durch die individuelle Expression viraler Nicht-Struktur- (NS-) Proteine fanden 
wir heraus, dass NS5A mit Annexin II kolokalisiert, was darauf hinweist, dass NS5A möglicherweise in 
die Rekrutierung von ANXA2 involviert ist. SiRNA-vermitteltes silencing reduzierte die Annexin II-
Menge deutlich, führte jedoch nicht zur Hemmung der HCV Replikation. FACS-Analysen zeigten 
hingegen eine starke Korrelation von intrazellulären HCV- und ANXA2-Mengen, auch in Anwesenheit 
von ANXA2-siRNA. Daher ist anzunehmen, dass NS5A die ANXA2-Expression induziert, wodurch 
dem siRNA-vermittelten knockdown entgegengewirkt wird. Dennoch reduzierte ANXA2-Silencing 
moderat die Anzahl HCV-positiver Zellen. Interessanterweise verursachte die Anwesenheit 
replizierender HCV-Sequenzen in HepG2-Zellen, die äußerst wenig endogenes ANXA2 besitzen, eine 
ANXA2-Expression von deutlich nachweisbaren Mengen, welche mit den viralen NS-Proteinen perfekt 
kolokalisierten. Die Rolle und die Funktion von ANXA2 im HCV-Lebenszyklus müssen allerdings noch 
definiert werden. 
Als Zweites wurde eine detaillierte stöchiometrische Analyse der HCV-Replikations-Komplexe 
durchgeführt. Auf diese Weise konnte das für die HCV-RNA-Replikation erforderliche Verhältnis von 
NS-Proteinen zu RNA ermittelt werden. Fast die gesamte Negativ- und Positiv-Strang-RNA, jedoch 
<5% aller Nicht-Struktur-Proteine, die in HCV-replizierenden Zellen vorhanden sind, waren gegen 
Nuklease- und Protease-Behandlungen geschützt. Dennoch war dieser Protease-resistente Anteil der 
NS-Proteine für die gesamte in vitro Replikase-Aktivität verantwortlich. Folglich war nur eine kleinere 
Fraktion der HCV Nicht-Struktur-Proteine aktiv an der RNA-Synthese beteiligt. Allerdings machte dies 
aufgrund der in Replikon-Zellen vorhandenen großen Mengen verglichen mit viraler RNA immer noch 
einen enormen Überschuss aus. Basierend auf dem Vergleich Nuklease-resistenter viraler RNA zu 
Protease-resistenten viralen Proteinen enthält ein aktiver HCV Replikations-Komplex wahrscheinlich 
eine Negativ-Strang-RNA, zwei bis zehn Positiv-Strang-RNA-Moleküle und einige hundert Kopien der 
Nicht-Struktur-Proteine. Diese werden möglicherweise als strukturelle Komponenten der vesikulären 
Kompartimente benötigt, welche die Stätten der HCV Replikation repräsentieren. 
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1. Introduction 
1.1 Hepatitis C virus overview 
The Hepatitis C Virus (HCV) is a major cause of chronic liver disease, including 
cirrhosis and liver cancer. Before the identification of the causative agent in 1989, the 
viral Hepatitis C infection had been referred to as parenterally transmitted “non A, 
non B hepatitis”41,59. Today, almost 20 years after the identification of the virus, the 
World Health Organization (WHO) estimates that about 180 million persons, 3% of 
the world's population, are chronically infected with HCV and 3 to 4 million persons 
are newly infected each year. The global prevalence of HCV is shown in Fig. 1. The 
discovery and the characterization of HCV led to the understanding of its primary role 
in causing hepatitis after blood transfusion and its tendency to induce persistent 
infection.  
 
 
Fig. 1: Prevalence of HCV infection throughout the world. 
 
HCV is transmitted by parenteral or permuscosal exposure to infected blood or body 
fluids165. Transmission through organ transplantations and blood transfusions not 
screened for HCV infection, through the reuse of inadequately sterilized needles, 
syringes or other medical equipment, or through needle-sharing among drug-users, 
is well documented233. Sexual and perinatal transmission may also occur, although 
less frequently. 
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1.2 Course of disease and therapy 
Primary infection with HCV is predominantly asymptomatic, and in the majority of 
cases leads to persistent infection64. Individuals with chronic infection develop 
progressive hepatic fibrosis leading to an increased risk of cirrhosis, liver failure and 
hepatocellular carcinoma (HCC) with proceeding endurance of infection191. 15-30% 
of infected individuals succeed in eliminating the virus but in most cases (70-85%) 
persistent viremia and chronic hepatitis develop165. Hepatocellular carcinoma evolves 
in 1-4% of the cases per year. The stages of the progression after HCV infection are 
shown in Fig. 2. High virus titers are observed during the first few weeks of HCV 
infection, but inflammatory processes leading to liver injury are delayed, usually 
occurring after 2–3 months93. Chronically infected patients have viral loads that 
typically range from 103–107 genomes per ml of serum135. Mathematical modeling of 
viral dynamics during treatment with interferon-α (IFN-α) indicates that HCV virions 
turn over rapidly (with a half-life of about 3 h), and up to about 1012 viruses are 
produced per day in an infected person161. This is about 100-fold greater than the 
rate reported for HIV. 
 
 
Fig. 2: Progression steps of HCV infection. Hepatitis C virus persists in most patients with acute 
hepatitis C virus infection, and some develop progressive hepatic injury and subsequent complications 
of end stage liver disease. Adapted from Patel et. al., BMJ, 2006165. 
 
Although the liver seems to be the major site of HCV replication, evidence exists for 
extrahepatic reservoirs including peripheral blood lymphocytes, epithelial cells in the 
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gut44 and the central nervous system62. In infected tissues, HCV is proven by 
detection of either HCV-specific antibodies by ELISA or the viral genome by RT-
PCR. Direct detection of virus antigens is difficult due to their low levels in infected 
cells in vivo. Nevertheless, gene-profiling studies of HCV-infected livers indicate that 
this organ is the major region of viral replication and host antiviral defenses22,23,203,209. 
The current standard of care for treating previously untreated patients with chronic 
HCV infection is combination of polyethylene glycol (PEG-) conjugated IFN-α and 
ribavirin165. The interferons are a group of naturally occurring cytokines that exhibit a 
variety of immunomodulatory, antiproliferative, and antiviral effects. Ribavirin is a 
purine nucleoside that has antiviral effects against hepatitis C virus only when 
combined with IFN-α. Combinated PEG-IFN-α and ribavirin therapy can achieve a 
sustained virological response in 54%-56% of patients, including 42%-46% of 
patients with genotype 1 infection and about 80% of those with genotype 2 or 3 
infection. Therefore, the development of new antiviral strategies against HCV is 
imperative. The development of efficient cell culture systems for HCV140,219 has led to 
the identification of several novel therapeutic targets and the subsequent 
development of hepatitis C virus specific antiviral compounds.  
 
1.3 Molecular organization of HCV 
1.3.1 Genetic diversity 
HCV is an enveloped positive-strand RNA virus belonging to the genus Hepacivirus 
in the family Flaviviridae. Based on sequence analyses, HCV genomes can be 
classified into six major genetic groups. On average, these genotypes differ in 30-
33% of their nucleotide sites198. Each HCV genotype comprises a series of more 
closely related subtypes which show a nucleotide sequence heterogeneity of circa 
20-25% and are designated with subtype labels such as 1a and 1b. Furthermore, 
since the RNA synthesis is error-prone, HCV exists as a mixture of variants, the so-
called “quasispecies”, within an infected individual. 
 The most common variants found in Western countries are genotype 1 and 
genotype 2. During the past 50 to 70 years, these variants have become widely 
distributed as a result of transmission through blood transfusion and various other 
medical procedures, and by needle sharing between injection drug users. They now 
represent the vast majority of infections in Western countries, for which the most 
INTRODUCTION 
 
4
information has been collected on disease progression and response to IFN-α-based 
treatment. Nevertheless, the widespread distribution of genotypes 1-6 in human 
populations indicates that each is equally successful in maintaining infections197. 
 
1.3.2 Genome organization and function of viral proteins 
The Hepatitis C virus particle is about 50-60 nm in diameter. HCV possesses an RNA 
genome of positive polarity that is approximately 9.6 kb in length. The genome 
encodes a large polyprotein of roughly 3000 amino acids (aa) that is flanked at the N-
and C-terminus by highly structured nontranslated regions (NTRs) (Fig. 3). The 5’-
NTR is about 341 nucleotides (nts) in length and contains an internal ribosome entry 
site (IRES) mediating the cap-independent expression of the polyprotein213,223. This 
process is additionally regulated by an RNA pseudoknot structure upstream of the 
initiation codon AUG critical for translation initiation222. It has been shown that the 
first 125 nucleotides are essential for RNA replication, but that the entire 5’-NTR is 
required for maximal replication efficiency69,112. It is generally believed that the 
function of the 5’-NTR in RNA replication, namely initiation of positive-strand 
synthesis, is exerted by the complementary sequence, corresponding to the 3’-end of 
the negative-strand, which adopts a secondary structure that is different from the 
mirror image of the 5’-NTR189,199. The 3’-NTR of the positive-strand RNA has a 
tripartite structure: (i) a variable region, that is in part dispensable for replication in 
vivo 232 and in vitro but seems to be important for efficient RNA replication67,234; (ii) a 
polyU/UC tract of variable length, which is essential in vivo and in vitro and which 
requires a minimal length of 26 to 50 nucleotides67,234; (iii) the very 3’-end of the HCV 
genome designated X-tail. It comprises an almost invariant 98 nucleotides 
sequence115,206 containing 3 highly conserved stem-loop structures (SL I-III)28, which 
are all critical for RNA replication in vitro and in vivo67,232,234. Further important cis-
acting RNA elements are located in the coding region of NS5B237, one of which 
undergoes a kissing loop interaction with SL II in the X-region being essential for 
RNA replication68. In addition, both NTRs contain genotype-specific signals that are 
critical for efficient initiation of RNA synthesis24. 
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Fig. 3. Genomic organization of HCV and processing pathways of the polyprotein. A schematic 
representation of the HCV genome with the 5’- and 3’-NTRs is shown in the top, the translation 
products are given below. Proteinases involved in the processing of the polyprotein are indicated by 
arrows that are specified at the bottom of the picture. The major cleavage pathways leading to distinct 
processing intermediates, most notably E2-p7-NS2 and NS4B-5A, are indicated. The 
hyperphosphorylation of NS5A probably occurs after full proteolytic cleavage. Glycosylation of E1 and 
E2 is indicated by branched lines. The F protein generated by ribosomal frameshifting is depicted 
above the polyprotein. Adapted from Bartenschlager et. al., Adv. Virus Res., 2004.15. 
 
The polyprotein is co- and posttranslationally processed by cellular and viral 
proteinases into at least ten different polypeptides: the structural proteins core, E1, 
and E2, forming the virus particle, the p7 protein functioning as an ion channel78,167, 
as well as the non-structural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B which are involved in HCV RNA replication. Besides, the expression of a novel 
HCV protein has been reported31,220,230. Translation of this additional viral gene 
product begins at the same AUG start codon as core, but then ribosomes shift into an 
alternative reading frame. The resulting protein has a molecular weight of 17 kDa and 
is called the frameshift (F) or alternative reading frame (ARF) protein217,230. The role 
of the F protein in the HCV life cycle – if it has any at all – is currently unknown. 
The individual functional products of the polyprotein are liberated by various cleavage 
events (Fig. 3). The core to NS2 region is processed by the cellular enzymes signal 
peptidase and signal peptide peptidase, the carboxyterminus of NS2 is released from 
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NS3 by the NS2-3 proteinase, and all other cleavages are mediated by the main viral 
proteinase complex build by NS3 and NS4A. 
Core, a 21 kDa protein, functions primarily in the assembly of the viral capsid shell151 
and interacts with the envelope protein E1137,147.  
The glycosylated envelope proteins E1 (30-35 kDa) and E2 (70-72 kDa)77,180 
probably are responsible for the attachment to the cell by binding to cell surface 
receptors, e.g. CD81, SR-BI (scavenger receptor class B type I), and LDL (low 
density lipoprotein) receptor3,174,185. 
The integral membrane protein p7 is a small hydrophobic protein (63 aa) of unknown 
function that is located between the structural and non-structural regions of the 
polyprotein130,192. It was suggested that p7 belongs to the viroporin ion channel family 
since it can mediate membrane ion permeability78,167. Recently, it was shown that p7 
is essential for the production of infectious virions104,202.  
NS2 is a hydrophobic 23 kDa membrane protein184 which functions as a cysteine 
protease142,163. Together with the N-terminal third of NS3, this protein forms the NS2-
3 proteinase which is responsible for self-cleavage between NS2 and NS376,90,184. 
The precise biological function of NS2 still has to be clarified. Although NS2 itself is 
not required for RNA replication140, its cleavage from NS3 is essential116,226. Recent 
work suggests that NS2 plays a role in infectious virus production104,171,235. 
NS3, a primarily cytosolic 70 kDa protein91, is a multifunctional molecule. Besides 
being part of the NS2-3 proteinase responsible for autocatalytic cleavage at the NS2-
NS3 site14, NS3 contains a serine proteinase domain in the N-terminal 180 amino 
acids of the protein84,114,201,207, and a NTPase/helicase in the C-terminal portion108,204. 
Although the N-terminal serine proteinase domain of NS3 shows enzymatic activity 
on its own, NS4A, a 54-residue viral protein containing an N-terminal membrane 
anchor, is a proteinase cofactor required for efficient proteolytic processing 
downstream of NS314,58,131,208. The NS3 helicase is classified into the superfamily 2 
helicases124. The helicase/NTPase is essential for viral replication116, however, its 
precise role has yet to be defined. NS4B, a 27 kDa hydrophobic protein, associates 
with membranes of the ER presumably via an internal signal sequence98,110. It 
reorganizes intracellular membranes into distinct membranous structures that 
represent the site of viral replication in Huh-7 cells51,74,156. Thus, NS4B has been 
proposed to play a structural role in RNA replication by serving as the scaffold for 
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replication complex assembly170,177. Moreover, several replication-enhancing adaptive 
mutations map to NS4B81,138. 
NS5A is a predominantly hydrophilic, RNA-binding97 phosphoprotein containing an N-
terminal amphipathic α-helix that mediates association with the ER membrane33,169. 
Two phosphoproteins, the basally phosphorylated p56 and the hyperphosphorylated 
p58 (56 kDa and 58 kDa, respectively) are detectable due to differential 
phosphorylation106. Hyperphosphorylation depends on the presence of other viral 
non-structural proteins (NS3, NS4A, and NS4B)9,106,113,159 and is performed by casein 
kinase I178,179. p58 has a shorter half life than p56173, suggesting that both NS5A 
forms have distinct roles in the viral replication cycle which are so far unknown. It 
seems that NS5A is involved in genomic RNA replication140, since the central region 
of NS5A is a hot spot for cell culture adaptive mutations in the replicon system (see 
below and references13,25,120) and the protein itself is a pivotal regulator of 
replication25,139. 
The NS5B protein is the RNA-dependent RNA polymerase (RdRp) of HCV, the key 
enzyme of viral RNA replication. It has a molecular weight of 68 kDa and belongs to 
a relatively small class of membrane proteins termed tail-anchored proteins101,188. 
Characteristic features of these proteins include (i) posttranslational membrane 
targeting via a hydrophobic C-terminal insertion sequence (which in the case of NS5B 
was mapped to the C-terminal 21 amino acid residues), (ii) integral membrane 
association, and (iii) a cytosolic orientation of the functional protein domain (reviewed 
in29,225). NS5B can initiate RNA synthesis de novo or primer-dependent; presumably, 
de novo initiation occurs also in vivo145,162,241. The viral NTRs contain specific signals 
important for the efficient initiation of positive- and negative-strand RNA synthesis 
which are recognized (but not exclusively) by the HCV polymerase24. 
 
1.4 Model systems to study HCV replication in cell culture 
1.4.1 Tissue culture models 
Subgenomic replicons 
Despite the numerous attempts that have been undertaken, the propagation of HCV 
in cell culture turned out to be surprisingly difficult. Most experiments were based on 
the cultivation of primary cells isolated from tissues of persistently infected patients or 
the infection of primary cell cultures or cell lines with HCV (reviewed in16). However, 
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the reproducibility in these systems was poor, and the low level of HCV replication 
demanded the use of highly sensitive RT-PCR-based detection methods which were 
additionally subject to inherent technical problems80,127,205. 
A breakthrough came in 1999 when Lohmann et al. reported the first functional 
“subgenomic replicons”140 (Fig. 4). This system is based on the self-replication of 
selectable subgenomic HCV RNAs, the so-called replicons (Fig. 4A). These RNAs 
were derived from a cloned consensus genome of genotype 1b by deleting the region 
coding for core to p7 or core to NS2 and inserting a selectable marker instead 
(neomycin phosphotransferase (neo), conferring resistance against the antibiotic 
G418). A second IRES element from a picornavirus (EMCV, encephalomyocarditis 
virus) was introduced to allow translation of the HCV non-structural proteins. Upon 
transfection of the human hepatoma cell line Huh-7, a low number of neomycin 
(G418)-resistant colonies was obtained that carried high amounts of autonomously 
replicating HCV RNAs140. These cells provided a suitable tool for the investigation of 
HCV replication. When replicon cells are passaged under continuous selection 
pressure, these RNAs show stable replication and translation levels for many 
years173 (Fig. 4, B and C). With the identification of cell culture-adaptive mutations 
that enormously enhanced HCV RNA replication in Huh-7 cells, it was also possible 
to develop various replication assays with modified replicons25,81,120,139 harboring – for 
example – genes coding for luciferase or auto-fluorescent proteins (Fig.4A).  
Another important outcome from work with HCV replicons was the identification of 
highly permissive cell clones15. Individual cells within a given Huh-7 cell pool vary 
dramatically in their ability to support high levels of HCV RNA replication138; cells that 
can support high levels of RNA replication are enriched during selection (with G418 
in the case of neo replicons). Upon removal of HCV replicons from such established 
cell clones, for example by treatment with IFN-α or an HCV-selective drug, a “cured” 
cell clone is obtained, which, upon reintroduction of the replicon, in many cases 
supports HCV RNA replication to a much higher level as compared to that of the 
parental (naïve) cells. Two highly permissive cell clones designated Huh7.5 and 
Huh7-Lunet have been generated in this way27,68. 
In addition to subgenomic replicons, selectable full-length HCV genomes carrying cell 
culture-adaptive mutations were constructed that stably or transiently replicate 
efficiently in Huh-7 cells26,27,99,172. Despite the high levels of RNA amplification and 
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expression of all viral proteins, virus particle production was not obtained in these 
systems34. 
 
 
Fig. 4. Huh-7 cells harboring subgenomic replicon possess high levels of viral RNA and HCV NS 
proteins. (A) Structures of a selectable subgenomic replicon (top) and two different subgenomic 
reporter replicons (middle and bottom). All replicons contain the 5’ HCV-IRES, the EMCV-IRES, 
directly followed by the HCV sequences from NS3 up to the authentic 3’ end. The selectable replicon 
possesses additionally the neomycin phosphotransferase (neo) gene (top), the reporter replicons the 
firefly luciferase (luc) gene and the red fluorescent protein (RFP) gene fused to NS5A, respectively. In 
the bicistronic PI_luc_NS3-3’ construct the expression of the luciferase is driven by the Poliovirus-
IRES. (B) Detection of HCV RNA in Huh-7 replicon cells. Total RNA was isolated from the cells and 
analyzed by denaturing agarose gel electrophoresis. Replicon RNA was detected by Northern blot 
with a radiolabeled RNA probe complementary to the neo gene and the HCV-IRES. In vitro transcripts 
(109) corresponding to a NS2-3’ and a NS3-3’ replicon were analyzed in parallel (left and right lane, 
respectively). The blue arrow points to HCV RNAs. Lane M, positions of RNA size markers (in 
nucleotides); the position of the 28S ribosomal RNA is indicated on the right. The RNA marker 
fragments contained HCV sequences and therefore hybridized with the RNA probe. (C) Subcellular 
localization of HCV NS5B in Huh-7 replicon cells was determined by immunofluorescence. NS5B was 
detected by a polyclonal antibody raised against NS5B. Northern blot (B) adapted from Lohmann et 
al., Science, 1999140. 
 
Cell culture-produced Hepatitis C Virus (HCVcc) 
Studies on HCV entry were previously investigated by HCV pseudoparticles 
(HCVpp). These were based on retroviruses containing the HCV glycoproteins in 
their envelope17,95. 
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In 2005, three independent groups133,219,240 reported the production of authentic HCV 
particles in cell culture. All these reports were based on a genotype 2a isolate 
designated JFH1, that was obtained from a patient in Japan with fulminant 
hepatitis107. After RNA transfection of Huh-7 cells with full-length RNA from the JFH1 
genome, viral particles infectious for naïve cells as well as for chimpanzees are 
released from the cells, although the titers initially were rather low219. Different groups 
reported that this hurdle could be overcome by the construction of infectious 
intragenotypic and intergenotypic HCV chimeras whose transfection resulted in 
efficient virus production133,171. Moreover, Lindenbach et al. demonstrated that the 
recombinant viruses generated in Huh7.5 cells are infectious in chimpanzees and in 
a mouse model, and that viruses recovered from these animals remain infectious in 
cultured cells134. These results convincingly demonstrate that HCV grown in cell 
culture is authentic. Lately, the production of infectious genotype 1a HCV in cultured 
human hepatoma cells was shown236, demonstrating that other isolates apart from 
JFH1 can produce infectious viruses in vitro, however far less efficient. 
To facilitate studies of HCV infection, different genotype 2a-based reporter viruses 
had been generated. Koutsoudakis and colleagues constructed JFH1-based 
bicistronic luciferase reporter virus genomes119, and Schaller and coworkers inserted 
genes encoding fluorescent proteins (GFP) in frame into the 3'-terminal NS5A coding 
region resulting in fluorochrome gene-tagged viral genomes187. 
 
1.5 HCV life cycle 
The current understanding of the HCV replication cycle is still hypothetical in parts, 
since the fully permissive cell culture systems allowing efficient propagation became 
available only recently. However, some details began to emerge due to the 
availability of the other in vitro systems discussed above. Of most importance have 
been replicons that recapitulate the intracellular steps of RNA replication. HCV 
pseudoparticles were instrumental for analyzing the early events in the infection 
process before the production of infectious HCV particles in cell culture became 
possible. The overall outline of the HCV replication cycle is depicted in Fig. 5. HCV 
particles interact with specific surface receptor(s), e.g. CD81, SR-BI and Claudin 
157,174,185, and are internalized. Fusion of the viral and the cellular membranes, 
presumably triggered by the low pH of the endocytic compartment95,119,212 leads to 
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uncoating and subsequent release of the positive-stranded RNA ((+)ssRNA) genome 
into the cytoplasm of a newly infected cell. This RNA first functions as messenger 
RNA (mRNA) for the viral protein synthesis at the rough ER. Then, the non-structural 
proteins form together with the viral RNA the replication complex which resides in 
vesicular membrane structures, the so-called membranous web (described later in 
detail). An EM picture of the membranous web is shown in Fig. 5. The replication 
complexes are responsible for the amplification of the HCV genome. Probably, the 
(+)ssRNA is transcribed into a negative-stranded RNA that presumably remains 
base-paired with its template. The resulting double-stranded RNA, the so-called 
replicative form (RF), is then most likely copied multiple times semi-conservatively 
and asymmetrically into a single positive-stranded RNA via this replicative 
intermediate (RI) generating a five- to tenfold molar excess over negative-stranded 
RNA. This hypothetical model of viral RNA replication is depicted in Fig. 5. The 
progeny HCV RNA genomes may be used for translation, synthesis of new RFs, or 
packaging into new virus particles. Newly synthesized virions probably form by 
budding into the ER and leave the cell through the secretory pathway. 
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Fig. 5: Schematic diagram of HCV replication cycle. HCV binds to specific receptor(s) on the 
surface of the cells to gain entry. After entry into the cell and uncoating, the HCV genome serves three 
main roles: translation, replication and packaging into nascent virions. NS4B (perhaps in conjunction 
with other viral or cellular factors) induces the formation of membranous vesicles (referred to as the 
membranous web; electron micrograph lower right), which are supposed to serve as scaffolds for the 
viral replication complex. Newly produced virus particles leave the host cell by the constitutive 
secretory pathway. The upper right panel of the figure shows a schematic representation of an HCV 
particle. The envelope proteins E1 and E2 are drawn according to the proposed structure and 
orientation of the TBEV envelope proteins M and E, respectively. The middle panel shows a model for 
the synthesis of negative-strand (-) and positive-strand (+) progeny RNA via a double stranded 
replicative form (RF) and a replicative intermediate (RI). The bottom panel shows an electron 
micrograph of a membranous web (arrow heads) in a Huh-7 cell containing subgenomic HCV 
replicons. Bar, 500 nm. N, nucleus; ER, endoplasmic reticulum; M, mitochondria. The electron 
micrograph is adapted from Gosert et al. 2003, J Virol 200374. The diagram of HCV replication cycle is 
adapted from Bartenschlager et al., Adv. Virus Res., 200415. 
 
1.6 The HCV RNA Replication Complex 
The RNA replication mechanism of all positive-stranded RNA viruses shows a 
common peculiarity. Infection of cells leads to a rearrangement of intracellular 
membranes21,75,123,168,186,190,227 which is a precondition for the formation of viral 
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replication complexes (RCs). These membrane-associated complexes comprise the 
viral proteins, replicating RNA and most likely cellular host proteins that interact with 
their viral partners. This strategy may offer multiple advantages including (i) 
compartmentalization and local concentration of viral products, (ii) physical support 
and organization of the RNA replication complex, (iii) tethering of the viral RNA 
during unwinding146, (iv) provision of lipid constituents important for replication4,229, 
and (v) protection of the viral RNA from double-stranded RNA-mediated host 
defenses or RNA interference. 
After the establishment of the replicon system (see 1.4.1) it became clear that the 
proteins NS3-to-NS5B are necessary and sufficient for RNA replication in Huh-7 cells 
harboring autonomously replicating subgenomic HCV RNAs140. All NS proteins are 
associated with ER-membranes by one or several transmembrane domains or an 
amphipathic α-helix, as depicted in Fig. 6. The only exception is NS3 whose 
membrane-connection is mediated by its cofactor NS4A. 
 
 
Fig. 6. Membrane topology of HCV non-structural proteins after polyprotein cleavage. The location of 
the N terminus and C terminus of the proteins relative to the ER lumen is given. The phosphorylation 
of NS5A and the amphipathic helix are indicated. Note that in the case if NS2, some molecules may 
also carry their N terminus on the cytosolic side. Further note that the N-terminal transmembrane 
domain of NS4B may have a dual topology144. Adapted from Bartenschlager et. al., Adv. Virus Res., 
200415. 
 
Several groups demonstrated that the membrane-interactions of the NS proteins 
NS4B, NS5A, and NS5B are critical for viral RNA replication53,54,155,169. Likewise, their 
interaction with each other has been extensively studied and seems to be essential 
for replication, too48,100,132,176,195,196. Together with the viral RNA, the NS proteins NS3 
to NS5B form the so-called replication complex in which the replication of HCV RNA 
occurs. 
In subgenomic replicon cells as well as in liver cells of HCV-infected chimpanzees, a 
specific membrane alteration was identified51,74. It was shown that NS4B induced this 
tight structure, designated membranous web, consisting of vesicles in a membranous 
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matrix51. These membranous vesicular structures were closely associated with the 
rough ER and contained the HCV non-structural proteins necessary for viral 
replication as well as viral RNA74 Gosert and coworkers showed that the NS proteins 
colocalized with newly synthesized RNA (Fig. 7A). Therefore, it was assumed that 
the membranous web represents the HCV replication complex (RC), the site of viral 
RNA replication. A hypothetical model of the RC as well as an EM picture of the 
membranous web is shown in Fig. 7. 
 
 
Fig. 7. (A) Colocalization of nascent HCV RNA and NS5A in Huh-7 cells harboring a subgenomic 
replicon. 9-13 replicon cells were metabolically labeled with 5-bromouridine 5'-triphosphate in the 
presence of Actinomycin D. NS5A was detected of with a polyclonal antiserum specific for NS5A and 
newly synthesized, bromo-uridine-labeled viral RNA with a monoclonal antibody directed against 
bromo-deoxyuridine. (B) Hypothetical model of the HCV replication complex. HCV NS proteins are 
indicated by orange ellipses, potential cellular factors by pink ellipses, and viral RNA by a blue wavy 
line. Individual NS proteins and RNA are not drawn to scale. (C) Electron micrograph of the 
membranous web, membrane alterations in Huh-7 cells containing subgenomic HCV replicons. The 
web is composed of small vesicles embedded in a membrane matrix and closely associated to the 
rough ER. These vesicular structures (one highlighted by a yellow rectangle) harbor the HCV 
replication complexes containing viral NS proteins and RNA and represent the site of viral RNA 
replication. The immunofluorescence as well as the electron micrograph (A and C) are both adapted 
from Gosert et al., J Virol, 200374. 
 
One way of analyzing the properties of RCs has been the biochemical preparation of 
intracellular membrane fractions of HCV-containing cells by hypotonic lysis and 
differential centrifugation. These so-called crude replication complexes (CRCs) 
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contain the NS proteins and the viral RNA and exhibit distinct properties in vitro: upon 
addition of radiolabeled nucleotides, these membrane fractions are capable of RNA 
synthesis in vitro, without need of an exogenous RNA template5. CRCs were 
resistant to the detergents NP-40 and Triton X-100 at 4°C indicating that the RCs are 
associated with cholesterol-rich lipid rafts5,71,193. Positive- and negative-strand HCV 
RNA detected in RCs was resistant to nuclease, as well as the NS proteins were 
protected against proteases5,52,153. This resistance of RCs to enzymatic treatments 
was most probably mediated by membranes153. 
 
1.7 Known cellular cofactors of HCV replication 
Viruses are obligatory intracellular parasites always exploiting host cell resources: 
besides using general cellular mechanisms like translation, energy supply, secretion, 
etc., many viruses recruit specific host cell factors for particular purposes. These host 
cell factors may serve as targets of antiviral therapeutics and are therefore 
extensively studied. A number of cellular proteins important for HCV RNA replication 
has already been identified by proteomic approaches, for example Y2H assays. One 
class of those host factors are RNA-binding proteins. Besides the ribosomal proteins, 
other host cell factors are also involved in the viral translation process, e.g. the La 
antigen and the polypyrimidine tract-binding protein (PTB). It was shown that PTB 
interacts with HCV NS3 and NS5B49, whereas NS5A cooperates with the RNA-
binding protein La94. The important role of La in the HCV replication was proven by 
siRNA silencing49. 
Other cellular proteins acting as cofactors of viral replication include the F-box and 
leucine rich protein 2 (FBL2), amphiphysin II, Vap-A, Vap-B, and cyclophilin B 
(CyPB). 
Amphiphysin II is a multifunctional adaptor protein that is thought to act in clathrin-
mediated endocytosis. The interaction of amphiphysin II with HCV NS5A was first 
reported in 2003238; furthermore, it was shown that this interplay results in a reduction 
of NS5A phosphorylation149. 
Cyclophilin B (CyPB) is a cyclosporine A (CsA)-binding chaperone with a peptidyl 
prolylisomerase (PPI) activity. It is a member of the immunophilin family of soluble 
cytosolic receptors and is mainly localized within endoplasmic reticulum vesicles. 
Cyclophilin B is secreted in response to inflammatory stimuli and interferes in 
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complex with CsA the T-cell activation signaling cascade. Watashi and coworkers 
demonstrated that CyPB functions as a positive regulator of the NS5B polymerase by 
directly stimulating its RNA binding activity224. When CyPB is targeted by CsA, the 
HCV genome replication is drastically suppressed. 
The widely expressed F-box and Leucine rich protein 2 (FBL2) is likely involved in an 
ubiquitination reaction, but its substrates are not known. In its geranylgeranylated 
form, FBL2 interacts with HCV NS5A building a complex that is crucial for HCV RNA 
replication221. So far, the function of the interaction between NS5A and FBL2 is not 
known, since ubiquitination of NS5A has not been demonstrated.  
Interestingly, NS5A and NS5B also interact with the human vesicle-associated-
membrane-protein associated protein A(hVAP-A)214. hVAP-A belongs to the class of 
tSNARE (target-membrane soluble N-ethylmaleimide-sensitive fusion protein 
attachment protein receptor) proteins which are involved in intracellular vesicle 
transport and has been implicated in directing the non-structural proteins to 
cholesterol-rich, detergent-resistant membranes (rafts) on which HCV replication is 
thought to occur71. Furthermore, it was shown that an interruption of the interaction of 
NS5B with hVAP-A leads to a decrease in viral replication239. Recently, an interaction 
between VAP-B, NS5A and NS5B has also been described83. Both proteins, VAP-B 
in addition to VAP-A, seem to play an important role in the replication of the HCV 
genome. 
 
In spite of all these already identified cellular factors involved in HCV replication, the 
mechanism of the viral progeny RNA synthesis still remains largely unknown. In 
many cases, an interaction of cellular with HCV proteins is evident and even an effect 
onto viral replication is demonstrated but the function of many of these interplays has 
to be revealed. The continuous detection of new cellular interaction partners of HCV 
replication leads to the assumption that the viral replication mechanism has not yet 
presented all its secrets. Therefore, a comprehensive picture of the structure and 
biogenesis of the HCV RC including its host factors is still missing. 
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1.8 Aim of thesis 
At the beginning of this PhD thesis, the detailed composition of viral and cellular 
components of the replication complex was unknown.  
The first aim was the characterization of enzymatically active replication complexes 
in vitro as well as the development of an appropriate purification protocol for these 
membrane-bound complexes. Using this protocol, I intended to identify so far 
unknown cellular candidate proteins associated with the replication complex and 
therefore probably involved in HCV replication by proteomic approaches. 
Subsequently, candidate proteins found by mass spectrometry would be evaluated. 
Their association with viral components of the replication complex had to be 
analyzed intracellularly and biochemically. Furthermore, their effect onto HCV 
replication would be investigated. 
During the second part of the PhD thesis, a quantitative analysis of the HCV 
replication complex was aimed. Starting from a quantitative analysis of viral RNA and 
protein content in HCV harboring cells, a detailed stoichiometric analysis of the HCV 
replication complex should be carried out. The aim was to determine the ratio of viral 
positive- and negative-strand RNA to proteins in replicon cells and CRCs and to 
analyze which portions are actively involved in viral RNA synthesis. This should 
provide deeper insight into the structure and composition of HCV replication 
complexes. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Cells 
Bacteria:  
♦ DH5α: F'/endA1 hsdR17(rK-mK+) supE44 thi-1 recA1 gyrA (Nalr) relA1 Δ(lacZYA-argF)U169 deoR 
(Φ80dlacΔ(lacZ)M15) 
 
Mammalian Cell Lines:  
♦ 11-1: human hepatoma cell line with persistent HCV subgenomic replicon (NS2-3’)140 
♦ 5-15: human hepatoma cell line with persistent HCV subgenomic replicon (NS3-3’)140 
♦ 9-13: human hepatoma cell line with persistent HCV subgenomic replicon (NS3-3’)140 
♦ HEK293T: human embryonic kidney cells expressing the SV40 large T-antigen 
♦ Hep56D: murine liver derived cell line 
♦ HepG2: human hepatoma cell line 
♦ HuH6: human hepatoblastoma cell line228 
♦ Huh-7.5: Huh-7 cells which originally carried a selectable HCV replicon and were cured by 
treatment with an HCV-specific inhibitor. They are characterized by high permissiveness for HCV 
RNA replication27. 
♦ Huh-7: human hepatoma cell line158 
♦ Huh7-Lunet: Huh-7 cells which originally carried a selectable luciferase HCV replicon and were 
cured by treatment with an HCV-specific inhibitor. They are characterized by high permissiveness 
for HCV RNA replication68. 
♦ lucubineo ET: human hepatoma cell line with persistent HCV subgenomic replicon (lucubineo 
NS3-3’)65 
♦ Lunet-T7: Huh7-Lunet cells constitutively producing T7 RNA polymerase from a retrovirally 
transduced expression cassette (T.P. and R.B., unpublished observations). 
♦ sh ANXA2 Huh7.5: Huh-7.5 cells stably expressing a shRNA directed against ANXA2 (this work) 
♦ sh ANXA2 lunet: Huh-7 lunet cells stably expressing a shRNA directed against ANXA2 (this 
work) 
♦ sh p53 Huh7.5: Huh-7.5 cells stably expressing a shRNA directed against p53 (this work) 
♦ sh p53 lunet: Huh-7 lunet cells stably expressing a shRNA directed against p53 (this work) 
 
 
 
MATERIALS AND METHODS 
 
19
2.1.2 Media 
Bacteria:  
♦ LB-Medium: 10 g trypton, 5 g yeast extract, 5 g NaCl per 1 l medium; ampicillin was added at a 
concentration of 50-100 μg/ml. For hardening 1.5% agar-agar was added to the liquid medium. 
 
Yeast cells: 
♦ YPD: 20 g/l Difco peptone, 10 g/l yeast extract, 2% glucose, pH 6.5 with HCl. For plates 18 g/l 
agar was added. 
♦ SD -Leu/-Trp agar plates: 6.7 g/l Difco yeast nitrogen base without amino acids, yeast synthetic 
dropout medium supplement without leucine and tryptophane (Sigma, Y-0750), pH 6.5 with NaOH; 
20 g/l agar 
 
Mammalian cell lines:  
♦ DMEM complete: Dulbecco's modified minimal essential medium (Gibco-BRL, #41965-039; Life 
Technologies, Karlsruhe, Germany) supplemented with 2 mM L-glutamine, nonessential amino 
acids, 100 U/ml of penicillin, 100 μg/ml of streptomycin (all Gibco), and 10% fetal calf serum (FCS, 
Seromed, inactivated at 56°C for 30 min).  
For selections, antibiotics were added in the following concentrations: 100 µg/ml G418 
(Invitrogen), 10 μg/ml zeocin (Invitrogen), and 10 µg/ml blasticidin (Invitrogen). 
♦ DMEM without methionine and cysteine: DMEM supplied with 2% dialyzed fetal calf serum; 10 
mM Hepes; 2 mM L-glutamine 
♦ OptiMEM: defined medium formulation with reduced serum (Gibco #31985) 
♦ Cryo medium: for long term storage, cells were frozen in liquid nitrogen in 90% FCS, 10% DMSO 
 
2.1.3 Antibodies and antisera 
Primary Antibodies: 
Method antibody comments 
WB Dil. IP Dil. IFA Dil. FACS Dil. 
Company/ 
Ordering number 
α-Annexin II 
(ANXA2); 
HH7; mouse 
   + 10 
µl/IP 
+ 1:100 + 1:100 Prof. Gerke; Uni 
Münster 
α-LAMP1 
(H4A3); 
mouse 
late 
endosome 
marker 
    + 1:200   EMBL 
α-BrdU; 
mouse 
     - 1:50   Roche; Clone 
BMC 9318; 
#1170376 
α-Rab5B; 
rabbit 
         Santa Cruz 
SC-598 
α-Annexin IV 
(ANXA4); 
K411; rabbit 
     + 1:50   Prof. Gerke; Uni 
Münster 
α-p11; 
mouse 
     + 1:100   Prof. Gerke; Uni 
Münster 
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C7-50, 5B3.5.1, and 12B7.54.1 antibodies kindly provided by D. Moradpour154,157; 9E10 Ab kindly 
provided by T. Tellinghuisen133; HH7, K411 and anti-p11 kindly provided by V. Gerke. 
 
α-dsRNA; 
J2; mouse 
     -  1:50    
α-Annexin II 
(ANXA2); H-
50; rabbit 
 +/- 1:500 - 6 
µl/IP 
+/- 1:200   Santa Cruz; 
SC-9061 
α-Annexin I 
(ANXA1); 
mouse 
     + 1:100   BD 
#610066 
α-Annexin V 
(ANXA5); 
mouse 
     + 1:100   Sigma 
A8604 
α-Vap-A; 
rabbit 
 + 1:1000        
α-EEA1; 
rabbit 
early 
endosome 
marker 
    + 1:300 
to 
1:500 
  Acris antibodies 
SP5141P 
α-Annexin II 
(ANXA2); 
mouse 
 + 1:5000 - 10 
µl/IP 
+/- 1:100   BD 
#610068 
α-Calnexin ER marker + 1:2000   + 1:100   Stressgen, SPA-
865 
α-E2; rabbit Only used 
as negative 
control 
   6 
µl/IP 
     
α-Core (C7-
50); mouse 
 + 1:2600        
α-NS3 (new 
batch, NS3B 
04/10/01); 
rabbit 
Recognizes 
genotypes 
1b and 2a 
+ 1:1000 + 6 
µl/IP 
     
α-NS3 (old 
batch, NS3B 
#8); rabbit 
Recognizes 
genotypes 
1b and 2a 
+ 1:2500   + 1:1000    
α-NS3 
(protease, 
136.14.2); 
mouse 
 + 1:500        
α-NS4B 
(7/99; #86); 
rabbit 
Recognizes 
genotypes 
1b and 2a 
+ 1:2500 + 6 
µl/IP 
+ 1:200    
α-NS5A 
(11/01); 
rabbit 
Recognizes 
genotype 
1b 
  + 6 
µl/IP 
+ 1:100    
α-NS5A 
(9E10/A3); 
rabbit 
Recognizes 
genotypes 
1b and 2a 
    + 1:250    
α-NS5B 
(pool 2, `93); 
rabbit 
Recognizes 
genotypes 
1b 
  + 6 
µl/IP 
+ 1:100    
α-NS5B Con 
(12B7.54.1); 
mouse 
Conformati
onal 
epitope 
         
α-NS5B Con 
(3B1.5.3); 
mouse 
Linear 
epitope 
+ 1:1000        
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Secondary antibodies: 
♦ α-mouse IgG, HRP conjugate (Sigma-Aldrich): 1:10,000 for Western Blot 
♦ α-rabbit IgG, HRP conjugate (Sigma-Aldrich): 1:25,000 for Western Blot 
♦ α-mouse IgG , Alexa 488 conjugate (Molecular Probes, Leiden, Netherlands): 1:1,000 for IF 
♦ α-mouse IgG , Alexa 546 conjugate (Molecular Probes, Leiden, Netherlands): 1:1,000 for IF 
♦ α-rabbit IgG , Alexa 488 conjugate (Molecular Probes, Leiden, Netherlands): 1:1,000 for IF 
♦ α-rabbit IgG , Alexa 546 conjugate (Molecular Probes, Leiden, Netherlands): 1:1,000 for IF 
♦ α-mouse IgG , PE conjugate (eBioscience, San Diego, USA): 1:200 for FACS analysis 
♦ α-mouse IgG , APC conjugate (Dianova, Hamburg, Germany): 1:200 for FACS analysis 
♦ α-mouse IgG , FITC conjugate (Sigma-Aldrich): 1:200 for FACS analysis 
 
2.1.4 Vectors 
♦ pACT2-ANXA2: NcoI-BamHI fragment from pACT2 replaced with NcoI-BamHI fragment from 
pTM-ANXA2 endo. 
♦ pBABE-HI-SV40-EGZ-ΔU3 shANXA2ivt: pBABE-HI-SV40-EGZ-ΔU3-based retroviral vector121 
encoding ANXA2-specific shRNA. 
♦ pBABE-HI-SV40-EGZ-ΔU3 shANXA2mwg: pBABE-HI-SV40-EGZ-ΔU3-based retroviral vector121 
encoding ANXA2-specific shRNA. 
♦ pBABE-HI-SV40-EGZ-ΔU3 shlacZ: pBABE-HI-SV40-EGZ-ΔU3-based retroviral vector121 
encoding lacZ-specific shRNA. 
♦ pCMV XM: construct encodes a chimeric protein (XM) comprising the 18 N-terminal aa of Annexin 
II fused to the complete p11 molecule. XM acts as transdominant mutant of the (ANXA2-p11)2 
heterotetramer85. Construct was kindly provided by V. Gerke. 
♦ pCMV-ΔR8.91: HIV-Gag-Pol expression construct244. 
♦ pCZ VSV-G: CMV promoter-dependent expression construct for the expression of the G protein of 
the Vesicular Stomatitis Virus105. 
♦ pECFP-N1-ANXA2-CFP: ANXA2-CFP fusion protein expression construct242; CFP was fused to 
the C-terminus of ANXA2. Construct was kindly provided by V. Gerke. 
♦ pFKi341PI-luc-EI-NS3-3’/ET: PI_luc_ET, construct encodes bicistronic subgenomic Con1 replicon 
in which luciferase expression is driven by a poliovirus IRES (PI). 
♦ pFKi341PI-luc-EI-NS3-3’/JFH: PI_luc_JFH, construct encodes bicistronic subgenomic JFH1 
replicon in which luciferase expression is driven by a poliovirus IRES (PI). 
♦ pFKi389lucEIJFH1/J6/C-846/δg: Jc1, bicistronic luciferase construct that encodes chimeric HCV 
polyprotein which consist of codons 1-846 derived from J6/CF combined with codons 847 to 3033 
of JFH1. 
♦ pFKi389lucEIJFH1wt/δg/ΔE1E2: luciferase construct that encodes HCV full-length polyprotein of 
JFH1 but lacks the envelope proteins. 
♦ pFKi389neoNS3-3’/δg/JFH/NS5A-RFP: neo-5A-RFP, construct encodes subgenomic JFH1 
replicon in which GFP is fused to NS5A. 
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♦ pFKi389neoNS3-3’δg/JFH/NS5A-cherry_aa383: XbaI-PmeI fragment from pFKi389neoNS3-
3’δg/JFH/NS5A-RFP_aa383 replaced with XbaI-PmeI fragment from PCR with S cherry Xba and 
A cherry Pme on Cl cherry. 
♦ pGex6P ANXA2: BamHI-SpeI fragment from pGex6P Vap-A replaced with BamHI-HindIII 
fragment from PCR with S ANXA2 Bam and A ANXA2 stop Spe on pTM-ANXA2 endo and HindIII-
SpeI fragment from pTM-ANXA2 endo. 
♦ pHIT60: CMV promoter-dependent expression construct for the expression of gag and pol protein 
of the Murine Leukemia Virus200. 
♦ pTM NS3-5B JFH/5A-RFP: NsiI-BsrGI fragment from pTM NS3-5B/JFH replaced with NsiI-BsrGI 
fragment from pFKi389neoNS3-3’/δg/JFH/NS5A-RFP. 
♦ pTM-ANXA2 endo: NcoI-SpeI fragment from pTM NS4B replaced with NcoI-SpeI fragment from 
PCR with S ANXA2 Nco and A ANXA2 stop Spe on reverse transcribed endogenous ANXA2 
sequence. 
♦ pTM-ANXA2-eGFP: NcoI-AgeI fragment from pTM DV4A GFP replaced with NcoI-AgeI fragment 
from PCR with S ANXA2 Nco and A ANXA2 inframe Age on pEGFP-N1-A2-CFP. 
♦ pWPI-BLR: KpnI-XbaI fragment from pWPI MCS replaced with KpnI-XhoI fragment from pTM BLR 
and with XhoI-XbaI fragment from pWPI MCS. 
♦ pWPI-BLR-ANXA2: AscI-SpeI fragment from pWPI-BLR replaced with AscI-SpeI fragment from 
PCR with S ANXA2 Asc and A ANXA2 stop Spe on pTM ANXA2 endo. 
♦ pWPI-GUN-ANXA2: AscI-SpeI fragment from pWPI-GUN replaced with AscI-SpeI fragment from 
PCR with S ANXA2 Asc and A ANXA2 stop Spe on pTM ANXA2 endo. 
 
2.1.5 Oligonucleotides 
Name Sequence (5` → 3`) 
A ShANXA2ivt agcttttccaaaaaccttatgacatgttggaaatctcttgaatttccaacatgtcataaggggg 
S ShANXA2ivt gatccccccttatgacatgttggaaattcaagagatttccaacatgtcataaggtttttggaaa 
A ShANXA2mwg agcttttccaaaaattaacagagtctacaaggatctcttgaatccttgtagactctgttaaggg 
S ShANXA2mwg gatccccttaacagagtctacaaggattcaagagatccttgtagactctgttaatttttggaaa 
S ANXA2 Nco ataccatggccatgtctactgttcacgaaatcctg 
A ANXA2 stop Spe tatactagtcagtcatctccaccacacag 
A ANXA2 inframe Age tatactagtcagtcatctccaccacacag 
S mRFP Age ataaccggtatggcctcctccgaggacgtcatc 
A mRFP Spe tatactagtttaggcgccggtggagtggcgg 
S Anxa2 360 seq gctgggaaccgacgaggactctc 
S Anxa2 739 seq gaggttaaaggagacctggaaaatg 
S Anxa2 Asc ataggcgcgccatgtctactgttcacgaaatcc 
S Nhe Anxa2 gtacgctagcgccatgtctactgttcacg 
S ANXA2 Bam ctgggatccatgtctactgttcacgaaatc 
S cherry Xba aattctagagtgagcaagggcgaggagg 
A cherry Pme cacgtttaaaccccttgtacagctcgtccatgc 
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2.1.6 siRNAs 
Name Sequence (5` → 3`) 
HCV-321 aggucucguagaccgugcatt 
sip53 gacuccagugguaaucuactt 
lacZ agcuggcuggagugcgauctt 
ANXA2mwg uuaacagagucuacaaggatt 
ANXA2ivt ccuuaugacauguuggaaatt 
DV 3’UTR agaagucaggccauuacaatt 
 
2.1.7 Buffers and Solutions 
2D equilibration solution: 6 M urea; 50 mM Tris (pH 8.8); 2% SDS; 30% glycerol 
2D protein solubilization buffer: 5 M urea; 2 M thiourea; 2% CHAPS; 2% SB3-10; 2 mM 
tributylphosphine; 0.5% IPG buffer; 1x protease inhibitor mix; 75 U/ml benzonase; trace 
bromophenolblue 
30% Acryl amide stock solution: acryl amide and bisacrylamide were mixed in a concentration 29:1; 
solution was filtered and degassed before use 
Bradford reagent: 100 mg Coomassie Brilliant Blue G250 solved in 50 ml 95% ethanol; add 100 ml 
85% phosphoric acid; ad 1 l with H2O; filter; store at 4°C 
Coomassie destaining solution: 5% methanol; 5% acetic acid 
Coomassie staining solution: 0.6 g/l Coomassie brilliant blue R250 (Serva) dissolved in 50% 
methanol/10% acetic acid, filtered 
Core ELISA 1x washing buffer: mix 150ml 20x washing buffer concentrate with 3l deionized H2O and 
add 1 bottle of urea (180 g) additive and mix carefully 
Core ELISA cell lysis buffer: 1% Triton X-100 in PBS; before use add proteinase inhibitors 1 mM 
PMSF; 0.001 U/ml aprotinin and 4 μg/ml leupeptin 
Core ELISA Conjugate solution: for 10x 10-well strips mix 170 µl conjugate concentrate with 16.83 
µl conjugate diluent at least 30 min before usage 
Cytomix: 120 mM KCl; 0.15 mM CaCl2; 10 mM potassium phosphate buffer (pH 7.6); 25 mM Hepes 
(pH 7.6); 2 mM EGTA; 5 mM MgCl2; pH of the solution was adjusted to pH 7.6 with KOH; before use, 
ATP (pH 7.6) and glutathione were freshly added to a final concentration of 2 mM and 5 mM, 
respectively. 
DNA loading buffer: 1 mg/ml bromophenolblue blue; 2 mg/ml xylene cyanol; 1mM EDTA; 50% 
sucrose 
FACS assay buffer: 1x PBS; 0.1% BSA (w/v); 0.005% sodium azide (w/v) 
GITC solution: 4 M Guanidine thiocyanate; 25 mM sodium citrate; 0.5% sarcosyl.  
0.1 M β-mercapto-ethanol (70 µl per 10 ml) was added before use, solution was then usable for one 
month. 
Glyoxal loading buffer: 0.25 mg/ml bromophenolblue blue; 0.25 mg/ml xylene cyanol; 10 mM NaPO4 
(pH 7.0); 50% (v/v) glycerol 
HBS (2x): 50 mM Hepes pH 7.05; 10 mM KCl; 12 mM Dextrose*H2O; 280 mM NaCl; 1.5 mM 
Na2HPO4; pH adjusted with HCl; sterile filtration; store at -20°C. 
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Ligase buffer (10x): 400 mM Tris-HCl; 100 mM MgCl2; 100 mM DTT, 5 mM ATP 
Luciferase assay buffer: 25 mM glycyl glycine; 15 mM potassium phosphate-buffer (pH 7.8); 15 mM 
MgSO4; 4 mM EGTA; before use, addition of 1 mM DTT and 2mM ATP 
Luciferase lysis buffer: 1% Triton X-100; 25 mM glycyl glycine; 15 mM MgSO4; 4 mM EGTA; storage 
at 4 °C; before use, addition of 1 mM DTT  
Luciferase substrate solution: 1:5 dilution of 1 mM luciferin solution with 25 mM glycyl glycine 
solution  
Methylene blue: 0.03% methylene blue; 0.3 M NaAc; pH 5.2 
Mops buffer (10x): 0.4 M Mops, 0.1 M NaAc; 0.01 M EDTA; pH 7 with NaOH  
NaPO4 pH 7.0 (1 M): mix 423 ml 1M NaH2PO4 with 577 ml 1M Na2HPO4 
Northern blot hybridization solution: 5x SSC; 5x Denhardt-Solution; 50% (w/v) formamide; 1% (w/v) 
SDS; after addition of 100 μg/ml salmon sperm DNA, solution was used for prehybridization  
Northern blot wash I: 2x SSC; 0.1% SDS 
Northern blot wash II: 0.2x SSC; 0.1% SDS 
NPB buffer: 50 mM Tris/HCl (pH 7.5); 150 mM NaCl; 1% DOC; 1% NP-40; 0.1% SDS; store at 4°C. 
Before use add 1 mM PMSF and 1 mU Aprotinin per ml 
OPD substrate solution: for 10x 10-well strips dissolve 4 OPD tablets in 24 ml substrate buffer  
PBS (10x): 80 mM Na2HPO4; 20 mM NaH2PO4; 1.4 M NaCl 
PCR buffer (10x): 100 mM Tris/HCl (pH 8.3); 500 mM KCl; 15 mM MgCl2; 0.01% gelatin 
PEG/LiAc: 40% PEG 4000; 10 mM Tris-HCl; 1 mM EDTA; 100 mM LiAc; pH 7.5 
Protein sample buffer new (2x): 150 mM Tris/HCl (pH 6.8); 1.2% SDS; 30% (v/v) glycerol; 15% (v/v) 
β-mercapto-ethanol; 1.8 mg bromophenolblue blue 
Protein sample buffer old (2x): 200 mM Tris/HCl (pH 8.8); 5 mM EDTA; 0.1% bromophenolblue;  
10% (w/v) sucrose; before use add 3% SDS and 2% β-ME 
Protein sample buffer old (6x): 600 mM Tris/HCl (pH 8.8); 15 mM EDTA; 0.3% bromophenolblue;  
30% (w/v) sucrose; before use add 9% SDS and 6% β-ME 
RC assay buffer (10x): 200 mM Tris/Cl pH 7.5; 100 mM MgCl2; 50 mM KCl 
RC lysis buffer: 10 mM Tris/Cl pH 7.5; 10 mM KCl; 1.5 mM MgCl2; 0.5 mM PMSF;  
2 µg/ml Aprotinin 
RC resuspension buffer: 10 mM Tris/Cl pH 8.0; 10 mM NaCl; 15% glycerol 
RNA loading buffer for formaldehyde gels: 50% (v/v) glycerol; 0.25 mg/ml bromophenolblue blue; 
0.25 mg/ml xylene cyanol; 1 mM EDTA (pH 8.0) 
SDS-PAGE resolving gel buffer: 1.5 M Tris/HCl pH 8.8; 0.4% (w/v) SDS 
SDS-PAGE stacking gel buffer: 1M Tris/HCl pH 6.8; 0.8% (w/v) SDS 
SSC (20x): 3 M NaCl; 0.3 M sodium citrate 
TAE (50x): 242 g Tris; 100 ml 0.5 M Na2EDTA (pH 8.0) and 57.1 ml glacial acetic acid. The volume 
was adjusted to 1 liter. 
TE/LiAc: 10 mM Tris-HCl; 1 mM EDTA; 100 mM LiAc; pH 7.5 
TE: 10 mM Tris/Cl (pH 8.0), 1 mM EDTA 
TGS (10x): 250 mM Tris; 1.92 M glycine; 1% SDS 
Thermo-Pol-Puffer (10x): 100 mM Tris/Cl (pH 8.3); 500 mM KCl; 15 mM MgCl2; 0.01% gelatine 
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Transcription buffer RRL (5x): 400 mM Hepes (pH 7.5); 60 mM MgCl2; 10 mM spermidine; 200 mM 
DTT 
Western blot blocking buffer: 1x PBS; 0.5% (w/v) Tween 20; 2-5% milk powder 
Western blot semi-dry buffer: 48 mM Tris; 39 mM glycine; 0.00375% SDS; 20% methanol 
Western blot stripping solution (PVDF): 0.2 M NaOH 
Western blot tank blot buffer: 20 mM Tris; 150 mM glycine; 20% methanol; store at 4°C  
Western blot wash buffer: 1x PBS; 0.5% (w/v) Tween 20 
Z buffer/X-gal: per 100 ml Z buffer add 270 µl β-ME and 1.67 ml [20mg/ml; in N,N-dimethyl-
formamide] X-gal 
Z buffer: 60 mM Na2HPO4; 40 mM NaH2PO4; 10 mM KCl; 1 mM MgSO4; pH 7.0; sterile filtrated 
 
2.2 Preparation, analysis, and manipulation of nucleic acids 
2.2.1 Plasmid DNA isolation 
Small scale preparations of low copy plasmid DNA were performed with the NucleoSpin® Plasmid kit 
from Macherey-Nagel (Düren, Germany) according to the manufacturer’s protocol.  
Small scale preparations of high copy plasmid DNA were performed with the NucleoSpin® Plasmid 
Quick Pure kit from Macherey-Nagel (Düren, Germany) according to the manufacturer’s protocol.  
Medium scale preparations of plasmid DNA were performed with the NucleoSpin® Plasmid kit from 
Macherey-Nagel (Düren, Germany). Bacteria from 80-100 ml of overnight culture were pelleted by 10 
min centrifugation at 6,000 x rpm (4°C; rotor F15, FIBERLite®, Piramoon Technologies, in a Sorvall 
RC 5C plus centrifuge) and resuspended in 5 ml buffer A1. Then, cells were lysed by addition of 5 ml 
buffer A2 and incubated for 5 min at RT. After addition of 6 ml buffer A3 and further 5 min incubation 
at RT, solution was clarified by centrifugation for 20-30 min at 12,000 x rpm (4°C; rotor F15). The 
supernatant was filtered through gauze and loaded onto four NucleoSpin® Plasmid columns. These 
were then washed twice with AW buffer (500 µl, 50°C) and once with 700 µl buffer A4. After drying the 
columns, DNA was eluted twice by applying 50 µl 10 mM Tris pH 8.0 (70°C). 
Large scale preparation of plasmid DNA was performed by using QIAGEN® Plasmid Maxi kit from 
QIAGEN (Hilden, Germany) according to the manufacturer’s protocol.  
 
2.2.2 Agarose gel electrophoresis 
DNA molecules can be separated according to their size by agarose gel electrophoresis. Therefore 
DNA was mixed with 1/10 vol 10x bromophenolblue blue loading dye and loaded onto an agarose gel. 
A molecular weight marker from MBI Fermentas (Lambda-DNA/Eco130I/MluI or pUC19 DNA/MspI; St. 
Leon-Rot, Germany) was used for comparison to determine the size of the DNA fragments. In general 
1-2% agarose gels were prepared for separation of DNA fragments. 1x TAE was used as running 
buffer; running-conditions were 5-10V/cm. For a better separation of very small fragments, agarose 
concentration was increased up to 2.5%. In the case of very large fragments, it was decreased to 
0.8% agarose. For visualization of the DNA, ethidium bromide was added to the gel in a final 
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concentration of 1 μg/ml. Gels were documented by a video supported system after radiation with UV-
light (312 nm).  
 
2.2.3 DNA extraction from agarose gels 
Extraction and purification of DNA from agarose gels was performed by using the NucleoSpin® Extract 
II kit from Macherey-Nagel, (Düren, Germany) according to the manufacturer’s protocol. 
 
2.2.4 Phosphorylation and dephosphorylation of DNA 
Linearized plasmid vectors were dephosphorylated by calf intestine phosphatase (CIP; NEB) to avoid 
religation. 2 U CIP per µg vector were used in the appropriate buffer, subsequently to restriction 
digest, for 30-60 min at 37°C. The dephosphorylated DNA was purified by a preparative agarose gel. 
For the phosphorylation of synthetic oligonucleotides, the polynucleotide kinase (PNK, Amersham) 
was used. 150 pmol of the oligonucleotide was mixed with 1 µl 10x ligase buffer (400 mM Tris-HCl; 
100 mM MgCl2; 100 mM DTT, 5 mM ATP) and 2 µl [10 U/µl] PNK in a total volume of 50 µl and 
incubated for 1 h at 37°C. For the annealing of complementary oligonucleotides, 25 µl of each 
phosphorylated oligonucleotide were mixed and incubated for 5 min at 98°C. During cooling down to 
RT, the annealing of the single strands to a double strand fragment occurred, which subsequently 
could be cloned into an appropriate vector. 
 
2.2.5 Ligation of DNA-fragments 
For standard ligation 0.1 pmol of digested vector DNA and 0.3 pmol of insert were used. For achieving 
reaction conditions 1 µl 10x ligase buffer (MBI-Fermentas, St. Leon-Rot), 1U T4-DNA ligase (MBI-
Fermentas) and water were added to a final volume of 10 µl. After incubation at RT for 2 h (or ON at 
16°C) the ligation mix was added directly to competent bacteria for transformation. To avoid a high 
number of background colonies caused by religation of the vector, the vector DNA was incubated 
subsequent to the restriction digest for 30 min at 37°C in 1x reaction buffer with 2 U calf intestinal 
alkaline phosphatase (CIP; NEB, Frankfurt/Main, Germany) per µg linearized vector DNA, in order to 
dephosphorylate the 5’ ends. After preparative gel electrophoresis, DNA was extracted, purified, and 
used for ligation.  
 
2.2.6 Transformation of E. coli 
Competent bacteria DH5α were generated by the CaCl2-method. For transformation 100 µl bacteria 
suspension were incubated with plasmid DNA or ligation reactions for 30 min on ice. After heat shock 
of the cells at 42°C for 2 min, a 5 min incubation on ice followed. Cells were mixed with 1 ml of LB-
medium and incubated for 20-40 min at 37°C (rocking thermo bloc). After centrifugation for 2 min at 
6,000 rpm, supernatants were removed and cells resuspended in 200 µl of LB medium. After plating 
the cells on an antibiotic-containing LB-agar plate, colonies were grown over night at 37°C. 
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2.2.7 Analysis of DNA with restriction enzymes 
Restriction digests of DNA were performed with enzymes from the manufacturers NEB (Frankfurt/M) 
and Böhringer (Mannheim). Depending on the amount of DNA, restrictions were performed in a total 
volume of 15 to 200 µl (≤ 0.1 µg/µl, standard: 15 µl analytic digestions, preparative digestions 100 µl). 
Usually, reactions were performed in 1x reaction buffer for 2 h at the recommended temperature. The 
amount of enzyme added to the reactions was dependent on the DNA concentration and on the unit 
definition given by the manufacturers. One unit of endonuclease activity is defined as the amount of 
enzyme that is needed to completely digest 1 µg substrate DNA (often DNA of the λ-bacteriophage) 
within one hour. 1 µg λ-DNA corresponds to 1/32 pmol of λ-DNA molecules. Therefore, complete 
digestion of 1 pmol λ-DNA within one hour is achieved when 32 units of an enzyme cutting the DNA 
once are added. 
 
2.2.8 Purification and precipitation of DNA  
Purification of DNA after digestion was performed by phenol/chloroform extraction. In general, the 
DNA was mixed with 1/10 volume of 3M NaAc pH 6.0 and extracted twice with 1 volume TE-saturated 
phenol and once with 1 volume chloroform (3 min, 13,000 rpm). The upper phase harboring the DNA 
was constantly transferred into a new tube. Finally, the DNA was precipitated by addition of 2.5 
volumina ethanol. The sample was then incubated for 30 min at –20°C and centrifuged for at least 25 
min at 13,000 rpm. The precipitated DNA was washed once with 70% ethanol and dissolved in an 
appropriate volume of water. As an alternative method the ‘QIAEX II Gel extraction Kit’ of Qiagen 
(Hilden) was used according to the manufacturer’s protocol to purify and concentrate DNA in a small 
volume of buffer.  
 
2.2.9 Polymerase Chain Reaction (PCR) 
PCR is a method to selectively multiply a defined DNA sequence from a complex template DNA. The 
flanking sequences of the target DNA are used to generate a sense and an anti-sense oligonucleotide 
primer (usually 18-30 bp). The opposed primers are designed in a way that they surround the target 
sequence. The primers are used as the starting point by the polymerase for amplification. Chain 
elongation in 5´- to 3´-direction is yielded by addition of dNTPs. The steps of PCR amplification are as 
follows: 
o Heat denaturation of the double-stranded template DNA at 95°C 
o Primer annealing to the complementary sequences of the single stranded target (42-59°C) 
o Extension by the action of DNA polymerase at 68°C or 72°C (synthesis efficiency around 1 
kb/min) 
After primer extension the mixture is heated again to separate the strands. Cooling down the mixture 
allows the primers to hybridize with the complementary regions of newly synthesized DNA. Each cycle 
literally doubles the content of the original target DNA. In general, 20-30 cycles are run yielding a 106- 
to 109-fold increase of the target DNA. 
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The reaction mixture was prepared on ice. Each reaction contained 250 µM dNTPs (each dNTP), 1x 
buffer, 1 pmol/µl primer, H2O, 100 ng-1µg template DNA (for cloning PCR) and  
1 µl of polymerase (FideliTaq™) which was added in a final step. The total reaction volume usually 
was 50 µl. Annealing temperature and also elongation time depended on the primer composition and 
the length of the amplified sequence, respectively. All nucleotide sequences of PCR products were 
confirmed by sequencing. 
Standard program for PCR: 
 
 
2.2.10 Site directed mutagenesis 
To introduce mutations in a nucleotide sequence, an overlap PCR92 was performed. For each 
mutagenesis, two mutagenesis primers were required, one in sense, the other one in anti-sense 
direction. Both were complementary to each other and harbored the desired mutation. Furthermore, 
two primers flanking the region that will be mutated upstream and downstream were necessary. Two 
separated PCRs were performed. One PCR contained the upstream binding sense primer and the 
anti-sense mutagenesis primer, the second one the sense mutagenesis primer and the anti-sense 
primer binding downstream. The PCR products overlapped in the mutagenesis region, i.e. the 
mutagenesis primer binding sites. PCR products were purified by agarose gel electrophoresis and 
used for a third PCR containing the sense and anti-sense primer flanking the mutagenesis region 
upstream and downstream. The PCR product possessed now the mutation at the desired site and was 
cloned into the appropriate vector. 
 
2.2.11 DNA sequencing analysis  
Nucleotide sequences of the final constructs were confirmed by automated nucleotide sequencing 
using an ABI 310 sequencer (Applied Biosystems). Big dye version 1.1 (Applied Biosystems) was 
used for cycle sequencing according to the instruction of the manufacturer with slight modifications. 
200-500 ng of plasmid DNA was mixed with 2 µl big dye mix (containing buffer, deoxy- and 
fluorochrome-labeled di-deoxy-nucleotides and polymerase), 1 µl sequencing primer (5 pmol/µl), 1 µl 
5x buffer and water to a final volume of 10 µl. The following program was used for cycle sequencing: 
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To remove unincorporated dye-labeled di-deoxy nucleotides the reaction was scaled up to 100 µl 
containing 0.2% SDS and boiled for 5 min at 98°C. Afterwards DNA solution was mixed with 10 µl 3M 
NaAc and DNA fragments were precipitated with 2.5 volumina ethanol by centrifugation for 20 min at 
maximum speed, RT. Finally, the DNA pellet was washed once with fresh 80% ethanol, air-dried and 
dissolved in 20 µl formamide. Analysis of the resulting sequences was done by using vector NTI 
(Invitrogen). 
 
2.2.12 Transfection of cells with plasmid DNA 
DNA was transfected by Effectene (Qiagen) or Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. 
 
2.2.13 Quantification of DNA and RNA with absorption spectroscopy 
The concentration of nucleic acid-containing solutions was determined by using spectrophotometry. 
A260 measurements are quantitative for nucleic acid preparations in microgram quantities, but 
absorbency readings at 260 nm cannot discriminate between DNA and RNA. The ratio of absorbance 
at 260 and 280nm can be used as an indicator of nucleic acid purity. Proteins for example, have peak 
absorption at 280 nm that will reduce the A260/A280 ratio. Absorption at 320 nm is an indicator for 
particulates in the solution or dirty cuvettes. Contaminations by aromatic moieties such as phenol 
absorb at 230 nm. Before measurement, samples were diluted 1:50 to 1:100 with 10 mM Tris pH 8. 
The concentration of the sample was calculated by using the Lambert-Beersche law CDNA[µg/ml]= 
OD260 x ε x dilution factor. (εDNA: 40; εRNA: 50)  
 
2.2.14 In vitro transcription 
For the generation of defined 5’-ends either plasmids were linearized with the appropriate restriction 
endonucleases to prepare “run off” transcripts, or constructs were used carrying the genomic ribozyme 
of hepatitis δ (δg) just downstream of the 5’-end of the RNA. DNA was extracted with phenol and 
chloroform, precipitated with ethanol, and dissolved in RNase-free water. In vitro transcription reaction 
mixtures contained 80 mM HEPES (pH 7.5), 12 mM MgCl2, 2 mM spermidine, 40 mM dithiothreitol 
(DTT), 3.125 mM of each nucleoside triphosphate, 1 U of RNasin (Promega)/µl, 0.05 µg of plasmid 
DNA/µl, and 0.8 U of T7 RNA polymerase (Promega)/µl. After 2 h at 37°C, an additional 0.4 U of T7 
RNA polymerase/µl was added, and the reaction was incubated for another 2 h. Transcription was 
terminated by the addition of 1.2 U of RNase-free DNase (Promega) per µg of plasmid DNA and a 30 
min incubation at 37°C. After extraction with acidic phenol and chloroform, RNA was precipitated with 
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isopropanol and dissolved in RNase-free water. The concentration was determined by measurement 
of the optical density at 260 nm, and the RNA integrity was checked by denaturing agarose gel 
electrophoresis. 
 
To generate α-32P-radiolabelled riboprobes for Northern hybridization, 0.5 µg linearized, 
phenol/chloroform extracted DNA was added to 4 µl 5x transcription buffer RRL, 2 µl 100 mM DTT, 40 
U RNasin, 2 µl 5 mM non-radioactive NTP mix (ATP, GTP, UTP), 2 µl 100 µM non-radioactive CTP, 5 
µl 50 µCi α-32P-CTP and 1 µl T3- or T7-RNA polymerase in a total volume of 20 µl. The mixture was 
incubated for 1 h at 37°C. Afterwards DNA, was degraded by addition of 1 µl DNase and the probe 
was cleared from non-incorporated nucleotides by using a Sephadex G25 column (Amersham). The 
probe was eluted from the column with 1 ml H2O according to the manufacturer’s protocol. 
 
2.2.15 RNA transfection by electroporation 
Single cell suspensions of naïve Huh7-Lunet cells were prepared by trypsinization of monolayers, and 
subsequent resuspension with DMEM complete. Cells were washed with PBS, counted, and 
resuspended at 107 cells per ml in Cytomix containing 2 mM ATP and 5 mM glutathione. Unless 
otherwise stated, 10 µg of in vitro transcribed RNA was mixed with 400 µl of the cell suspension by 
pipetting, electroporated, and immediately transferred to 12-20 ml of complete DMEM. Electroporation 
conditions were 960 µF and 270 V by using a Gene Pulser system (Bio-Rad, Munich, Germany) and a 
cuvette with a gap width of 0.4 cm (Bio-Rad). Transfected cells were harvested at different time points 
and analyzed by Northern blot, luciferase assay or FACS. 
For selection of cell lines with persistent replicons, 1 µg in vitro transcript of a selectionable replicon 
was transfected and the cells seeded after electroporation in 20 ml complete DMEM on a 15 cm dish. 
24 h after electroporation medium was replaced by DMEM complete containing the appropriate 
antibiotic and changed weekly until resistant colonies appeared. These colonies were either picked or 
unified and passaged until enough cells were present for cell stocks. 
 
2.2.16 RNA formaldehyde gel electrophoresis 
To obtain 100 ml of a 1% gel, 1 g agarose was dissolved in 72 ml of water by boiling and then cooled 
down to 60°C. Before gel polymerization, 10 ml 10x MOPS buffer and 18 ml 12.3 M formaldehyde 
were added. For preparation of the samples, 3 µl of in vitro transcript were mixed with 2.5 µl 10x 
MOPS buffer; 4.5 µl 12.3 M formaldehyde and 12.5 µl formamide in a total volume of 25 µl and 
incubated for 15 min at 55°C. Then the mixture was incubated for 5-10 min at RT and 1.5 µl ethidium 
bromide solution (10 mg/ml) was added. After further 5 min incubation time, 10 µl RNA loading dye 
was added and the sample was loaded onto the gel. Electrophoresis was performed in 1x MOPS-
buffer at 5 V/cm. 
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2.2.17 Total RNA isolation from eukaryotic cells 
Total RNA from mammalian cells was prepared by a single-step isolation method as previously 
described40.  Briefly, 1x107 cells were lysed with 750 µl of GITC solution. Pipetting the solution up and 
down sheared the genomic DNA. Then 1/10 volume 2 M NaAc (pH 4) and 1 volume acidic phenol were 
added to the mixture. After addition of 1/5 volume chloroform, the mixture was vortexed and incubated 
on ice for 15 min. The phases of the milky solution were separated again by 10 min centrifugation at 
13,000 rpm, 4°C, and the RNA containing upper phase was transferred into a new tube. During this 
step, the interphase should not be swirled up, since it contains the degraded DNA. Now the RNA was 
precipitated by addition of 1 volume isopropanol. After 30 min incubation at minus 20°C, the RNA was 
pelleted by centrifugation for 15 min at maximum speed, 4°C. Finally the pellet was washed once with 
70% ethanol and dissolved in an appropriate volume of water (25 µl for 6 cm dish). The RNA was 
stored at -70°C, whereas 2 µl of it were used for quantification. 
For quantitative RT-PCR, total RNA from eukaryotic cells was prepared by using the NucleoSpin RNA 
II kit from Macherey-Nagel (Düren, Germany) according to the manufacturer’s protocol. 
 
2.2.18 RNA glyoxal gel electrophoresis 
Denaturing glyoxal agarose gel electrophoresis was performed for Northern blot analysis or in vitro 
replicase activity assays. 1% agarose was solved in H2O, then NaPO4 pH 7.0 to final concentration of 
10 mM was added. During sample preparation, up to 10 µg RNA in a volume of 10 µl were mixed with 
4.1 µl 100 mM NaPO4 pH 7.0, 6 µl 6 M deionized glyoxal, and 20.5 µl DMSO (no premix!), incubated 
at 50°C for 1 h, briefly cooled on ice, and mixed with 10.9 µl glyoxal loading buffer. 25 µl of the sample 
were loaded onto the gel. Electrophoresis was performed in 10 mM NaPO4 pH 7.0 at 4V/cm gel. To 
keep the pH constant, the buffer was mixed by magnetic stir bars from 5-10 min after begin of the 
electrophoresis until its end. 
 
2.2.19 Northern blot analysis 
To determine the quantity of HCV RNA within total cellular RNA, Northern hybridization was performed 
using α-32P CTP labeled complementary riboprobes. Total RNA was prepared by a single-step 
isolation method as described previously (paragraph 2.2.13). Up to 10 µg of total RNA in 10 µl H2O 
were mixed 4.1 µl 100 mM NaPO4 ph 7, 6 µl 6M glyoxal, and 20.5 µl DMSO, and denatured for 1 h at 
50°C. Samples were mixed with 10.9 µl glyoxal RNA loading dye and separated by denaturing 
agarose gel electrophoresis. RNA was transferred to positively charged nylon membranes (Hybond-
N+; Amersham Biosciences, Freiburg, Germany) with 50 mM NaOH (0.2 bar low pressure for 1 h, 
vacuum transfer machine from Keutz, Gießen) and cross-linked by UV-irradiation. For prehybridization 
of the membrane, it was incubated for 15 min at 58°C in hybridization solution containing salmon 
sperm DNA. Positive-strand HCV RNA was detected by hybridization with α-32P-labeled negative-
sense riboprobe complementary to nt 5979 to 6699 of the HCV JFH1 isolate (pBSK- C1 5979-6699 x 
KpnI → T3) in hybridization solution at 58°C ON. Negative-strand HCV RNA was detected by 
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hybridization with α-32P-labeled positive-sense riboprobe complementary to nt 5979 to 6699 of the 
HCV JFH1 isolate (pBSK- C1 5979-6699 x EcoRI → T7). Hybridization with a β-Actin-specific 
riboprobe was used to monitor equal sample loading in each lane of the gel (pBSK β-Actin x HindIII → 
T7). Membranes were washed twice with 2x SSC/0.1% SDS for 15 min at 58°C, and then washed 
twice with 0.2x SSC/0.1% SDS for 15 min at 58°C (additional third wash at 80°C for 15 min possible to 
reduce background), briefly dried and signals were detected by autoradiography. 
As quantity standards for the positive-strand RNA served defined numbers (109, 108, and 107 RNA 
molecules per 25 µl) of in vitro transcripts of pFKi389neoNS3-3’/ET (x AseI x ScaI → T7) and for the 
negative-strand RNA served in vitro transcripts of pFKi389neoNS3-3’/5.1 (x AscI → T3). 
 
2.2.20 HCV RNA quantification by RT-PCR 
For quantitative analysis of HCV RNA from HCV-harboring cells RT-PCR, RNA was prepared by using 
“NucleoSpin® RNA II” columns (Macherey-Nagel, Düren, Germany), and eluted in a volume of 40 µl 
RNase-free water. Concentration of the RNA was determined spectrometrically and adjusted to 0.1 
µg/µl. Five microliter of the respective sample was used for quantitative RT-PCR analysis employing 
an ABI PRISM 7000 Sequence Detector (Applied Biosystems, Darmstadt, Germany). Amplifications 
were conducted at least in duplicate with the One Step RT-PCR Kit (Qiagen, Hilden, Germany) using 
the following primers and 3´-phosphate-blocked, 6-carboxyfluorescine (6-FAM)- and tetrachloro-6-
carboxyfluorescine (TAMRA)-labeled probes (TIB Molbiol, Berlin, Germany): HCV-Con1 Taqman 
probe, 5´-6FAM-TCC TGG AGG CTG CAC GAC ACT CAT-TAMRA-3´; HCV-Con1-S66, 5´-ACG CAG 
AAA GCG TCT AGC CAT-3´; and HCV-Con1-A165, 5´-TAC TCA CCG GTT CCG CAG A-3´; HCV-
JFH1 Taqman probe, 5´-6FAM-AAA GGA CCC AGT CTT CCC GGC AA-TAMRA-3´; HCV-JFH1-
S147, 5´-TCT GCG GAA CCG GTG AGT A-3´; HCV-JFH1-A221, 5´-GGG CAT AGA GTG GGT TTA 
TCC A-3´. GAPDH S  5’-GAA GGT GAA GGT CGG AGT C-3’; GAPDH A  5’-GAA GAT GGT GAT 
GGG ATT TC-3’. Reactions were carried out in three stages exactly as already described172.  
For SYBR green based qRT-PCR, the QuantiTect SYBR green kit from Qiagen was used and gene 
specific primer pairs were designed and ordered from MWG. The reaction mix was set up to the 
manufacturer’s recommendation but scaled down to 15 µl (1.5 µl total RNA). Reactions and detections 
were performed using an ABI PRISM 7000 Sequence Detector (Applied Biosystems). The passive dye 
ROX had to be disregarded due to the small volume. ANXA2 SYBR green primer: ANXA2 SYBR S 5’-
GCCATCAAGACCAAAGGTGT-3’; ANXA2 SYBR A 5’-TCAGTGCTGATGCAAGTTCC-3’. GAPDH 
primers see above. 
Each gene was typically measured in triplicates in each RNA sample. For data evaluation, in most 
cases, automatic detection of baseline and threshold values was used. Resulting Ct values for a target 
gene were subtracted from the Ct value of the GAPDH gene in the same sample RNA to yield the ΔCt 
value. To compare expression levels of a given gene between several RNA samples (cell lines), the 
average difference between their ΔCt values was calculated, ΔΔCt, and, for the sake of easier 
interpretation, delogarithmized using a base of 2, assuming an idealized PCR reaction (doubling the 
product level in every cycle). Error bars in diagrams represent the limits of the standard deviation as 
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calculated on basis of the ΔCt values and only subsequently delogarithmized. They can therefore be 
looked at as conservative estimates of the standard error. 
 
2.3 Expression, purification, and analysis of proteins 
2.3.1 Isolation of HCV replication complexes 
Replicon cells showing an 80-90% confluency were washed once with PBS, scraped in PBS (2 ml per 
15 cm dish) and pelleted at 800 g (4°C, 10 min). Cells were resuspended to a density of 2.5 x 107 
cells/ml in hypotonic buffer (10 mM Tris/Cl pH 7.5; 10 mM KCl; 1.5 mM MgCl2; 0.5 mM PMSF; 2 µg/ml 
Aprotinin) and lysed by 75 strokes with a dounce homogenizer. Nuclei and unbroken cells were 
removed by centrifugation at 1,000 x g for 10 min at 4°C. The intracellular membranes in the resulting 
supernatant (S1) were then sedimented on 300 µl of 60% (w/w) sucrose in 10 mM Tris-HCl (pH 7.5), 
10 mM KCl, 1.5 mM MgCl2 in an ultracentrifuge at 71,000 x g for 1h at 4°C. The resulting supernatant 
(S2) was carefully removed, the membrane fraction containing the CRCs was resuspended in the 
sucrose cushion to obtain ca. 500 µl CRC fraction from 2x108 cells. Total protein concentrations of 
standard CRC preparations are in the range of 5 mg /ml CRC. Alternatively, S1 obtained from 2x108 
cells was directly pelleted for 1 h at 71,000 x g, resuspended in 200 µl 10 mM Tris-HCl, pH 8.0, 10 mM 
NaCl, 15% glycerol to obtain the CRC fraction and stored in aliquots at -70°C.  
 
2.3.2 Sucrose density gradient centrifugation 
Resuspended CRCs that were sedimented on a sucrose cushion were loaded under a continuous 15-
60% (w/w) sucrose gradient (sucrose in 10 mM Tris-HCl (pH 7.5), 10 mM KCl, 1.5 mM MgCl2) and 
spun in an ultracentrifuge at 71,000 x g for 16 h at 4°C. The gradient was aliquoted in 1 ml fractions 
whose density was determined by their index of refraction using a refractometer. Glycerol was added 
to an end concentration of 15%, before the fractions were stored at -70°C. 
 
2.3.3 Bradford assay for protein quantification 
Using this method, protein amounts ranging from 1-10 µg can reliably be quantified. 5 µl of a sample 
were filled up to 100 µl with an appropriate buffer, mixed with 1 ml Bradford reagent, and incubated at 
RT for 2 min. 100 µl buffer was used as blank value and incubated in the same way. To generate a 
standard curve, BSA was used in serial dilutions (1-20 µg). Absorption was measured at 595 nm and 
was correlated with the protein amount via the standard curve. Measurement was performed using 
duplicates. 
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2.3.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins can be separated by their molecular weight under denaturing conditions in a sodium dodecyl 
sulfate polyacrylamide gel. Therefore, gels were made using an acryl amide concentration of between 
8 and 12% for the resolving gel. The acryl amide/bisacrylamide amide solution was a 30% stock 
solution, containing a 29:1 composition of acryl amide: bisacrylamide amide. The polymerization 
reaction was started after addition of 1/1,000 volume TEMED and 1/1,000 volume saturated 
ammonium persulphate to the separating gel and it was poured immediately into gel casts. 5 ml of 
isopropanol was applied to remove air bubbles, and the gel was left to set for around 30 minutes. The 
stacking gel contained 5% acryl amide stock solution. Protein samples were denatured in protein 
sample buffer for 5 min at 95°C before loading onto the gel. Electrophoresis was performed in 1x TGS 
buffer at a steady current of 45 mA. To estimate the molecular weight of the sample proteins, a protein 
standard designated “Prestained Protein Marker“ (NEB, Schwalbach) was used for comparison. This 
standard was composed of a mixture of proteins with defined molecular weight. After electrophoresis, 
proteins were transferred onto a PVDF or nitrocellulose membrane for western blot analysis 
(described below in paragraph 2.3.5) or were stained with Coomassie blue solution for 20 min at 60°C. 
Thereby proteins were fixed within the gel. For destaining, gels were incubated for 20 min at 60°C in a 
5% methanol/5% acetic acid solution. For analysis of immunoprecipitated or radiolabeled proteins, the 
separating gel was dried and signals were detected by autoradiography. 
 
2.3.5 Western blot 
Proteins were separated by SDS-PAGE and after electrophoresis transferred to a polyvinylidene 
difluoride membrane (PVDF) (PolyScreen; NEN Life Science Products, Zaventem, Belgium) or 
nitrocellulose (Protran®, Whatman Schleicher & Schuell) using a semidry blotter (Bio-Rad, Munich, 
Germany). Blotting conditions were 1mA/cm2 for ≥ 1 h. Membranes were incubated at least 1 h in 
blocking buffer (PBS containing 0.5% Tween 20 and 5% milk powder [w/v]) to saturate unspecific 
binding sites, and a primary antibody was added thereafter at a given dilution for 1 h (for dilutions of 
antibodies see Table in paragraph 2.1.3). After being washed three times with 0.5% Tween 20 in PBS, 
the membrane was incubated with a secondary antibody conjugated with horse radish peroxidase 
(Sigma-Aldrich) in blocking buffer for 1 h and washed three times as described above. Bound 
antibodies were detected by chemiluminescence using luminol and a specific enhancer (SuperSignal 
West Dura Extended Duration Substrate; KMF Laborchemie, St. Augustin, Germany) or the ECL+-
system (Amersham) according to the manufacturer’s protocol. Chemiluminescence was detected by 
exposure to X-ray films. 
 
2.3.6 Proteinase K, S7 nuclease and Triton X-100 treatment of CRCs 
To test the protease and nuclease resistance of the CRCs, different amounts of [20 mg/ml] proteinase 
K (Sigma; 0.8 or 8 mg/ml final concentrations) and/or S7 nuclease (0.2 or 2 U/µl final concentrations; 
together with 1 mM CaCl2) and/or 1% (v/v) Triton X-100 were directly added to 50 µl of freshly 
prepared CRCs and incubated for 60 min at 25°C. After the incubation, proteinase K and S7 nuclease 
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were inactivated by the addition of 1 µl 100 mM PMSF and 1 µl 200 mM EGTA, respectively. 4 µl 
CRCs were directly analyzed by in vitro replicase assays, 2 µl were mixed with protein sample buffer 
and analyzed by SDS-PAGE and immunoblot. 10 µl CRCs were used for total RNA-preparation. Total 
RNA was dissolved in 10 µl water and 5 µl were subjected to Northern blot analysis. 
Fivefold concentrated fractions of proteinase K treated CRCs were generated by TCA precipitation.  
 
2.3.7 TCA precipitation 
The sucrose and glycerol concentration of CRC fractions were diluted at least twofold by addition of 
RC lysis buffer. This fraction was then mixed with 1 volume 100% TCA (trichloroacetic acid) and 1/5 
volume 20% SDS (end concentration 2%). After incubation for 1 h on ice, protein precipitates were 
pelleted for 20 min at 10,000 g (4°C). The supernatant was removed qualitatively. Pellets were solved 
in an appropriate volume of protein sample buffer by shaking for 10 min at RT. After solving, samples 
were denatured at 95°C for 5 min and then analyzed by SDS-PAGE. 
 
2.3.8 2-dimensional gel electrophoresis 
Sample preparation 
CRCs were prepared from 2x108 cells (replicon 9-13 or cured cells as negative control) by 
sedimentation of the intracellular membranes onto a sucrose cushion. This fraction was then treated 
with Proteinase K (final: 8 mg/ml) for 60 min at 25°C. After the incubation, proteinase K was 
inactivated by the addition of 1 µl 100 mM PMSF per 50 µl CRC fraction. This fraction was then 
subjected to sucrose gradient centrifugation and subsequently aliquoted into 1 ml fractions. The 
fractions were analyzed for density and protein amounts (by Bradford) as well as for in vitro replicase 
activity. The fraction containing most in vitro replicase activity and proteins was combined with its 
neighboring fractions and diluted with RC lysis buffer to reduce the sucrose concentration. The therein 
comprised intracellular membranes were pelleted by ultracentrifugation at 284,300 g for 60 min. The 
pellet was lysed in 500 µl 2D protein solubilization buffer (for 4 ml: 608 mg thiourea; 80 mg CHAPS; 80 
mg SB3-10; 2.32 ml 8.5 M urea solution (deionized); 40 µl 100x protease inhibitor mix (2D compatible, 
Sigma); 100 µl tributylphosphine (2D compatible, Sigma); 40 µl IPG buffer pH 3-11NL (Amersham); 
300 U benzonase; ad 4 ml H2O (caution: very small volume needed!)) by vortexing and incubated for 
60 min at RT with regular vortexing. Then iodoacetamide was added to final concentration of 15 mM 
(15 µl of a freshly prepared 500 mM solution) and incubated for additional 90 min. Insoluble material 
was pelleted during 30 min at 100,000 g in a bench top ultracentrifuge (Beckman TL-100) and the 
cleared supernatant was collected. 
 
Isoelectric focusing 
IPG strips (Amersham 3-11NL) were loaded passively during rehydration. 1000 µg protein sample in 
350 µl 2D protein solubilization buffer were loaded in a strip holder, the IPG strip was placed on top, 
gel-side down, and overlaid with 2D mineral oil. After 10 h of rehydration, moist wedges of Whatman 
paper were placed between the ends of the strip and the electrodes to ensure conductivity. Then, 
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isoelectric focusing was performed in an IPGphor II unit (Amersham) using the following voltage 
scheme: 0 h 300 V – 3 h gradient to 3,500 V – 3 h 3,500 V – 12 h 5,000 V. 
 
Strip equilibration 
After isoelectric focusing, strips were either drained and frozen at -80°C or processed directly. 
Equilibration was done in two steps. In the first step 10 ml of 2D equilibration buffer were used per 
strip, supplemented with 2% DTT for reduction of thiol groups. The strip was incubated for 10 min, 
gently shaking in this solution. The first equilibration solution was discarded and the strip drained and 
then placed for 10 min into 10 ml of fresh 2D equilibration solution, supplemented with 2.5% 
iodoacetamide for alkylation of the reduced thiol groups, preventing unspecific disulfide-bridge 
formation. Afterwards, the strip was drained and ready for loading on the second dimension gel. 
 
2nd dimension electrophoresis 
Second dimension electrophoresis was standard SDS-PAGE. A 30x20 cm gel was prepared (typically 
10% polyacrylamide) without SDS; gels were 1 mm thick; no stacking gel (and no comb) was needed. 
The strip was carefully placed on the top surface of the polymerized gel plastic backing facing the 
glass plate. The strip was then overlaid with 0.5% high purity agarose in TGS to fix its position. 15 µl of 
prestained protein marker (NEB) were applied to a 0.5x1 cm piece of Whatman paper, which was then 
stuck into the agarose overlay next to one end of the IPG strip. The gel was run in standard TGS 
buffer at 45 mA per gel for 5-6 h until dye front reached the end of the gel. Gels were the fixed, silver 
stained and sealed in clear plastic foil. Protein spots of interest were investigated by mass 
spectrometry analysis in the Core Facility for Mass Spectrometry and Proteomics at the ZMBH, 
Heidelberg. 
 
2.3.9 Silver staining of proteins after SDS-PAGE 
Gels were fixed ON (or at least 1 h) in fixation solution 1 (50% methanol, 12% acetic acid). Then, they 
were fixed once for 30 min in fixation solution 2 (10% ethanol, 5% acetic acid) and twice for 15 min in 
fixation solution 3 (10% ethanol). Subsequently, gels were impregnated for 2 min in 0.0185% 
formaldehyde and 0.018% sodium thiosulfate and washed three times in H2O for 60 s. The gels were 
then stained with 0.2% silver nitrate and 0.0185% formaldehyde for 12 min. After washing twice with 
H2O for 30 s, the stain was developed in developer solution (3% sodium carbonate; 0.0185% 
formaldehyde; 0.000258% sodium thiosulfate) until staining intensity was as desired. Developing was 
stopped by addition of acetic acid directly to the developing solution (3%) and cooling on ice. The gel 
was then washed in 3% acetic acid and put in 3% acetic acid for longer term storage. 
 
2.3.10 HCV replicase activity assay 
HCV in vitro replicase activity was determined in a reaction mixture containing 20 mM Tris-HCl (pH 
7.5), 10 mM MgCl2, 5 mM DTT, 5 mM KCl, 40 µg/ml Actinomycin D, 20 µCi α-[32P]CTP, 10 µM CTP, 1 
mM each of ATP and UTP, 5 mM GTP, 2.5 mM phosphoenol pyruvate, 1 U pyruvate kinase (Sigma, 
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Taufkirchen, Germany), 1 U of RNasin, and 4 µl sample fraction in a total volume of 10 µl at 35°C for 
60 min. A radioactively labeled in vitro transcript corresponding to the length of a replicon RNA was 
used to determine the size of the reaction products. This length standard was generated by 
radiolabeled run-off transcripts of pFKi389neoNS3-3’/ET (x AseI x ScaI). In a total volume of 20 µl, 0.5 
µg linearized template DNA were incubated with 4µl 5x transcription buffer RRL buffer (400 mM Hepes 
(pH 7.5); 60 mM MgCl2; 10 mM spermidine; 200 mM DTT), 0.5 µl RNasin, 2.5 µl 25mM NTPs, 0.5 µl 
[α-32P]-CTP, and 1 µl T7 RNA polymerase, for 1 h at 35°C. After adjusting the volume of the samples 
with RC lysis buffer to 100 µl, reaction products were purified by phenol/chloroform extraction (1:1 mix, 
1 vol) and isopropanol precipitation (0.7 vol) and analyzed by denaturing glyoxal agarose gel 
electrophoresis followed by autoradiography. 
 
2.3.11 Metabolic 35S-labeling of proteins 
Lunet-T7 cells were seeded in 6-well plates and transiently transfected with T7 promoter dependent 
expression constructs encoding the Con1-derived NS proteins NS3-5B proteins or an individual NS 
protein, or the empty vector (pTM1) by Lipofectamine™ 2000 (Invitrogen) according to the 
manufacturer’s protocol. 4 h after transfection, cells were washed with DMEM without methionine and 
cysteine (DMEM; 2% dialyzed fetal calf serum; 10 mM Hepes; 2 mM L-glutamine) and then incubated 
in this medium for 60 min at 37°C (starving phase). Subsequently, medium was exchanged for DMEM 
without methionine and cysteine containing 100 µCi 35S per ml. Cells were incubated for 4-6 h at 37°C, 
then cells were washed with PBS and lysed for the subsequent immunoprecipitation by NPB buffer or 
0.5% TX-100 in PBS. 
 
2.3.12 Immunoprecipitation 
50 µl per IP of a 1:1 slurry of protein A (for polyclonal antibodies) or protein G (for monoclonal 
antibodies) SepharoseTM beads (Amersham Biosciences, Munich, Germany) were washed thrice in 
lysis buffer (NPB or 0.5% TX-100 in PBS) for equilibration (6,000 g, 4°C). Then they were incubated 
≥2 h at 4°C with the antibodies on a rotating wheel in lysis buffer (per IP: 6 µl polyclonal; 10 µl 
monoclonal) and afterwards washed three times. Equal amounts of cell lysates were incubated at 4°C 
for ≥2 h with equal amounts of protein A or G beads coupled with the antibodies. Subsequently, beads 
were washed three times with lysis buffer and bound proteins were resolved by 10% SDS-PAGE. 
Finally, in case of metabolic 35S-labeling, gels were dried and subjected to autoradiography or, in case 
of replicon cells, proteins were transferred to a PVDF membrane and detected by immunoblot assay.  
For stabilization of weak or transient protein interactions, cells were treated with the crosslinker DSP 
(Pierce). DSP was dissolved immediately before crosslinking in DMSO (20 mM). Cells were washed 
twice with PBS, and then DSP was added to a final concentration of 2 mM (in PBS) and incubated for 
30 min at RT. To stop the reaction , stop solution (1 M Tris pH 7.5) was added to final concentration of 
20 mM and incubated for 15 min at RT. Cells were washed once with PBS and lysed in NPB. 
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2.3.13 Transient silencing by siRNA 
Cells were transfected with siRNA by Lipofectamine™ 2000 (Invitrogen) or HiPerFect (QIAGEN). 
siRNA transfections of cell culture dishes up to 10 cm dishes by Lipofectamine™ 2000 were 
performed according to the manufacturer’s protocol but using 2.5 fold more siRNA and 1.5 fold more 
Lipofectamine reagent than recommended.  
15 cm dishes were transfected with siRNA by HiPerFect as following:  
4.8 µl [100 pmol/µl] siRNA were diluted in 2.4 ml DMEM without FCS (final 25 nM siRNA). Then 96 µl 
of HiPerFect reagent were added, mixed, and incubated for 5-10 min at RT. This solution was then 
added dropwise to the cells which were incubated for up to 3 d at 37°C. 
 
2.3.14 Immunofluorescence analysis (IF) 
In general, cells were seeded on cover slips in 24-well plates to be confluent at the time point of 
fixation. For infection, naïve cells were seeded on cover slips in 24-well plates at a density of 2 x 104 
per well 24 h prior to infection, followed by inoculation with 250 µl of filtered cultured supernatant for 4 
h. Transiently transfected cells were seeded on cover slips directly after electroporation (250 or 500 µl 
of cell suspension). For fixation, cells were washed three times with PBS and fixed in 4% 
paraformaldehyde solution for about 10 min at RT. Thereafter, cells were again washed three times 
with PBS and then stored for 2-3 days at 4°C or directly used for further preparation. For 
permeabilization, cells were incubated for 5 min with 0.5% Triton X-100 in PBS and washed 3 times 
with PBS prior to incubation with the first antibody. The primary antibody was diluted to the desired 
concentration with a 1x PBS buffer containing 3% BSA, to prevent unspecific binding of the antibody. 
After 45 min incubation at RT the cells were washed 3 times with PBS and incubated with the second 
antibody. This antibody was conjugated with fluorescent dyes (Alexa 488, Alexa 546) again diluted in 
3% BSA in PBS. After 30 min incubation in the dark, the cells were washed once with PBS and 
counterstaining of the nucleus was performed using DAPI (4’, 6’-diamidino-2-phenylindole; Molecular 
Probes, Karlsruhe, Germany). To this end, the cells were incubated for 1 min with a 1:4,000 diluted 
DAPI solution and immediately washed 3 times for 10 min with PBS. Finally, the cells were washed 
once with water and mounted on glass slides with Fluoromount G. 
 
2.3.15 Flow cytometry analysis 
For analyses of ANXA2 and HCV expression in silenced cells, cells were silenced twice by siRNAs. 
First silencing was performed using HiPerFect (Qiagen), second silencing was performed by co-
electroporation of siRNA (1000 pmol per electroporation) and HCV sg replicon RNA (10 µg; luc-
JFH/5A-eGFP). Cell monolayers were treated with PBS/0.2% EDTA to prepare single cell 
suspensions which were washed with PBS (700 rpm, 5 min) and passed through a cell strainer. Cells 
were fixed in 4% PFA (10 min, RT), stored at 4°C or directly used for antibody staining. 
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Staining of fixed cells 
Fixed cells were washed with PBS (4,000 rpm, 4 min, 4°C; in eppendorf table top centrifuge) and 
incubated with the first antibody (α-ANXA2, Gerke) diluted in PBS/0.5% saponin (500,000 cells per 
100 µl) on ice for 1 h. Permeabilization of the cells occurred during this incubation step. Cells were 
washed once with PBS and then incubated with the secondary fluorescence-coupled antibody 
(allophycocyanin, APC) diluted in PBS/0.5% saponin (500,000 cells per 100 µl) on ice for 1 h in the 
dark. Cells were washed twice with PBS, were resuspended in 200-500 µl PBS and analyzed 
immediately using a FACScan or FACSCalibur apparatus (BD Biosciences) and Cell Quest Pro 
software (Becton Dickinson). 
 
2.3.16 Luciferase assay 
For assaying the luciferase activity, cells were washed once with PBS, lysed directly on the plate in ice 
cold lysis buffer (500 µl/6-well; 350 µl/12-well) and frozen. Upon thawing, lysates were resuspended 
by pipetting and 100 µl were mixed with 360 µl of assay buffer and, after the addition of 200 µl of a 
200 µM luciferin solution, measured in a luminometer (Lumat LB9507; Berthold, Freiburg, Germany) 
for 20 s. All luciferase assays were done in duplicate measurements. 
 
2.3.17 Competence induction and transformation of yeast cells 
Y2H assays were performed according to the MATCHMAKER Two-Hybrid System 2 protocol 
(CLONTECH Laboratories).  
Briefly, a 50 ml YPD culture was inoculated with several colonies (2-3 mm in diameter) of the yeast 
strain Y187 and incubated at 30°C for 16-18 h. 250 ml fresh YPD medium were added to produce an 
OD600 of 0.2-0.3 and incubated at 30°C for 3 h. Cells were pelleted at 1,000 g (5min, RT) and then 
washed with 25-50 ml H2O (vortex). After pelleting the cells again (1,000 g, 5min, RT), the cell pellet 
was resuspended in 1.5 ml freshly prepared, sterile 1x TE/LiAc (10 mM Tris-HCl; 1 mM EDTA; 100 
mM LiAc; pH 7.5). These competent cells were now ready for transformation. 
0.2 µg of the DNA BD vector construct and 0.2 µg of the DNA AD vector construct were mixed with 0.1 
mg of herring testes carrier DNA and freshly denatured at 98°C for 20 min. Afterwards, this was mixed 
with 0.1 ml of competent yeast cells. Then 0.6 ml sterile PEG/LiAc solution (40% PEG 4000; 10 mM 
Tris-HCl; 1 mM EDTA; 100 mM LiAc; pH 7.5) were added, vortexed and incubated for 30 min at 30°C 
with shaking. DMSO was added to 10% and mixed gently by inversion. After heat shock (15 min at 
42°C), cells were chilled on ice and subsequently pelleted (5 s, 13,000 rpm). The cell pellet was 
resuspended in 0.5 ml H2O. 100 µl of the cell suspension were plated on a SD -Leu/-Trp agar plate 
and incubated at 30°C until colonies appeared. 
 
2.3.18 Y2H β-galactosidase filter assay  
This was a colony lift filter assay for qualitative blue/white screening from the MATCHMAKER Two-
Hybrid System 2 protocol (CLONTECH Laboratories). Fresh colonies (1-3 mm in diameter) should be 
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used. For each plate of transformants, a sterile Whatman #5 filter was presoaked in Z buffer/X-gal 
solution. A clean, dry filter was placed over the surface of the colony plate, carefully lifted and 
completely submerged (colonies facing up) in liquid nitrogen for 10 s. Filters thawed for 10 min at RT 
(permeabilization of cells) and were placed (colonies facing up) on a presoaked filter. They were 
incubated at 30°C (≤ 8 h) and checked for the appearance of blue colonies indicating an interaction of 
prey and bait. 
 
2.3.19 Quantitative detection of HCV core protein 
HCV core protein was quantified using the Trak C Core (Ortho Clinical Diagnostics, Neckargemünd, 
Germany) enzyme-linked immunosorbent assay (ELISA) according to the instructions of the 
manufacturer. When intracellular core expression was analyzed, cells were lysed in ice-cold PBS 
supplemented with 1% Triton X-100, 1 mM PMSF, and 0.1 µg/ml aprotinin. Lysates were cleared at 
20,000 g for 10 min and measured at a dilution of 1:10 (or higher) in PBS. Cell culture medium was 
filtered through 0.45 µm pore-size filters and either directly used for ELISA or diluted with DMEM 
complete medium prior to measurement. 
 
2.4 Working with viruses 
2.4.1 Lentiviral transduction of cells 
Calcium phosphate transfection of DNA was performed to introduce lentiviral vector plasmid DNA 
(pWPI) along with two packaging constructs into HEK293T cells in order to produce viral particles. We 
used the CalPhos mammalian transfection kit from Becton-Dickinson. 1.2x106 cells were seeded into a 
6 cm cell culture dish one day prior to transfection. On the next day, medium on the cells was changed 
for 4 ml of fresh complete DMEM. At least 1 h later, for transfection, 6.42 µg lentiviral vector (pWPI), 
6.42 µg gag-pol plasmid (pHIT60 for shRNA cell lines, pCMVΔR8.91 for HepG2 cells overexpressing 
ANXA2) and 2.14 µg VSV envelope glycoprotein plasmid (pCZ VSV-G for shRNA cell lines, pMD.G for 
HepG2 cells overexpressing ANXA2) were mixed and diluted to a final volume of 438 µl in H2O. Then, 
62 µl 2M CaCl2 and 500 µl of 2x HBS buffer were added and mixed well by pipetting up and down. 
The mixture was immediately added dropwise to the cells and the plate was gently swirled to evenly 
distribute the transfection mix throughout the plate. After 3-4 h. a fine precipitate formed which could 
be easily confirmed under the microscope. After 6-16 h, the medium was changed to fresh complete 
DMEM. On the day after transfection, the target cells (lunet, Huh7.5, and HepG2 cells, respectively) 
were seeded at 4x104 cells per well into a 12-well plate. 24 h later (48 h post transfection), the 
lentiviral particle containing supernatant from the 293T cells was harvested and replaced by another 4 
ml of fresh complete DMEM. The supernatant was filtered through a 0.45 µm syringe mounted filter 
twice to remove cells. From the target cells, the medium was aspired and 500 µl of the infectious 
supernatant were added to them per cell. 6-8 h later, the supernatant on the target cells was replaced 
with fresh infectious supernatant. On the next day, the medium from the 293T cells was harvested a 
second time (cells were discarded), again filtered twice through a 0.45 µm filter and pooled with the 
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infectious supernatant from the previous day (if remainders were left). Target cells were a third time 
supplied with new 500 ml of infectious supernatant for 4-6 hours and were then supplied with complete 
DMEM containing the appropriate selection antibiotic, zeocin, G418 or blasticidin. Target cells were 
incubated for another 72 hours or until they reached confluence and were then expanded to a 25 cm2 
cell culture flask. 
 
2.4.2 Preparation of Hepatitis C virus stocks 
Huh7-Lunet cells were electroporated with virus constructs as described above. Culture fluid of 
transfected cells was harvested and cleared by passing through 0.45 mM pore size filters. In case of 
Luc-JFH1 and Luc-Con1 medium was harvested 72 to 96 h after transfection, whereas maximal yield 
for Luc-Jc1 was obtained at 48 h. Jc1 wild type and Con1/wt virus containing supernatant was 
harvested as early as 24 h post electroporation. Virus preparations were used directly, or stored at 4 
°C or -80 °C. (Each cycle of freeze and thaw resulted in 2-fold reduction of infectivity!). As the virus is 
stable at 4 °C for at least several days, for short term storage virus preparations were kept at this 
temperature. 
 
2.4.3 HCV infection of cells 
For standard infection assays, cells were seeded at a density of 4 x 104 per well of a 12-well plate 24 h 
prior to inoculation with 500 µl of virus preparation. Maximum infectivity can be achieved when cells 
are inoculated for 4 h at 37°C. Depending on the experimental setup, cells were harvested or fixed at 
the appropriate time point. 
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3. Results 
It is known that the HCV replication complex harbors the non-structural proteins NS3 
to NS5B which are necessary and sufficient for viral RNA amplification as well as the 
viral RNA. However, different cellular host proteins seem to play an important role in 
the HCV RNA replication, too. Since most of the NS proteins possess membrane 
anchors or transmembrane domains, the HCV replication complex is tightly 
associated with intracellular membranes, probably derived from the ER. The first aim 
of the present work was the development of purification strategies in order to isolate 
enzymatically active HCV replication complexes thus allowing the identification of 
cellular host factors involved in HCV replication. 
3.1 Development of purification strategies for active viral 
replication complexes from HCV subgenomic replicon cells 
The source for the isolation and characterization of HCV replication complexes were 
Huh-7 cell clones persistently harboring subgenomic HCV replicons. These cells 
keep constant HCV RNA and protein levels over years, even in the absence of 
selective pressure173. 
3.1.1 Establishment of a replicase activity assay for purified HCV 
replication complexes 
Since the HCV replication complex (RC) is associated with intracellular 
membranes74, we decided to enrich and concentrate the replication complexes by 
differential centrifugation. Similar procedures for the preparation of RCs have already 
been described for HCV and related viruses8,52,86,125,210. The method is shown 
schematically in Fig. 8A. In order to isolate RCs, replicon cells of cell clone 9-13140 
were lysed in a hypotonic buffer and homogenized (total lysate, TL). The nuclei were 
pelleted (nuclei pellet; NP) and the cytoplasmic supernatant (S1) was again 
centrifuged. Thereafter, I received a second, largely membrane-free supernatant (S2) 
and a membrane-containing pellet in which the so-called crude replication complexes 
(CRCs) could be found in high concentrations. To test for in vitro replicase activity, 
the cell lysates were incubated with radiolabeled nucleotides in the presence of 
Actinomycin D and in the absence of exogenous template RNA. Reaction products 
were further analyzed by denaturing agarose gel electrophoresis (Fig. 8C). The 
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dominant product of in vitro replication was a single band which corresponded in size 
to the full-length replicon RNA (ca. 8 kb, arrowhead). HCV replicase activity was 
already detectable in the total hypotonic lysate of replicon cells but was enriched in 
CRCs that were obtained by pelleting the membranous material contained in 
supernatant 1. The resulting supernatant 2 contained only marginal replicase activity.  
Contrary to the corresponding fractions of naïve Huh-7 cells, fractions of the RC 
preparation of replicon cells should contain the viral NS proteins and probably 
associated cellular proteins. We wanted to analyze whether this can already be 
detected in a SDS-PAGE by variations in the protein band patterns, especially in the 
CRC fraction. However, differences in the complex protein band pattern between 
corresponding fractions of naïve Huh-7 and replicon cells were not observed  
(Fig. 8D).  
The distribution of the non-structural proteins in different fractions of the CRC 
preparation was investigated by immunoblot analyses and is shown in Fig. 8B. 
Similar proportions of NS3, NS4B, NS5A, and NS5B were retrieved in S1 and 
concentrated in parallel to the replicase activity in the CRC fraction, in S2 only minor 
amounts were detected. 
A variable amount of NS proteins and replicase activity always stayed associated 
with the nuclear pellet. This could not be recovered even by vigorous douncing, 
probably due to the accumulation of replication complexes in the perinuclear region74 
and due to the mild extraction conditions omitting any detergents. 
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Fig. 8. Preparation and characterization of CRCs from HCV replicon cells. (A) Schematic diagram of 
the CRC preparation protocol. (B) Detection of NS3, NS4B, NS5A and NS5B in different fractions of 
the CRC preparation. The volume of the NP fraction was adjusted to the volume of S1 and 10 µl of 
each fraction were analyzed by immunoblot using a polyclonal antiserum raised against HCV NS3 (top 
panel), NS4B (upper middle panel) or NS5A (lower middle panel) or monoclonal antibodies specific for 
NS5B154 (lower panel) and compared to 10 µl of “CRC” fraction from naive Huh-7 cells (Huh-7). (C) 
Analysis of in vitro replicase activity in total lysates (TL) and different subcellular fractions of replicon 
cells (left half) and naïve Huh-7 cells (right half). In vitro replicase activity was determined in 4 µl of 
each fraction, reaction products were analyzed by denaturing glyoxal gel electrophoresis followed by 
autoradiography of the dried gel. A radioactively labeled in vitro transcript identical in size to the 
replicon was loaded as a marker (M). The major reaction product of the in vitro replicase assay is 
indicated by an arrowhead. (D) Distribution of proteins in the different fractions of the CRC preparation 
from replicon cells (left half) and naïve Huh-7 cells (right half). The volume of the NP fraction was 
adjusted to the volume of S1 and 10 µl of each fraction were analyzed by SDS-PAGE. Proteins were 
visualized by Coomassie stain. 
 
3.1.2 CRC activity is different from polymerase activity 
The replicase activity shown in Fig. 8C could be exclusively due to the RdRp activity 
of NS5B present in the cellular lysates. To exclude this, we were looking for criteria 
by which the activity of replication complexes could be differentiated from polymerase 
activity. Previous reports have shown that HCV replication complexes act selectively 
on endogenous templates in vitro and are blocked by an inhibitor of NS3 helicase86, 
indicating that replicase activity can be distinguished from RNA synthesis exerted by 
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isolated NS5B polymerase. To search for additional differentiators, we wanted to 
analyze different compounds inhibiting RdRp activity in vitro for their impacts on in 
vitro replicase activity. 
Using recombinant NS5B protein for screening, nucleotide and non-nucleoside 
inhibitors of HCV polymerase activity have been identified. Nucleotide analogs target 
the polymerase active site, are mostly competitive inhibitors relative to the natural 
nucleotide substrates, and can cause chain termination upon incorporation into the 
RNA molecules36,152,194. Non-nucleoside inhibitors of NS5B RNA synthesis activity 
have been independently identified by several laboratories and belong to a number of 
different structural classes18,37,38,46,150. Furthermore, Moradpour and coworkers 
generated a monoclonal antibody (α-NS5B 12B7) that efficiently inhibits the HCV 
RdRp in vitro by binding to a conformational epitope in NS5B154.  
We tested whether this monoclonal antibody, as well as the chain-terminating 
nucleotide analog 3'-deoxy-CTP and the non-nucleoside NS5B polymerase inhibitor 
Japan Tobacco DB-III-17-02 also had an impact on in vitro replicase activity. 
The inhibitory effects of the monoclonal antibody α-NS5B 12B7 were compared to 
those of the NS5B-specific monoclonal antibody α-NS5B 3B1 which did not interfere 
with polymerase activity in vitro154. As shown in Fig. 9A, neither the control antibody 
α-NS5B 3B1 (right half). nor the α-NS5B 12B7 antibody (left half), generally inhibiting 
the polymerase activity in vitro, interfered with the activity of HCV replication 
complexes in any used concentration, even not when used in an up to 30-fold molar 
excess. 
Likewise, the non-nucleoside NS5B polymerase inhibitor Japan Tobacco DB-III-17-
02 was tested in different concentrations in an in vitro replicase activity assay  
(Fig. 9B). Though, this non-nucleoside inhibitor did also not show any impact on the 
replicase activity. 
Solely 3'-deoxy-CTP, the chain-terminating nucleotide analog, interfered with the 
activity of the viral replication complex (Fig. 9C). This inhibition occurred in a 
concentration-dependent manner. 
These results further confirmed that in vitro replicase activity exhibited features 
distinct from isolated HCV polymerase, since it was not inhibited by a monoclonal 
antibody or a non-nucleoside inhibitor generally interfering with RdRp activity in vitro. 
Moreover, these data indicated that CRCs most likely depicted a representative 
fraction of HCV replication complexes in replicon cell clones and were therefore the 
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appropriate tool to develop a purification strategy for the identification of associated 
host factors.  
 
 
Fig. 9. Different effects of various inhibitors on in vitro replicase activity. (A) Effect of NS5B specific 
monoclonal antibodies on in vitro replicase activity. 2 µl of a standard CRC preparation containing 40 
ng NS5B were preincubated 5 min on ice with 0.1, 1 or 3 µg of purified monoclonal antibodies as 
indicated in the top, resulting in a 1x, 10x or 30x molar excess, or incubated in the absence of 
antibodies (CRC) and analyzed for in vitro replicase activity. The same amount of “CRC” fraction from 
naive Huh-7 cells was used as a negative control (Huh-7). (B) Effect of the non-nucleoside 
polymerase inhibitor Japan Tobacco DB-III-17-02 on in vitro replicase activity. 3 µl of a standard CRC 
preparation were preincubated 30 min on ice with different amounts of the non-nucleoside polymerase 
inhibitor or its solvent DMSO (concentration in assay 1.25%), resulting in an total concentration of 0.2, 
1, 5 or 25 µg/ml as indicated in the top or incubated in the absence of inhibitor (CRC) and analyzed for 
in vitro replicase activity. The same amount of “CRC” fraction from naive Huh-7 cells was used as a 
negative control (Huh-7). (C) Effect of 3’-dCTP on in vitro replicase activity. 3 µl of a standard CRC 
preparation were preincubated 30 min on ice with different concentrations of 3’-dCTP or its solvent 
H2O, resulting in an total concentration of 1, 10, or 100 µM as indicated in the top or incubated in the 
absence of inhibitor (CRC) and analyzed for in vitro replicase activity. The same amount of “CRC” 
fraction from naive Huh-7 cells was used as a negative control (Huh-7). For further details refer to the 
text. 
 
3.1.3 Purification of HCV replication complexes by sucrose floatation 
gradient centrifugation 
As shown in Fig. 8D, preparation of CRCs by pelleting heavy-membrane fractions 
from hypotonic cell lysates resulted in a fraction comprised of numerous cellular 
proteins in addition to the viral and cellular components of the HCV replication 
complex. Therefore, it was necessary for the characterization of these complexes to 
eliminate as many as possible of the cellular proteins not involved in HCV replication. 
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Fig. 10. Purification of HCV replication complexes by membrane floatation in a sucrose gradient.  
(A) Schematic diagram of the CRC purification protocol. (B) Analysis of total lysate, subcellular 
fractions and gradient fractions (F1 to F10) of the CRC purification by a sucrose floatation gradient. 
The CRC fraction was loaded under a continuous 15-60% (w/w) sucrose gradient and spun about 16 h 
at 71,000 g in an ultracentrifuge at 4°C. The gradient was subsequently fractionated in 1 ml aliquots. 
10 µl of each fraction were analyzed by SDS-PAGE; the proteins were stained by Coomassie brilliant 
blue (upper panel) and NS5B was detected by immunoblot using a monoclonal antibody specific for 
NS5B (middle panel). In vitro replicase activity was determined in 4 µl of each fraction; the major 
reaction product of the in vitro replicase assay is indicated by an arrowhead (lower panel). 
 
On that account, I tried to purify the viral replication complexes contained in the CRC 
fraction by a sucrose floatation gradient. CRCs were prepared as described before 
and loaded under a continuous sucrose gradient (15-60% (w/w) sucrose). The 
method is shown schematically in Fig. 10A. Following an overnight 
ultracentrifugation, the gradient was fractionated and the different fractions were 
analyzed by density and protein concentration determination (Bradford assay), 
Coomassie protein stain, immunoblot analysis against NS5B, and replicase activity 
assay. As demonstrated in Fig. 10B (middle panel), the major amount of the viral 
polymerase was retrieved in fraction F5 at a density of 1.17 g/ml. Minor amounts of 
NS5B were detected in the fractions F6 and F7, whereas in all other gradient 
fractions NS5B was not detectable. Corresponding to the immunoblot results, fraction 
F5 also comprised the maximum replicase activity (Fig. 10B, lower panel). In the 
neighboring fractions F4 and F6, only traces of replicase activity were detected; the 
remaining gradient fractions showed no evidence for viral RNA synthesis.  
The fraction F5 contained about 30% of the total protein amount but almost the entire 
replicase activity as well as the bulk of NS5B polymerase. Therefore, a noticeable 
purification of the replication complexes was achieved by this floatation gradient 
centrifugation. However, this peak fraction F5 still displayed a very complex protein 
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pattern not much different from the other fractions (Fig. 10B, upper panel, compare 
lanes F1-F10), indicating that further purification steps were necessary for proteomic 
analyses of the HCV RCs. 
 
3.1.4 Purification of HCV replication complexes by detergent treatment 
A partial purification of the replication complexes was obtained by sucrose gradient 
centrifugation. Since almost all HCV non-structural proteins are tightly associated 
with intracellular membranes, many cellular membrane proteins are unavoidably also 
purified by this method. Furthermore, I forfeit approximately one half of the replication 
complexes linked with the nuclear pellet as this bond was not broken by the used 
lysis conditions. I tried to increase the yield and the purification by application of 
detergents. It has previously been shown that the HCV replication seems to proceed 
at detergent-resistant membranes, the so-called lipid rafts5,193. Proteins located at 
detergent-sensitive membranes lose their membrane-association upon detergent 
treatment which leads to a change in their buoyant density. Therefore, they can be 
separated from the membrane-bound RCs by a density gradient centrifugation. 
Based on the observation mentioned above, I treated a CRC fraction with 1% Triton 
X-100 (TX-100) at 4°C and performed a sucrose floatation gradient centrifugation. 
The different fractions were analyzed by density and protein concentration 
determination, silver staining of the proteins, immunoblot analysis to detect NS5B, 
and replicase activity assay (Fig. 11). In contrast to the previous sucrose floatation 
gradient shown in Fig. 10B, NS5B was detected in all gradient fractions apart from 
fractions F1 and F13 (Fig. 11A, bottom panel). Two different peak gradient fractions 
for the polymerase were found, F4 and F8, at a density of 1.11 g/ml and 1.19 g/ml, 
respectively. Fraction F8 also contained the highest protein concentration (Fig. 11A, 
top panel). I assumed that gradient fractions F3 to F5 may represent the detergent-
resistant membranes and analyzed all gradient fractions in an in vitro replicase 
assay. As shown in Fig. 11B, replicase activity was not clearly detectable in any of 
the gradient fractions. Only in the assays corresponding to fractions 7 and 8 a smear 
was visible which might have been an indication for RNA synthesis.  
However, different laboratories previously reported that the HCV RCs were 
associated with lipid rafts or detergent-resistant membranes5,71,193. Potentially, RCs 
stayed intact when treated with TX-100 at 4°C but replicase activity was destroyed 
due to the heating-up to the replicase assay incubation temperature of 35°C. This 
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probably left the lipid rafts not intact any longer in the presence of the remaining TX-
100. 
 
 
Fig. 11. Purification of CRCs by treatment with Triton X-100 at 4°C. A CRC fraction was incubated 
with 1% Triton X-100 (TX-100) 1h at 4°C. This fraction was then loaded under a sucrose floatation 
gradient and spun about 16 h at 71,000 g at 4°C. The gradient was fractionated in 1 ml aliquots. (A) 10 
µl of the CRC fraction with or without TX-100 incubation as well as 20 µl of each gradient fraction (F1-
F13)  were analyzed by SDS-PAGE; both the proteins were visualized by silver staining (top panel) 
and NS5B was detected by immunoblot using a monoclonal antibody specific for NS5B (bottom 
panel). 10 µl of total lysates (TL) of naïve Huh-7 cells and replicon cells served as negative and 
positive control, respectively. (B) In vitro replicase activity was determined in 4 µl of each gradient 
fraction; the CRC fraction of replicon cells was used as a positive control, the corresponding fraction of 
naïve Huh-7 cells as negative control. The major reaction product of the in vitro replicase assay is 
indicated by an arrowhead. 
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The membrane association seemed be crucial for the activity of the HCV replication 
complex, therefore I controlled which detergents did not affect replicase activity in 
vitro (Fig. 12) and could be used for further purification studies. CRC fractions were 
incubated in the presence of different detergents on ice and subsequently subjected 
to an in vitro replicase assay. 
 
 
Fig. 12. Effect of various detergents on HCV replication complex activity. Equal volumina of CRC 
fraction were incubated 5 min on ice in reaction buffer together with 0.1% or 1% of the detergents 
desoxycholic acid (DOC), CHAPS, NP40, Triton X-100 (TX-100), octyl glucoside (OG), and dodecyl 
maltoside (DM), respectively. Subsequently, the replicase activity assay was started by addition of 
nucleotides and incubated 1 h at 35°C. A CRC fraction preincubated with H2O instead of detergent 
served as positive control, an analog membrane fraction of naïve Huh-7 cells as negative control. An 
in vitro transcript with a length of 8 kb was used as size control. 
 
The results exhibited clearly that the replication complexes were only still active at a 
concentration of 0.1% of the detergents desoxycholic acid (DOC) or octyl glucoside 
(OG). A ten fold higher concentration of DOC or OG inhibited the replication in the in 
vitro assay. The other detergents (CHAPS, NP40, TX-100, and dodecyl maltoside) 
already blocked the activity of the replication complexes completely at a 
concentration of 0.1%. However, a concentration of 0.1% of DOC or OG lies below 
the critical micellar concentration (CMC), i.e. the proteins were not entirely solubilized 
from the membrane and thus the cellular proteins not involved in HCV replication 
could not be disposed by this detergent treatment. The replicase activity inhibition on 
the one hand and the insufficient solubilization of cellular proteins on the other hand 
rendered the application of detergents for the purification of HCV replication 
complexes not practicable.  
Although the isolation of detergent-resistant membranes might be a plausible way to 
purify RCs193, we decided to search for alternative strategies because in our hands 
replicase activity could not be determined in these fractions. Miyanari and colleagues 
showed that in vitro replicase activity in digitonin-permeabilized cells was resistant to 
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protease treatment153. To evaluate whether this treatment was also applicable as a 
purification strategy for HCV replication complexes, CRCs were treated with high 
concentrations of proteinase K (PrK), the reaction was stopped by adding PMSF, and 
aliquots of the pretreated CRCs were analyzed for in vitro replicase activity, 
immunoblot against NS5B, and protein silver stain following SDS-PAGE. As shown in 
Fig. 13A, in vitro replicase activity was not affected by pretreatment with proteinase K 
(upper panel, lanes 5 and 6). In contrast to the fully maintained replicase activity, 
NS5B protein was not detectable in the PrK treated fractions (Fig. 13A, lower panel, 
lanes 5 and 6) until the sample was TCA-precipitated and fivefold concentrated (lane 
7). Consistent with this result, cellular proteins were massively degraded to nearly 
undetectable amounts even with the lower protease concentrations (Fig. 13B, lanes 
8-11), whereas detergent treatment as expected had no significant effect (lanes 6 
and 7).  
 
 
Fig. 13. Proteinase K does not affect the in vitro replicase activity of HCV replication complexes. Equal 
amounts of CRCs prepared from replicon cell clone 9-13 were incubated for 60 min at 25°C in the 
presence or absence of 1% Triton X-100 and/or 0.8 (+) or 8 (++) mg/ml proteinase K, respectively as 
indicated above each lane. The reaction of proteinase K was stopped by addition of 1.4 mM PMSF. 
(A) Effect of proteinase K on in vitro replicase activity and on HCV NS5B. In vitro replicase activity was 
determined in 4 µl of each fraction, a “CRC” fraction of naïve Huh-7 cells was used as negative control 
(top panel). Total protein equivalent to 2 µl CRCs was subjected to SDS-10%PAGE. In case of the 5x 
concentrated sample, proteins were TCA-precipitated and the equivalent of 10 µl CRCs was loaded. 
Proteins were either subjected to immunoblot analysis using monoclonal antibodies specific for HCV 
NS5B (A, bottom panel) or visualized by silver staining (B) as indicated at the right. The concentrated 
fraction (A, lane 7) is shown from the identical exposition of the same blot. 
 
The PrK treatment of CRCs led to the degradation of the bulk of cellular proteins as 
well as a large part of the viral NS proteins. However, the in vitro replicase activity 
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was fully maintained. Therefore, the application of PrK seemed to be a useful method 
to enrich and purify replication complexes and their associated cellular cofactors 
which potentially could be identified by following proteomic approaches. 
 
3.2 Identification of Cellular Factors Associated with the Hepatitis 
C Virus Replication Complex 
Based on the previous results, we developed a purification strategy by combining the 
PrK treatment with the sucrose density gradient centrifugation. This allowed us to 
enrich and purify enzymatically active HCV replication complexes and to investigate 
their associated cellular cofactors by two-dimensional (2D) SDS-PAGE. The 
purification strategy is shown schematically in Fig. 14. CRCs were isolated from 
replicon cells (cell clone 9-13) as described in chapter 3.1.1. Thereafter, the CRC 
fraction was treated with PrK and subsequently loaded under a sucrose floatation 
gradient after stopping the PrK activity by addition of PMSF. The gradient was 
fractionated, and the fractions containing the major part of replicase activity and 
NS5B polymerase were combined. The therein comprised membranes and 
accordingly RCs were pelleted by ultracentrifugation. After resuspension of the pellet 
in an appropriate lysis buffer, this fraction was investigated by 2D gel electrophoresis, 
and proteins were visualized by silver stain. A corresponding fraction prepared from 
naïve Huh-7 cells that were cured from an HCV replicon was analyzed in the same 
way and the resulting protein spot patterns of the different cell lines were compared. 
Protein spots that were present in the CRC fraction of HCV replicon cells but missing 
or expressed at lower levels in the control fraction of cured Huh-7 cells could 
represent either viral proteins or cellular factors probably involved in viral replication 
and were subjected to mass spectrometry analysis. 
We first tested whether this combination of purification steps would preserve the 
activity of RCs. Therefore, equal amounts of CRCs prepared from replicon cells were 
incubated in the presence or absence of proteinase K. After stopping PrK activity by 
adding PMSF, the CRC fraction was subjected to a sucrose floatation gradient assay. 
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Fig. 14. Schematic diagram for the biochemical purification of HCV replication complexes by 
proteinase K to identify associated cellular factors and hypothetical model of HCV replication 
complexes. HCV NS proteins are indicated by orange ellipses; potential cellular factors by pink 
ellipses, and viral RNA by a blue wavy line. Individual NS proteins and RNA are not drawn to scale. 
 
In order to identify the gradient fraction encompassing the bulk of replicase activity, 
the individual gradient fractions were analyzed by density and protein concentration 
determination, as well as by in vitro replicase activity assay. The highest protein 
concentration was found at a density of 1.14 g/ml, both in gradient fractions of non-
treated CRCs and those treated with PrK. In both cases, the same fraction (#6) also 
featured the principal part of the replicase activity (Fig. 15A). This showed that the 
combination of the two different purification steps (PrK treatment and sucrose 
gradient centrifugation) had no negative effect on the activity of the RCs. 
Furthermore, these results clearly excluded a different behavior of PrK treated CRCs 
and non-treated CRCs in a sucrose floatation gradient.  
Having defined the gradient fraction from PrK treated CRCs containing the majority of 
replicase activity and proteins, I pooled it with the two neighboring fractions and 
pelleted the therein enclosed intracellular membranes. This pellet was then 
resuspended in lysis buffer and subjected to a one-dimensional (1D) SDS-PAGE. 
Proteins were either visualized by Coomassie staining or analyzed by immunoblot 
using antibodies specific for the detection of NS3, NS5A, and NS5B, respectively 
(Fig. 15B). As control, I used a corresponding fraction prepared from cured Huh-7 
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cells. Despite the purification that was achieved, no significant differences in the 
protein band pattern between CRCs from replicon and cured Huh-7 cells were 
observed (Fig. 15B, top panel). This indicated that the protein composition of the 
CRC fraction was too complex to be investigated by 1D SDS-PAGE. For subsequent 
analyses, this fraction was subjected to 2D gel electrophoresis. As shown in Fig. 
15B, the HCV NS proteins NS3, NS5A, and NS5B were still clearly detectable in this 
fraction by a 1D immunoblot. 
 
 
Fig. 15. Analysis of different fractions of the biochemical purification of HCV replication complexes by 
proteinase K (PrK). (A) Replicase activity of sucrose gradient fractions of CRCs treated or non-treated 
with PrK. 4 µl of each gradient fraction as well as PrK non-treated (- PrK) and treated (+ PrK) CRCs 
were analyzed for in vitro replicase activity. The upper panel represents the gradient fractions of PrK 
non-treated CRCs, the lower panel those of PrK treated CRCs. A non-incubated CRC fraction from 
replicon cells served as positive control, a corresponding fraction from naïve Huh-7 cells as negative 
control. (B) CRC fraction for 2D gel analysis subjected to 1-dimensional SDS-PAGE. Membranes 
contained in the peak gradient fractions were pelleted and lysed. Proteins included in this fraction 
were either visualized by Coomassie staining (top panel) or subjected to immunoblot analysis using 
either a polyclonal antiserum raised against HCV NS3 (middle upper panel) or monoclonal antibodies 
specific for HCV NS5A (middle lower panel) or monoclonal antibodies specific for HCV NS5B (lower 
panel). Huh-7 refers to a corresponding fraction prepared from cured Huh-7 cells. 
 
Purification of HCV replication complexes by the protocol depicted in Fig. 14 seemed 
to be an appropriate method to investigate which cellular proteins are involved in viral 
replication, since HCV replicase activity was retained while most of the cellular 
proteins were removed by this procedure. As the purified CRC fraction still contained 
a complex mixture of proteins, we decided to analyze this fraction by 2D SDS-PAGE. 
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3.2.1 Comparative 2-dimensional gel analysis of CRCs from replicon 
cells and naïve cells 
As shown in the previous chapter, purification of CRCs by PrK and sucrose density 
gradient did result in the elimination of most cellular proteins without affecting HCV 
replicase activity. However, the protein pattern was still to complex for 1D gel 
electrophoresis. Therefore, I analyzed the cellular proteins that stayed associated 
with the PrK treated CRCs by 2-dimensional SDS-PAGE. Resolution of the 
heterogenous protein mixture contained in the CRC fraction occurred in the first 
dimension by isoelectric focusing (IEF), e.g. segregation of proteins by their charge 
(pI; isoelectric point). In the second dimension, proteins were separated by their 
molecular weight in a standard SDS-PAGE. 
 
 
Fig. 16. Silver stained 2-dimensional SDS-PAGE of proteinase K treated CRC fraction prepared from 
cured Huh-7 cells and subgenomic replicon cells, respectively. Black ellipses indicate regions of spots 
corresponding to proteinase K; red ellipses regions of spots corresponding to Annexin II. 
 
A typical outcome of such an analysis is shown in Fig. 16. Despite the substantial 
application of proteinase K, I still found a great variety of different proteins probably 
protected by membranous structures. The exceeding amount of proteinase K used 
for the purification of the replication complexes was reflected by massive protein 
spots at the corresponding size of 30 kDa (Fig. 16, black ellipses). The complex 
protein spot patterns were very similar between the investigated samples of replicon 
and cured cells and readily reproducible. However, distinct differences between the 
two gels also were detected. We were looking for additional protein spots in the HCV 
CRC gel that were absent or at least present in lower amounts in the control gel as 
exemplified by the spots encircled by red ellipses in Fig. 16. Those spots were then 
subjected to mass spectrometry analysis. 
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Unexpectedly, protein spots representing the HCV non-structural proteins were 
neither identified by mass spectroscopy nor verified in an immunoblot assay of  
2D gels; however, in an immunoblot assay of a one-dimensional SDS-PAGE of PrK 
treated CRCs they were clearly detectable (Fig. 15B). The reason might be that 
membrane and hydrophobic proteins (like the viral NS proteins) are poorly 
represented in the second dimension, which is probably due to protein/gel 
interactions during IEF 2. Some larger proteins might also have been lost and it has 
been suggested that this is due to size exclusion when the proteins are loaded onto 
the gel. In addition, it was possible that the NS protein amount was simply below the 
detection limit, since the majority of proteins had been digested by PrK (see also  
Fig. 13). 
The analysis of the CRC fraction by 2-dimensional SDS-PAGE showed a protein spot 
pattern that was reproducible from gel to gel and comparable between the HCV CRC 
gel and the control gel, however some differences were detectable. 
 
3.2.2 Identification of cellular proteins associated with HCV replication 
complexes by mass spectrometry 
Protein spots present in the CRC fraction of replicon cells after PrK treatment but 
missing or present in lower amounts in the control fraction of cured Huh-7 cells were 
analyzed by matrix-assisted laser desorption/ionization (time of flight) mass 
spectrometry (MALDI-TOF MS) in order to identify cellular proteins associated with 
the viral RC. The results of two independent experiments are depicted in Fig. 17; 
several spots found by 2D gel analyses to show different expression levels (marked 
by circles) were subjected to mass spectroscopy.  
We analyzed eight comparative 2D SDS-PAGEs and found three to nine differentially 
expressed protein spots in each gel. These were subsequently investigated by 
MALDI-TOF mass spectrometry; by virtue of too little protein content not every spot 
could be identified by this method. 
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Fig. 17. Silver stained 2D SDS-PAGEs of proteinase K treated CRC fractions from replicon cells 
(right) and their corresponding control gels (left). (A and B) Analysis of different CRC preparations as 
indicated on the far left. Proteins spots missing or expressed at a lower level in the corresponding 2D 
SDS-PAGE of cured Huh-7 CRCs are highlighted by circles. Black circles and numbers indicate 
protein spots identified by mass spectrometry, grey circles and numbers represent non-identified 
protein spots. The protein identities are specified beneath each SDS-PAGE. 
 
After having identified a particular protein by MALDI-TOF, the spots corresponding to 
this protein were also analyzed on all other gels and judged for differential 
representation. Table 1 summarizes which proteins were found by mass 
spectroscopy and in how many gels they were present in the CRC fraction of replicon 
cells but missing or present in lower amounts in the control fraction of cured Huh-7 
cells. In seven of eight experiments, Annexin II (ANXA2) was present at higher levels 
in the investigated CRC fraction prepared from replicon cells compared to the 
corresponding fraction from cured Huh-7 cells. The β-subunit of the ATP synthase 
was detected in half of all analyses, but the locations of these identified protein spots 
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varied greatly in molecular weight in each experiment (demonstrated in Fig. 17B, 
spots #1 and #4). Therefore, this protein was not considered for further 
investigations. Peroxiredoxin 3, Annexin IV (ANXA4), and Annexin V (ANXA5) were 
found twice, other cellular proteins, e.g. Calnexin and BiP, were only identified once. 
 
Table 1. Proteins identified by mass spectrometry and their frequency of differential representation in 
all comparative 2D gel analyses. 
 
 
 
In Fig. 18, the differences in the expression levels of two of these cellular candidate 
proteins, ANXA2 and Peroxiredoxin 3, respectively, are shown in several 
comparative 2D SDS-PAGEs. Both proteins were located at the expected molecular 
weights and isoelectric points. In the case of ANXA2, both protein spots were verified 
by mass spectrometry and were found differentially represented in seven cases  
(Fig. 18A). In contrast to this, Peroxiredoxin 3 was only twice present at higher levels 
in the replicon CRCs than in the control fraction from cured Huh-7 cells (Fig. 18B; 
050811 and 050817). In all other experiments the expression levels of this protein 
were identical. 
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Fig. 18. Divers sections of comparative 2D gel analyses to contrast the differential representation of 
two disparate cellular candidate proteins found to be associated with the HCV replication complex. 
Red circles assign the positions of the protein spots. Annexin II was differentially represented in seven 
comparative 2D gel analyses (A; exception: 041110), Peroxiredoxin 3 twice (B; 050811 and 050817). 
Gel sections showing a differential representation are encircled by a blue line. For further details refer 
to the text. 
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Fig. 19. Differential representation of two disparate cellular candidate proteins found to be associated 
with the HCV replication complex by 2D SDS-PAGEs. Red circles assign the positions of the protein 
spots. Annexin IV and Annexin V, respectively, were differentially represented in two comparative 2D 
gel analyses (050720/050824 and 050413/050720). Gel sections showing a differential representation 
are encircled by a blue line. For further details refer to the text. 
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Fig. 19 shows the differential representation of two other cellular candidate proteins, 
ANXA4 (A) and ANXA5 (B), respectively. Both were found twice to be present in the 
CRC fraction of replicon cells but missing or present in lower amounts in the control 
fraction and were identified by mass spectrometry. However, the spots for these 
proteins were not detectable in every gel (ANXA4: 050413, 050811, 050817; ANXA5: 
050817, 050920), therefore, only the assumed spot positions were marked by circles 
in these cases. Especially the protein spots for ANXA4 showed a very low intensity 
due to little protein amounts. In most of the experiments, the expression levels of 
ANXA4 and ANXA5 did not show any variations or were not even traceable. 
In summary, Annexin II (ANXA2) was the most promising candidate of the proteomic 
studies and was further analyzed for a potential role in the HCV life cycle. 
 
3.3 Analysis of the role of Annexin II in HCV replication 
The frequency of differential expression of ANXA2 found in the comparative 2D gel 
analyses of HCV replication complexes turned this cellular protein into a promising 
candidate as a potential cofactor of HCV replication. ANXA2 belongs to the great 
family of Annexins which are involved in many membrane-related events, such as the 
regulated organization of membrane domains and/or membrane-cytoskeleton 
linkages, certain endocytic and exocytic transport steps, and the regulation of ion 
fluxes across membranes39,73. Recently, Ryzhova and coworkers showed that 
ANXA2 is essential for the proper assembly of HIV in monocyte-derived 
macrophages183; furthermore, it is able to bind to mRNA and is involved in the 
organization of lipid rafts12,218. Therefore, we decided to investigate if this protein 
really played a role in the viral RNA replication.  
The differential representation of ANXA2 in PrK-resistant CRCs and their 
corresponding control fraction in 2D gel analyses led to the question whether this 
was also detectable in a 1D immunoblot assay. Previous studies showed that the 
RC-associated cellular protein Vap-A is important for HCV replication71,214,239, 
although its precise mode of action has yet not been classified. Therefore, its 
presence in the PrK treated CRC fraction was also investigated in this approach. The 
ER marker Calnexin served as additional control since the site of viral RNA 
replication, the membranous web, is derived from ER membranes. In a one-
dimensional immunoblot assay, the levels of these distinct cellular proteins in the 
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CRC fraction prepared from HCV replicon cells were analyzed and compared to the 
protein levels in a corresponding fraction from cured Huh-7 cells (Fig. 20).  
 
 
Fig. 20. Expression levels of different cellular proteins in PrK treated CRC fractions. Equal amounts of 
CRCs prepared from replicon cell clone 9-13 or cured Huh-7 cells were incubated for 60 min at 25°C 
in the presence (+) or absence (-) of 8 mg/ml proteinase K, respectively as indicated above each lane. 
The reaction of proteinase K was stopped by addition of 1.4 mM PMSF. Total protein equivalent to 2 µl 
CRCs was subjected to SDS-10%PAGE. In case of the 5x concentrated sample, proteins were TCA-
precipitated and the equivalent of 10 µl CRCs was loaded. Proteins were subjected to immunoblot 
analysis using either monoclonal antibodies specific for ANXA2 (left panel), a polyclonal antiserum 
raised against the cellular protein Vap-A (middle panel), and a polyclonal antiserum raised against the 
N-terminus of Calnexin (right panel). The corresponding sizes of the different proteins are indicated by 
arrowheads to the right of each immunoblot. 
 
The levels of Vap-A as well as the levels of the ER marker Calnexin - which has not 
yet been shown to be involved in HCV replication – showed no difference between 
CRCs from replicon and cured cells, independent whether the CRC fractions were 
treated with PrK or not. Calnexin is a type I transmembrane protein with a cytosolic 
C-terminus and a luminal aminoterminus. The Calnexin-specific antibody used in the 
immunoblot assay was directed against the N-terminus of this protein. The shift in the 
mobility of Calnexin observed after PrK treatment was due to the digestion of the 
cytosolic protein part resulting in a shortened polypeptide (see also153). 
In contrast to Vap-A and Calnexin, the level of ANXA2 was enhanced in replicon 
CRCs compared to the control fraction. This phenotype was observed before as well 
as after PrK digest, the latter was confirming the results of the 2D gel analyses. The 
difference before PrK treatment indicated that either ANXA2 expression may be 
induced by the replicon or that the mRNA or the protein could be stabilized by HCV 
or that more ANXA2 is bound to membranes in the presence of HCV. 
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The results of this experiment clearly showed that ANXA2 was enriched in the CRC 
fraction and – compared to the control fraction – more ANXA2 protein was resistant 
to PrK. 
 
3.3.1 Colocalization studies of Annexin II with viral proteins in different 
cell types 
ANXA2 was found to be associated with purified CRCs from replicon cells by 
comparative 2D gel analyses. In contrast, the ER marker Calnexin and other cellular 
candidates (e.g. Vap-A) were not identified by this proteomic approach. As a first 
step to evaluate the role of ANXA2 in the HCV life cycle, we investigated whether 
ANXA2 colocalizes with HCV proteins in immunofluorescence analyses (IFA). 
We started with two different subgenomic replicon cell clones (9-13 and 5-15140); 
both harboring genotype 1b replicons as used in the proteomic study. In naïve Huh-7 
cells, ANXA2 showed a cytoplasmic distribution, whereas HCV NS3 was of course 
not detectable (Fig. 21A, lower panels). In the stable subgenomic replicon cells a 
rearrangement of ANXA2 took place, resulting in a punctuated staining perfectly 
colocalizing with the spot pattern of HCV NS3. This phenotype was more pronounced 
in 9-13 replicon cells (Fig. 21A, middle panels) than in cells harboring the 5-15 
replicon (upper panels) in which the spot pattern of NS3 was less prominent, too. 
These spot patterns are generally believed to harbor the membranous web, the site 
of HCV RNA replication74. Therefore, the spot patterns of the viral NS proteins 
generally showed an explicit colocalization, which is exemplary shown with the 
colocalization of NS3 and NS5A (Fig. 21B), indicating that ANXA2 colocalized with all 
viral components of the HCV replication complex. Colocalization of ANXA2 with the 
HCV RNA could not be proven because the viral RNA was neither detected by a 
dsRNA-specific antibody nor by BrdU-labeling (data not shown). However, Gosert 
and colleagues showed that the sites of HCV NS proteins colocalized with the sites 
of newly synthesized RNA in the cytoplasm indicating that those spots represented 
the viral replication complexes74. 
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Fig. 21. Colocalization of ANXA2 and viral NS proteins in HCV subgenomic replicon cells. 
Paraformaldehyde-fixed (PFA-fixed) and permeabilized monolayers of replicon cells were subjected to 
IFA using either monoclonal antibodies specific for ANXA2 (A) or HCV NS5A (B), and a polyclonal 
antiserum raised against HCV NS3 (A and B). (A) Colocalization of ANXA2 with HCV NS3 in different 
subgenomic replicon cell clones. (B) Colocalization of HCV NS5A with HCV NS3 in different 
subgenomic replicon cell clones. Naïve Huh-7 cells served as negative control for the viral proteins. 
 
Since ANXA2 colocalized with viral non-structural proteins in cells persistently 
replicating HCV RNA from genotype 1b, I analyzed whether this colocalization and 
the relocation of ANXA2 depended on a particular viral genotype. Huh-7 cells 
harboring HCV RNA from genotype 1b and genotype 2a, respectively, were 
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investigated and again the rearrangement of ANXA2 was found in both cells 
harboring the different viral genotypes (Fig. 22). In addition, in the cells containing 
HCV genotype 2a ANXA2 perfectly colocalized with HCV NS3, just as in cells 
comprising HCV genotype 1b, indicating that ANXA2 colocalization with HCV NS 
proteins might be common feature of HCV RCs. 
 
 
Fig. 22. Colocalization of ANXA2 and viral NS3 from different HCV genotypes. PFA-fixed and 
permeabilized monolayers of Huh-7 cells harboring subgenomic HCV replicon RNA of either genotype 
1b (upper panels) or 2a (lower panels) were subjected to IFA using monoclonal antibodies specific for 
ANXA2 and a polyclonal antiserum raised against HCV NS3. The structures of the different 
subgenomic RNAs contained in the cells used in this experiment are depicted above the IF pictures. 
 
In the previous colocalization studies of ANXA2 and viral NS proteins, I used cells 
replicating only subgenomic HCV RNAs. I was interested if the redistribution of 
ANXA2 would also occur in cells harboring HCV full-length RNA. To answer this 
question, naïve Huh7.5 cells - which are a Huh-7 subclone and most permissive for 
HCV infection118 - were infected with Hepatitis C viruses expressing the complete 
viral genome of Jc1 (Fig. 23A). This chimeric full-length genome was constructed by 
fusing fragments from two different genotype 2a isolates, J6CF231 and JFH1. The 5’-
NTR and the part from the second transmembrane domain (TMD) of NS2 to the 3’-
NTR originate from JFH1 and the region encoding core to the first TMD of NS2 from 
J6CF. This hybrid yielded infectious titers 100- to 1,000-fold higher than the parental 
JFH1 isolate171. 
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48 hours post infection (p.i.), the cells were fixed in paraformaldehyde (PFA) and 
subjected to IFA. The normal cytosolic ANXA2 localization was seen in the non-
infected cells (Fig. 23 B-D, right panels). In the infected cells however, the same 
alteration in the cytoplasmic ANXA2 distribution was observed as in cells containing 
subgenomic HCV replicons. Likewise, as illustrated in Fig. 23B-D left panels, the 
non-structural HCV proteins NS3, NS4B, and NS5A all showed a clear colocalization 
with ANXA2 in infected cells. 
I wanted to exclude that the colocalization of ANXA2 and HCV NS proteins depends 
on the cell type of the different Huh-7 cells (naïve Huh-7, Huh7.5) I used for the 
previous colocalization studies. Therefore, other cell lines supporting HCV replication 
were examined. 
 
 
Fig. 23. Colocalization of ANXA2 and varying viral NS proteins in HCV infected cells. (A) Structure of 
the full-length RNA genome (Jc1) of the viruses used in this study. Shown in blue are the genes of the 
J6 isolate, in green are depicted the remaining genes and the NTRs of the JFH1 isolate. Both isolates 
belong to the HCV genotype 2a. (B-D) PFA-fixed and permeabilized monolayers of HCV-infected Huh-
7.5 cells were subjected to IFA using monoclonal antibodies specific for ANXA2 and either a 
polyclonal antiserum raised against HCV NS3 (B), or a polyclonal antiserum raised against HCV NS4B 
(C), or a polyclonal antiserum raised against HCV NS5A (D). Mock-infected Huh-7.5 cells served as 
negative controls for the viral proteins. 
 
Recently, it has been shown that genotypes 1b and 2a replicons also replicate 
persistently in the human hepatoblastoma cell line HuH6228. Similar to Huh-7 cells, 
efficient HCV replication in HuH6 cells depends on the presence of cell culture-
adaptive mutations and the permissiveness of the host cell. However, three major 
differences exist: in HuH6 cells, viral replication is (i) independent from ongoing cell 
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proliferation, (ii) less sensitive to certain antiviral compounds, and (iii) highly resistant 
to IFN-gamma228. Furthermore, Hep56D JFH cells were available, a murine liver 
derived cell line supporting the consistent replication of a genotype 2a replicon (Marc 
Windisch, PhD thesis).  
All these different cell lines were analyzed by IFA and it was tested whether the 
phenotype of ANXA2 redistribution to the HCV RCs could be retrieved in these cells. 
In naïve HuH6 and Hep56D cells, the regular cytoplasmic distribution of ANXA2 was 
observed (Fig. 24 and 25). In contrast, in HuH6 cells harboring subgenomic replicons 
from genotype 2a (HuH6 JFH, Fig. 24) or 1b (HuH6 Con, Fig. 25A), ANXA2 exhibited 
the typical HCV-associated rearrangement into dotted structures. Likewise, an 
evident colocalization of ANXA2 with the viral non-structural proteins NS3  
(Fig. 24A), NS4B (Fig. 24B), and NS5A (Fig. 24C) was found in the HuH6 JFH cell 
line.  
The same was true for murine Hep56D JFH cells (Fig. 25B), harboring a subgenomic 
genotype 2a replicon (JFH1).  
 
 
Fig. 24. Colocalization of ANXA2 with different viral NS proteins in HuH6 cells harboring a 
subgenomic replicon from genotype 2a (HuH6 JFH). PFA-fixed and permeabilized monolayers of 
HuH6 JFH cells were subjected to IFA using monoclonal antibodies specific for ANXA2 and either a 
polyclonal antiserum raised against HCV NS3 (A), or a polyclonal antiserum raised against HCV NS4B 
(B), or a polyclonal antiserum raised against HCV NS5A (C). Naïve HuH6 cells served as negative 
controls for the viral proteins. 
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Fig. 25. Colocalization of ANXA2 and viral NS3 in HuH6 cells and murine Hep56D cells harboring 
subgenomic HCV replicons from genotype 1b (Con) and genotype 2a (JFH), respectively. Cells were 
fixed by PFA and permeabilized by TX-100, subsequently subjected to IFA using monoclonal 
antibodies specific for ANXA2 and a polyclonal antiserum raised against HCV NS3. (A) Colocalization 
of ANXA2 and HCV NS3 in HuH6 Con cells (upper panels). Naïve HuH6 cells served as negative 
control for the viral protein (lower panels). (B) Colocalization of ANXA2 and HCV NS3 in Hep56D JFH 
cells (upper panels). Naïve Hep56D cells served as negative control for HCV NS3 (lower panels). 
 
3.3.2 No colocalization of HCV with other host proteins and of ANXA2 
with other positive-stranded RNA viruses 
So far, I had demonstrated that the change of the ANXA2 distribution upon HCV 
replication and its colocalization with viral NS proteins were found in different 
replication systems and cell types. The next step was to investigate whether other 
cellular proteins were colocalizing with the viral components of the HCV replication 
complex to address the specificity of the ANXA2-HCV colocalization. HCV replication 
takes place at the membranous web, vesicular membrane structures which are 
derived from the endoplasmic reticulum (ER) 50,51. On account of this, I analyzed 
replicon cells for a potential colocalization of HCV NS proteins with an ER marker 
protein. I transiently transfected naïve Huh-7 cells with a selectable subgenomic 
genotype 2a replicon (neo_JFH) whose structure is depicted in Fig. 26A. As shown in 
the same figure, a specific colocalization of the ER marker protein Calnexin and the 
viral NS5A protein in HCV-transfected cells could not be observed. A change in the 
pattern of the typical ER stain of Calnexin due to HCV replication was not noticed 
either. This result indicated that HCV RCs did not specifically colocalize with the ER. 
The major cellular interaction partner of ANXA2 is the protein p1119,102. Both proteins 
form a heterotetramer which brings two different membranes closely together103 but 
does not trigger membrane fusion. Thus, we were interested if p11 would colocalize 
with HCV NS proteins.  
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Fig. 26. Colocalization studies of HCV with different host cell proteins. After PFA fixation and 
permeabilization, Huh-7 cells transiently transfected with subgenomic HCV RNA (genotype 2a; 
Neo_JFH and Luc_5A_RFP, respectively) were subjected to IFA. (A) Colocalization study of HCV 
NS5A and Calnexin in Huh-7 cells transfected with subgenomic HCV RNA (Neo_JFH; upper panels) 
using monoclonal antibodies specific for HCV NS5A and a polyclonal antiserum raised against 
Calnexin. Mock-transfected Huh-7 cells served as negative control for HCV NS5A (lower panels). (B) 
Colocalization studies of RFP-coupled HCV NS5A with ANXA2 (upper panels) or p11 (lower panels) in 
transiently transfected Huh-7 cells, using monoclonal antibodies specific for the respective cellular 
protein. (A and B) The structure of the subgenomic RNAs used in these experiments are depicted 
above the corresponding IF pictures. 
 
To answer this question, I transiently transfected naïve Huh-7 cells with a 
subgenomic genotype 2a replicon (luc_5A_RFP). This replicon encoded a luciferase 
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(luc) reporter gene and comprises the sequence coding for a red fluorescent protein 
(RFP) fused to the NS5A sequence. The structure of this luc_5A_RFP replicon is 
illustrated in Fig. 26B. The rearrangement of ANXA2 and its colocalization with the 
RFP which corresponded to the HCV signal was clearly detectable in the transfected 
cells (Fig. 26B, top panels). However, neither a change in the localization pattern of 
p11 between naïve and HCV-transfected cells (naïve cells not shown) was 
recognized nor a colocalization with HCV proteins (Fig. 26B, bottom panels). This 
indicated that the ANXA2 colocalization with HCV was independent of the interaction 
with p11. 
ANXA2 belongs to the large family of Annexins which provide a link between Ca2+-
signalling and membrane functions exhibiting structural and functional homology73. 
Besides ANXA2, also ANXA4 and ANXA5 were identified as cellular candidate 
proteins to be associated with the HCV replication complex in the proteomic analyses 
(Table 1). Therefore, I wanted to know if other members of the Annexin family also 
were potentially involved in HCV replication and tested if they - like ANXA2 - 
colocalized with the HCV NS proteins building the replication complex. Naïve Huh-7 
cells were transfected with a selectable subgenomic genotype 2a replicon RNA 
(neo_JFH). The fixed cells were analyzed by IFA for a colocalization of HCV NS 
proteins with Annexin I (ANXA1), Annexin IV (ANXA4), and Annexin V (ANXA5). As 
shown in Fig. 27A, ANXA1 was found in the nucleus, in the cytoplasm and at some 
cytosolic granule structures in naïve Huh-7 cells. A redistribution of ANXA1 upon 
HCV replication was not observed and neither was a colocalization with HCV 
proteins. ANXA4 showed a homogeneous cytoplasmic distribution in mock 
transfected cells. In HCV-harboring cells, a rearrangement of the ANXA4 localization 
to the sites of viral RCs was not detectable and consequently no distinct 
colocalization with HCV proteins (Fig. 27B). ANXA5 exhibited a diffuse cytosolic 
localization as well but also associated with some granules in the cytoplasm in naïve 
Huh-7 cells (Fig. 27C). This phenotype was not changed in HCV replicating cells, and 
– just as ANXA1 and ANXA4 – ANXA5 did not colocalize with HCV proteins. This 
demonstrated that the colocalization of ANXA2 with HCV RCs was not a common 
attribute of Annexin family members and emphasized its specificity. 
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Fig. 27. No colocalization of other Annexins with HCV NS proteins. Huh-7 cells transiently transfected 
with a subgenomic genotype 2a HCV replicon (neo_JFH) were subjected to IFA. (A) Colocalization 
studies of ANXA1 and HCV NS3 using monoclonal antibodies specific for ANXA1 and a polyclonal 
antiserum raised against HCV NS3. (B) Colocalization studies of ANXA4 and HCV NS5A using 
monoclonal antibodies specific for HCV NS5A and a polyclonal antiserum raised against ANXA4. (C) 
Colocalization studies of ANXA5 and HCV NS3 using monoclonal antibodies specific for ANXA5 and a 
polyclonal antiserum raised against HCV NS3. Mock transfected naïve Huh-7 cells served as negative 
control for the HCV NS proteins. 
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After showing that the colocalization of ANXA2 with the sites of HCV RNA replication 
was not observed for other members of the Annexin family, we were interested if 
ANXA2 also colocalized with NS proteins of other positive-strand RNA viruses. To 
answer this question, naïve Huh-7 cells were infected with Dengue viruses (DV), 
fixed 24 hours post infection and analyzed by an immunofluorescence assay. Like 
HCV, DV is a member of the family Flaviviridae, but belongs to the genus Flavivirus. 
The DV replication complex was visualized by staining with antibodies raised against 
the DV non-structural proteins resulting in a punctuated pattern in the cytosol (Fig. 
28A, left panel). ANXA2 showed a very homogeneous cytoplasmic distribution in 
uninfected cells (top left-hand corner of the panels in Fig. 28A). Its cellular 
localization was neither changed due to DV infection nor did it colocalize with DV NS 
proteins. 
Another prominent member of the positive-strand RNA viruses is Semliki Forest virus 
(SFV) which is classified into the alphavirus family. To address a potential 
involvement of ANXA2 in SFV replication, a subgenomic replicon was transfected 
into naïve Huh-7 cells. 48 hours after transfection, cells were analyzed for 
colocalization of SFV NS3 with ANXA2. By staining with SFV NS3-specific antibodies 
the intracellular sites of viral RNA replication were determined. Similar to HCV and 
DV RCs, the SFV replication complexes appeared as cytosolic dot-like structures 
(Fig. 28B), although these structures have been shown to derive from late 
endosomes and lysosomes123. ANXA2 possessed its typical cytoplasmic distribution 
in non-transfected cells. In SFV-transfected cells, ANXA2 was mainly localized in the 
cytoplasm, although it was found in some granular structures, too. However, these 
granules did not colocalize with the dots representing the SFV RCs (Fig. 28B) 
indicating that this partial rearrangement of ANXA2 might not play a role in the SFV 
replication. These results confirmed that the redistribution of ANXA2 and its 
colocalization with viral NS proteins was specific for HCV and was not observed for 
other positive-stranded RNA viruses. 
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Fig. 28. No colocalization of ANXA2 with NS proteins of other positive-stranded RNA viruses.  
(A) Dengue virus infected Huh-7 cells were analyzed by immunofluorescence using monoclonal 
antibodies specific for ANXA2 and a polyclonal antiserum raised against Dengue virus NS3. The 
structure of the Dengue virus RNA is given above the IF panels. (B) Huh-7 cells transfected with 
Semliki Forest virus (SFV) RNA were analyzed by immunofluorescence using monoclonal antibodies 
specific for ANXA2 and a polyclonal antiserum raised against SFV NS3 (upper panels). Naïve Huh-7 
cells served as negative control for SFV NS3 (lower panels). 
 
Taken together, our studies showed that ANXA2 colocalized with HCV NS proteins 
and was redistributed to the sites of HCV RNA replication. This was independent 
from the experimental system, the HCV genotype, and the host cell type. I found no 
specific colocalization of HCV NS proteins with Calnexin and could rule out that p11, 
the major cellular interaction partner of ANXA2, interacted with the viral non-
structural proteins since a colocalization of p11 with HCV NS proteins was not 
observed. In addition, the HCV NS proteins did not colocalize with any member of the 
Annexin family, but specifically with ANXA2. Further on, I demonstrated that ANXA2 
was not colocalizing with the replication sites of other positive-stranded RNA viruses. 
The specific colocalization of HCV RCs with ANXA2 indicated that this protein might 
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play a vital role in viral replication. To answer this question, we evaluated the effects 
of ANXA2 overexpression and silencing onto HCV RNA replication. 
 
3.3.3 Studies of the role of Annexin II in HCV replication in HepG2 cells 
The previous colocalization studies indicated an interaction between the cellular 
protein ANXA2 and the viral protein components of the HCV replication complex. To 
gain further insights into the functional relevance of the ANXA2-HCV colocalization, 
we included the human hepatoma cell line HepG2 in our analysis. Puisieux and 
coworkers found that these cells comprised inherently no or only very low levels of 
ANXA2175. Interestingly, Date and colleagues established a HepG2 replicon cell line 
persistently replicating a subgenomic HCV genotype 2a replicon (JFH1)43. Due to 
their low endogenous ANXA2 levels, these cells appeared to be the appropriate tool 
to study overexpression as well as silencing of ANXA2 and its impact on HCV 
replication. 
In a first step, naïve HepG2 cells and those harboring persistently a subgenomic 
HCV JFH1 replicon (HepG2_JFH1) were analyzed by IFA in order to investigate 
whether a colocalization of ANXA2 could also be found in these cells. Concordantly 
with the publication mentioned before, ANXA2 was not detected in naïve HepG2 cells 
(Fig. 29). In HepG2_JFH1 cells however, the ANXA2 protein was explicitly visible 
and was located in the cytoplasm in distinct dotted structures which perfectly 
colocalized with the pattern of the HCV non-structural proteins NS3, NS4B, and 
NS5A (Fig. 29 A-C). This indicated that the expression of ANXA2 was maybe 
induced or that the protein itself was potentially stabilized by HCV, thereby reaching 
protein amounts that were detectable by IFA. Since HepG2_JFH1 cells were derived 
from selected cell clones, those HepG2 cells might be selected because they 
harbored higher endogenous level of ANXA2 allowing HCV replication.  
To evaluate whether an induction or a stabilization of ANXA2 occurred, HepG2 
replicon and naïve cells were analyzed by immunoblot and quantitative RT-PCR for 
their ANXA2 protein and mRNA content, respectively. The difference of the ANXA2 
protein level in these cells which was clearly visible in IFA could not be confirmed by 
immunoblot assay since ANXA2 was not detectable in the cell lysates (data not 
shown). The amount of ANXA2 mRNA between both different cell lines differed in 
one quantitative RT-PCR approach showing a higher level of ANXA2 mRNA in 
HepG2_JFH1 cells. However, this was not confirmed in a second experiment in 
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which both cell lines possessed similar mRNA amounts (data not shown). Therefore, 
it remains to be determined whether ANXA2 was induced or stabilized by HCV. 
 
 
Fig. 29. ANXA2 expression and colocalization with HCV NS proteins in HepG2 cells harboring a 
subgenomic replicon from genotype 2a (HepG_JFH1). PFA-fixed and permeabilized monolayers of 
HepG2_JFH1 cells were subjected to IFA using monoclonal antibodies specific for ANXA2 and either 
a polyclonal antiserum raised against HCV NS3 (A), or a polyclonal antiserum raised against HCV 
NS4B (B), or a polyclonal antiserum raised against HCV NS5A (C). Naïve HepG2 cells served as 
negative controls for the viral proteins as well as for ANXA2. 
 
The HCV replication level in HepG2 cells harboring subgenomic replicons was rather 
low, so I investigated whether an overexpression of ANXA2 in HepG2 cells would 
lead to an increase in HCV replication. To answer this question, cell lines 
constitutively expressing high amounts of ANXA2 were generated. Naïve HepG2 
cells were stably transduced using lentiviral vectors encoding the ANXA2 gene and a 
selection marker gene (neomycin phosphotransferase in GUN constructs, blasticidin 
resistance gene in BLR constructs) and selected by the appropriate antibiotic. 
Control cell lines were produced by transduction with lentiviral vectors only coding for 
the respective selection marker. The expression levels of ANXA2 in these different 
HepG2 cell lines were analyzed by immunoblot (Fig. 30B). In both cell lines 
overexpressing ANXA2 (HepG2_GUN_ANXA2 and HepG2_BLR_ANXA2) this 
protein was readily traceable by immunoblot assay, whereas it was not detected in 
the control cell lines HepG2_GUN and HepG2_BLR. Having succeeded in generating 
HepG2 cell lines permanently overexpressing ANXA2, I analyzed if permissiveness 
for HCV replication was increased in these cell lines. Therefore, the cells were 
transiently transfected with in vitro transcripts of a viral subgenomic JFH replicon 
(Fig. 30A) and a non-replicating GND construct harboring an inactivating point 
mutation in the NS5B gene; both possessed a luciferase reporter gene. At different 
time points post transfection, cells were lysed and analyzed for luciferase activity 
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which was taken as a correlate of HCV replication120,138. In Fig. 30C, the replication 
levels are depicted as fold 4h values; this time point marks the luciferase expression 
from the input RNA and was arbitrarily set to 1. In all transfected cells - regardless if 
they were overexpressing ANXA2 or not - the replication levels at 24, 48 or 72 hours 
were very similar: they were below the 4 hour value, but about tenfold higher than the 
respective negative control; revealing that in fact only low levels of replication 
occurred in these cells. The increased amount of ANXA2 did not lead to an 
advantage for HCV replication in HepG2 cells, indicating that ANXA2 is not limiting 
HCV replication in HepG2 cells. 
 
 
Fig. 30. ANXA2 overexpression in HepG2 cells and its effect on HCV replication. (A) Structure of the 
subgenomic RNA replicon used in this study. (B) Expression levels of ANXA2 in HepG2 cells stably 
transduced by recombinant lentiviruses. Equal cell amounts of different HepG2 cell lines were lysed 
and subjected to 10% SDS-PAGE. ANXA2 was detected in an immunoblot analysis using monoclonal 
antibodies specific for ANXA2. HepG2 cells durably transduced by lentiviruses expressing only the 
resistance gene (HepG2_GUN and HepG2_BLR) served as negative controls. (C) Time course of viral 
RNA replication levels in HepG2 cells stably overexpressing ANXA2. ANXA2 expressing HepG2 cells 
were transiently transfected with a subgenomic HCV RNA (JFH) harboring a luciferase reporter. Cells 
were harvested at the indicated time points and tested for luciferase activity. As controls, HepG2 cells 
permanently transduced by lentiviruses expressing only the resistance gene (HepG2_GUN and 
HepG2_BLR) were used. A non-replicating HCV replicon construct (GND) served as negative control 
for replication. 
 
This was further confirmed by a colony formation assay. The same cell lines used for 
the time course experiment were transfected with a selectable HCV subgenomic 
replicon (JFH) or a replication-deficient control replicon (ΔGDD) (neo_JFH/blr_JFH 
and neo_ΔGDD/blr_ΔGDD). The transfected cells were then selected by the 
appropriate antibiotics. ANXA2 overexpressing cells showed only a minor increase in 
colony formation numbers compared to the control cells (data not shown). This 
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indicated again that ANXA2 – despite its low levels in HepG2 cells - was not limiting 
HCV replication in these cells. However, the low endogenous levels provided a good 
starting point to impact HCV replication by further reduction of ANXA2 using siRNA in 
HepG2 cells. If ANXA2 really was directly involved in HCV replication, one would 
expect that a reduction of the endogenous ANXA2 would also result in a decrease of 
viral replication. To answer this question, I transfected HepG2_JFH1 cells already 
containing rather minor amounts of ANXA2 protein with siRNA directed against 
ANXA2. Further, as controls, cells were transfected with either a siRNA specific for 
HCV (HCV321) or an unrelated control (p53). The ANXA2 mRNA amounts as well as 
the number of HCV RNA copies in these cells were determined by RT-PCR. ANXA2 
mRNA levels of HepG2_JFH1 cells transfected repeatedly with different siRNAs were 
normalized to intracellular GAPDH mRNA levels and are shown in Fig. 31A. 
Compared to the HepG2_JFH1 cells transfected with siRNAs directed against p53 or 
HCV, the cells in which ANXA2 was silenced showed a slight decrease in ANXA2 
mRNA levels (by a factor of two; note that higher delta CT values correspond to 
lower mRNA levels). 
 
 
Fig. 31. ANXA2 silencing in HepG2_JFH1 cells. (A) ANXA2 mRNA levels in HepG2_JFH1 cells 
transfected with siRNAs effecting p53, ANXA2, and HCV RNA, respectively. The ANXA2 mRNA levels 
were analyzed by SYBR Green real-time PCR and were normalized to intracellular GAPDH mRNA 
levels. Note that higher bars represent lower mRNA levels. (B) HCV RNA levels in HepG2_JFH1 cells 
transfected with siRNAs effecting p53, ANXA2, and HCV RNA, respectively. The viral RNA was 
detected by real-time RT-PCR using HCV specific primers and probe and normalized for different 
loadings by GAPDH mRNA levels. It was quantified by means of a standard curve generated with 
known numbers of in vitro transcripts corresponding to a subgenomic replicon. 
 
Since the silencing of ANXA2 seemed to work out at least to some extent, I analyzed 
the same samples for their content of HCV RNA (Fig. 31B). The number of viral RNA 
copies in HepG2_JFH1 cells transfected with siRNA directed against ANXA2 was in 
the same range to that of the control-silenced (p53 siRNA) cells. The siRNA specific 
for HCV (HCV321) which should serve as a positive control for silencing seemed not 
RESULTS 
 
78
to work in this experiment, since the HepG2_JFH1 cells transfected by this siRNA 
showed no reduction in their HCV RNA level compared to the other silenced cells. 
This indicated that the overall transfection efficiency was low. The fact that a 
decrease of HCV RNA copies was not observed in ANXA2-silenced HepG2_JFH1 
cells was presumably due to the low silencing efficiency of about 50%.  
We found that the ANXA2 level was increased in HepG2 cells harboring a HCV 
subgenomic replicon compared to naïve HepG2 cells which was clearly seen in IFA. 
However, overexpression or silencing of ANXA in HepG2 cells had no impact on the 
viral replication. Since the protein levels of ANXA2 expressed from the endogenous 
locus were below the detection limit of an immunoblot, it remained an open question 
whether ANXA2 was induced or stabilized in presence of HCV. 
 
3.3.4 Silencing of Annexin II and its effect on HCV replication in Huh-7 
cells 
The most efficient cells to study HCV replication are Huh-7 cells. Therefore, we 
decided to analyze the impact of ANXA2 silencing onto transient HCV replication in 
these cells. However, their high endogenous levels of ANXA2 could complicate 
functional silencing. 
In a first line of experiments, shRNA cell lines stably silencing ANXA2 were 
generated to reach a sufficient decrease in the steady state protein level. An shRNA 
directed against p53 mRNA was chosen as a control, since it was shown by Krönke 
and colleagues that silencing of p53 did not affect HCV replication121 whereas 
several other control shRNAs had negative pleiotropic effects (data not shown). The 
differences in ANXA2 amounts between Huh-7 cells producing shRNAs directed 
against ANXA2 (sh ANXA2 lunet) and control cells generating p53-specific shRNAs 
(sh p53 lunet) were analyzed by immunofluorescence assay and are depicted in Fig. 
32A. The cells had been sorted by FACS (fluorescence activated cell sorting) due to 
their GFP co-expression to have a cell population providing high amounts of shRNA. 
However, there was still a substantial number of cells visible containing high levels of 
ANXA2 in the sh ANXA2 cell line. Nevertheless, these shRNA cell lines were 
transiently transfected with in vitro transcripts of subgenomic replicons from different 
HCV genotypes (PI_luc_JFH, PI_luc_ET, and PI_Luc_GND as non-replicating 
control), lysed at varying time points and tested for luciferase activity. As 
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demonstrated in Fig. 32B, PI_luc_JFH and PI_luc_ET, respectively, showed no 
variances in their replication levels in the different shRNA cell lines. This could be 
due to the inefficient silencing of ANXA2 in the sh ANXA2 lunet cell line, and 
therefore the remaining ANXA2 level was sufficient for an efficient HCV replication.  
 
 
Fig. 32. Stable silencing of ANXA2 in shRNA cell lines and its effect on transient HCV replication. (A) 
ANXA2 levels in different shRNA cell lines. ShRNA cells were subjected to IFA using monoclonal 
antibodies directed against ANXA2. (B) Time course of viral RNA replication in different shRNA cell 
lines. ShRNA cells were transiently transfected with different subgenomic HCV luciferase replicons, 
harvested and lysed at the indicated time points, and analyzed for luciferase activity. A replication-
deficient HCV replicon construct (GND) served as negative control. (C) Colocalization studies of 
ANXA2 with HCV NS3 in shRNA cells transiently transfected with a subgenomic HCV JFH1 replicon. 
Transfected cells were PFA-fixed, permeabilized and subjected to IFA using monoclonal antibodies 
specific for ANXA2 and a polyclonal antiserum raised against HCV NS3. 
 
Immunofluorescence analyses of the HCV-transfected sh ANXA2 cells revealed a 
strict correlation of HCV and ANXA2 levels: cells containing plenty of ANXA2 seemed 
to support high levels of HCV replication, no ANXA2 was visible in HCV non-
transfected cells, and lower levels of HCV NS proteins were observed in cells with 
low ANXA2 amounts (Fig. 32C). Although an impact of stable ANXA2 silencing onto 
HCV replication was not found, the findings of the colocalization studies pointed to a 
potential correlation of ANXA2 and HCV NS protein levels.  
I also tested whether stable ANXA2 silencing in Huh7.5 cells had an influence on 
HCV infection. However, neither the viral replication nor the infectivity of the resulting 
supernatants was affected, even if the cells were additionally transfected by siRNA to 
boost the silencing efficiency (data not shown). 
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Stable silencing of ANXA2 in shRNA cell lines was not as efficient as expected. 
Therefore, we decided to silence ANXA2 transiently using specific siRNAs. Since 
ANXA2 was identified as putative cofactor of the HCV replication complex by 
comparative 2D gel analyses of subgenomic replicon cells, it was obvious to analyze 
the effect of decreased ANXA2 amounts in those cell lines. Though, transient 
silencing of ANXA2 in subgenomic replicon cell lines persistently replicating viral 
RNAs (lucubineo ET, 9-13, and 5-15 cells) had no impact on the HCV replication 
levels and the HCV RNA copy numbers, respectively (data not shown).  
Likewise, I investigated whether transient ANXA2 silencing was affecting HCV 
infection. For this experiment, Huh7.5 cells were silenced twice with siRNA directed 
against ANXA2 or a control siRNA. The infection with virus harboring a full-length 
genotype 2a genome and a luciferase reporter gene (Jc1-luc) was performed 
between the two rounds of silencing. However, neither the replication of the virus nor 
the infectivity of the resulting supernatants was influenced by ANXA2 silencing (data 
not shown). 
To answer the question, whether ANXA2 silencing influences transient HCV 
replication, naïve Huh-7 cells were transfected twice with siRNA directed against 
ANXA2 or an unspecific control. Simultaneously with the second siRNA transfection, 
in vitro transcripts of subgenomic HCV replicons from different genotypes were 
transfected by electroporation. The luciferase replicons used in this experiment are 
depicted in Fig. 33A. The replicon PI_luc_JFH contains NTRs and NS protein-coding 
sequences of genotype 2a, PI_luc_ET those of genotype 1b. The ANXA2 protein 
levels in the differently silenced and transfected Huh-7 cells were determined 
qualitatively by immunoblot (Fig. 33B). The amount of ANXA2 was considerably 
lower in ANXA2-silenced cells compared to the control-silenced cells indicating that 
the silencing was efficient. This was also irrespective from the transfected HCV RNA 
genotype or a mock transfection. In order to investigate whether the transient 
silencing of ANXA2 in Huh-7 cells had an impact on HCV replication, I lysed the cells 
at different time points after transfection and analyzed them for luciferase activity 
(Fig. 33C). The replication of the PI_luc_ET construct was similar in ANXA2-silenced 
cells and in control-silenced cells, i.e. exhibited no differences due to ANXA2 
silencing. The PI_luc_JFH replicon also did not show any discrepancies in replication 
levels as a result of the reduction of ANXA2 compared to the control cells. Therefore, 
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silencing of ANXA2 by siRNA did not affect transient HCV replication rates 
irrespective from the viral genotype. 
 
 
Fig. 33. Transient silencing of ANXA2 and its effect on transient HCV replication. (A) Structures of the 
luciferase reporter replicon constructs used in this study. (B) ANXA2 protein levels in naïve Huh-7 
cells transiently transfected with subgenomic HCV replicons as well as with siRNA specific for ANXA2 
or an unrelated control siRNA. Cells were lysed 48 h p. tr., subjected to SDS-PAGE and analyzed by 
immunoblot assay using monoclonal antibodies raised against ANXA2 and Actin, respectively. The 
signal of the latter was used as loading control. (C) Time course of HCV RNA replication in naïve  
Huh-7 cells transiently transfected with HCV luciferase replicons and siRNA anti-ANXA2 or control 
siRNA. Cells were harvested at different time points and tested for luciferase activity.  
(D) Colocalization studies of ANXA2 with HCV NS3 in Huh-7 cells transiently transfected with a 
subgenomic HCV JFH1 replicon and siRNA directed against ANXA2 or a control siRNA. Transfected 
cells were PFA-fixed, permeabilized and subjected to IFA using monoclonal antibodies specific for 
ANXA2 and a polyclonal antiserum raised against HCV NS3. 
 
However, IFA of these cells still revealed a strict correlation of ANXA2 and HCV 
levels as indicated by colored arrowheads in the lower panels of Fig. 33D: (i) cells not 
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transfected by HCV showed hardly any signal for ANXA2 (yellow), (ii) cells containing 
high levels of HCV NS protein had still a large amount of ANXA2 (red), and (iii) in 
cells comprising low amounts of HCV and presenting only isolated spots for NS 
proteins, ANXA2 was found to colocalize with these spots but was barely recovered 
at other locations in the cytoplasm (blue). This result implied that low amounts of 
ANXA2 were associated with minor levels of HCV and was also observed upon 
stable silencing of ANXA2. As a putative cofactor of the HCV replication complex, 
ANXA2 was maybe protected and/or stabilized by HCV (at least partially) and 
therefore could still be found in HCV-transfected, ANXA2-silenced cells. In contrast, 
in the control-silenced cells only two distinct phenotypes were detected: HCV non-
transfected cells showed the general cytoplasmic distribution of ANXA2, whereas in 
cells replicating HCV the typical rearrangement of ANXA2 was observed as well as 
its colocalization with viral proteins (Fig. 33D, upper panels). 
 
 
Fig. 34. Transient silencing of ANXA2 and its effect on transient HCV replication. (A) Structure of the 
HCV replicon used in this study. (B) ANXA2 protein levels in naïve Huh-7 cells transiently transfected 
with a subgenomic HCV replicon as well as with siRNA specific for ANXA2 or an unrelated control 
siRNA. Cells were harvested and lysed at the indicated time points, subjected to SDS-PAGE and 
analyzed by immunoblot assay using monoclonal antibodies raised against either ANXA2 or Actin. 
The signal of the latter was used as loading control. (C) Colocalization studies of ANXA2 with HCV 
NS3 in Huh-7 cells transiently transfected with a subgenomic HCV JFH1 replicon and siRNA anti-
ANXA2 or a control siRNA. Transfected cells were PFA-fixed (48 h p.tr.), permeabilized and subjected 
to IFA using monoclonal antibodies specific for ANXA2 and a polyclonal antiserum raised against HCV 
NS3. 
 
A repetition of this experiment using a slightly different replicon construct illustrated 
the different stainings found in ANXA2-silenced cells yet even more obvious. In this 
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experimental setup, naïve Huh-7 cells were also transfected twice with siRNA 
specific for ANXA2 or a control siRNA. At the same time as the second silencing, 
these cells were transiently transfected with a selectable subgenomic RNA from 
genotype 2a harboring a neomycin phosphotransferase gene (Neo_JFH; Fig. 34A). 
Cells were harvested 24 and 48 hours after HCV transfection, and analyzed for 
ANXA2 protein levels by immunoblot assay. As shown in Fig. 34B, already 24 h post 
transfection a decrease in the ANXA2 amount was observed in ANXA2-silenced 
cells, and this reduction was even more obvious after 48 hours. The ANXA2 levels in 
the control cells stayed unchanged. The phenotypes of ANXA2 staining found in the 
preceding experiment and mentioned above were affirmed by immunofluorescence 
studies of ANXA2- and control-silenced cells both transfected with Neo_JFH RNA 
(Fig. 34C). Again, a strict correlation of ANXA2 and NS3 levels was observed in cells 
treated with siRNA directed against ANXA2. 
Transient as well as stable ANXA2 silencing did not massively affect any aspect of 
the HCV life cycle, in particular the viral replication. However, although the ANXA2 
silencing was done in different ways, we always found a clear correlation of ANXA2 
and HCV NS protein levels in individual cells in all experimental settings. 
To analyze this aspect more quantitatively, the same experiments were investigated 
by FACS. Therefore, naïve Huh-7 cells were transfected twice with siRNA specific for 
ANXA2 or - as control - the DV 3’UTR. Simultaneously with the second silencing, 
these cells were transiently transfected with a subgenomic RNA from genotype 2a 
harboring an emerald GFP (emGFP) inserted into the C-terminus of NS5A 
(luc_JFH/5A_emGFP). Therefore, the HCV replication could be directly correlated to 
the GFP expression, whereas the ANXA2 protein levels were determined by staining 
with a specific monoclonal antibody. Cells were fixed in PFA 48 hours after 
transfection, permeabilized, and stained intracellularly against ANXA2. GFP 
expression levels upon HCV replication and ANXA2 protein amounts were analyzed 
by FACS. To confirm a correlation between ANXA2 and HCV, cells being positive for 
HCV replication (GFP expression) should also be positive for ANXA2. Dot blot 
analyses of ANXA2- and control-silenced cells, both transfected with HCV, are 
shown in Fig. 35. To determine the cell pool negative for HCV as well as for ANXA2, 
mock silenced, mock transfected Huh-7 cells were investigated by FACS (Fig. 35A). 
These cells were only stained with a secondary fluorescence-coupled antibody to 
evaluate the background caused by this antibody as well as their autofluorescence. 
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Based on that, the dot blots were subdivided in four quadrant regions representing 
HCV- and ANXA2-negative cells (lower left), HCV-positive and ANXA2-negative cells 
(upper left), HCV- negative and ANXA2-positive cells (lower right), and HCV- and 
ANXA2-positive cells (upper right). After ANXA2 silencing in mock transfected cells, 
as expected, the portion of ANXA2-positive cells was diminished from 58.6% to 1%, 
compared to the control-silenced cells (Fig. 35B and C). This showed that the ANXA2 
silencing was efficient. In HCV-transfected cells, the portion of HCV- and ANXA2-
positive cells was reduced from 63% to 13.5% upon ANXA2 silencing (Fig. 35E and 
F). The increased number of HCV-transfected cells remaining positive for ANXA2 
despite ANXA2 silencing (13.5%, Fig. 35F) compared to the ANXA2-positive cell 
population in mock transfected, ANXA2-silenced cells (1%, Fig. 35C) pointed to 
possible induction or stabilization of ANXA2 by HCV. The FACS analyses also 
indicated a general correlation between HCV replication and ANXA2 protein level, 
irrespective of the silencing. This was reproducible in several independent 
experiments, thus, it was investigated in greater detail. 
 
 
Fig. 35. FACS analyses of ANXA2-silenced Huh-7 cells transiently transfected with an GFP-harboring 
HCV subgenomic replicon. (A) Mock transfected, mock silenced Huh-7 cells. Cells were only stained 
with the secondary antibody and served as control to evaluate the cell pool being negative for HCV as 
well as for ANXA2 and determine the quadrant regions. (B) Control-silenced (DV 3’UTR), mock 
transfected Huh-7 cells. (C) ANXA2-silenced, mock transfected Huh-7 cells. (D) HCV-transfected, 
mock silenced Huh-7 cells. (E) Control-silenced (DV 3’UTR), HCV-transfected Huh-7 cells. (F) 
ANXA2-silenced, HCV-transfected Huh-7 cells. (B-F) Cells were stained against ANXA2. The fraction 
of cells (in %) detected in the respective quadrants are given.  
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Therefore, the dot blots were subdivided into smaller regions, this is shown 
exemplarily for control-silenced, HCV-transfected cells in Fig. 36. The horizontal line 
separates the HCV-negative (below) from the HCV-positive cells (above). The blot 
was further subdivided by the logarithmic scale of the abscissa into smaller regions. 
For each upper region (HCV-positive) the mean fluorescence intensities (MFIs) for 
ANXA2 as well as for HCV were determined and compared with each other in order 
to investigate a possible correlation. 
 
 
Fig. 36. Example of a FACS dot blot subdivision to determine the mean fluorescence intensities 
(MFIs) of HCV and ANXA2. Cells negative for HCV are located in the regions below the horizontal 
line, HCV-positive cells in the regions above. Only the MFIs of the upper regions were determined.  
 
The MFI values were related to each other resulting in a graph which is exemplarily 
shown for a single experiment in Fig. 37. Increasing MFIs of ANXA2 were positively 
correlated with ascending MFIs for HCV, i.e. the more ANXA2 protein was contained 
in the cell the higher was the HCV replication level and vice versa. This phenotype 
was observed in all cells regardless of their siRNA treatment. This indicated that the 
level of HCV replication in a cell depended on its ANXA2 amount or that HCV 
induced higher ANXA2 levels. 
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Fig. 37. Positive correlation of ANXA2 levels and HCV replication. Naïve Huh-7 cells were transfected 
twice with siRNAs directed against ANXA2 or the 3’UTR of DV, or with PBS (as mock control), 
respectively. Additional to the second siRNA transfection, the cells were simultaneously transfected 
with a subgenomic HCV replicon comprising emGFP fused to NS5A. 48 hours post transfection, cells 
were singularized and fixed in PFA. Subsequently they were permeabilized, stained intracellularly by 
using monoclonal antibodies directed against ANXA2 and analyzed by FACS. The abscissa shows the 
mean fluorescence intensities (MFI) of ANXA2, the ordinate shows the corresponding MFI of HCV 
(GFP). Blue filled circles represent mock silenced cells, red filled triangles control-silenced cells (DV 
3’UTR), and green filled triangles ANXA2-silenced cells. 
 
 
 
Fig. 38. Slightly increased ANXA2 levels upon HCV transfection. (A) ANXA2 levels in HCV-transfected 
and non-transfected Huh-7 cells both additionally transfected with siRNA directed against the 3’-UTR 
of DV (DV siRNA). (B) ANXA2 levels in HCV-transfected and non-transfected Huh-7 cells both 
additionally transfected with siRNA directed against ANXA2 (ANXA2 siRNA). In both diagrams, the 
abscissa shows the fluorescence intensity of ANXA2, the ordinate specifies the number of cells. The 
silenced, HCV non-transfected cells are given in blue; the silenced, HCV-transfected cells are 
indicated by a red line. 
 
The latter aspect, increased ANXA2 levels in presence of HCV, was visible more 
clearly in a histogram, especially upon ANXA2 silencing (Fig. 38). The increased 
ANXA2 levels could be due to an induction of ANXA2 expression or a stabilization of 
the ANXA2 protein by HCV. To test the first alternative, the ANXA2 mRNA levels in 
different cell lines were analyzed by RT-PCR assay. If the ANXA2 expression was 
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induced by any HCV component, an increased ANXA2 mRNA level could be 
expected in cells persistently replicating viral RNA compared to the naïve cells. I 
compared different naïve cell lines with replicon cell lines originating from those naïve 
cells and - if present - also with corresponding cured replicon cell lines, e.g. 9-13 and 
cured 9-13 cells; naïve HuH6 cells, HuH6_JFH cells, and cured HuH6 cells, as well 
as further cell lines. Unfortunately, the results of two independent RT-PCR assays 
were not reproducible. Between the different experiments, the ANXA2 mRNA levels 
of the single cell lines showed big fluctuations and therefore did not permit reliable 
conclusions whether ANXA2 expression was induced by HCV replication (data not 
shown). On the other hand, as mentioned before, we observed a slight decrease in 
HCV replication when ANXA2 was silenced. This result was reproducible in several 
independent experiments and is depicted for two of them in Fig. 39. It was 
unambiguously visible that the number of cells harboring high levels of HCV was 
lower in ANXA2-silenced cells compared to control-silenced cells. This result clearly 
indicated that ANXA2 played a functional role in controlling HCV replication. 
 
 
Fig. 39. Slightly reduced HCV levels upon ANXA2 silencing. HCV levels in ANXA2-silenced and 
control-silenced (DV 3’UTR) cells transiently transfected with HCV. (A) and (B) represent two 
independent experiments. In both diagrams, the abscissa shows the fluorescence intensity of HCV, 
the ordinate specifies the number of cells. The control-silenced cells are given in blue; the ANXA2-
silenced cells are indicated by a red line. 
 
In summary, the ANXA2 silencing experiments showed a positive correlation 
between the ANXA2 protein amount and the rate of HCV replication. However, a 
strong reduction or even inhibition of HCV replication was not achieved by either of 
the used silencing methods. This possibly implies that the silencing of ANXA2 was 
not efficient enough to have a major impact on viral replication or was counteracted 
by a positive induction via HCV.  
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3.3.5 Studies to identify the viral interaction partner of Annexin II 
Since ANXA2 strictly colocalized with the sites of HCV replication in cell experimental 
systems and cell lines, it seemed likely that the cellular protein was retrieved by a 
viral NS protein. In order to identify the viral interaction partner of ANXA2, I first 
analyzed the subgenomic replicon cell line 5-15 by co-immunoprecipitation (co-IP) 
studies. Cured replicon cells were used as negative control. The cells were lysed in 
NPB and subjected to IP with different polyclonal antisera as indicated in Fig. 40. 
Antisera raised against NS proteins were used to co-precipitate ANXA2, the E2-
specific antiserum served as unspecific binding control because the used 
subgenomic replicon did not code for structural proteins. The antiserum raised 
against ANXA2 was used as positive control for binding. The proteins precipitated in 
this way were separated by SDS-PAGE and subsequently subjected to immunoblot 
assay using an anti-ANXA2 antibody. ANXA2 was detected in the total lysates (pure) 
of the different cell lines (upper panel; lanes 1 and 8). However, ANXA2 was not 
precipitated by any of the antibodies directed against a HCV NS protein and not even 
by the ANXA2-specific antiserum. This indicated either a very weak interaction of 
ANXA2 with the viral protein(s) or technical problems in this experiment.  
 
 
Fig. 40. Co-immunoprecipitation analysis of subgenomic replicon cells. Cells of the subgenomic 
replicon cell clone 5-15 were lysed in NPB and subjected to immunoprecipitation assay using protein 
A agarose-coupled polyclonal antibodies (rabbit) directed against the viral proteins E2, NS3, NS4B, 
NS5A, NS5B, and cellular ANXA2, respectively. Cured replicon cells served as control cells. 
Precipitated proteins were analyzed by SDS-PAGE followed by immunoblot assay using monoclonal 
antibodies either raised against ANXA2 (above) or specific for HCV NS3 (below). As positive controls, 
total cell lysates (pure) were analyzed in this immunoblot, too. 
 
To control the efficiency of the IP, the western blot membrane was stripped and 
reprobed against NS3. As shown in the lower panel of Fig. 40, NS3 was recovered in 
the total lysate of 5-15 cells and precipitated by NS3-specific antibodies using the 
same cell lysate (lanes 1 and 3), indicating that the IP worked in general. 
Nevertheless, ANXA2 could not be revealed. However, other experiments showed 
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that the ANXA2-specific antibody used in this experiment did not work in 
immunoprecipitation (data not shown).  
The viral interaction partner of ANXA2 could also not be identified by using the 
crosslinking reagent DSP prior to cell lysis and immunoprecipitation to stabilize weak 
or transient protein interactions (data not shown). 
Co-precipitation studies of stable subgenomic replicon cell lines did not reveal which 
NS protein interacted with ANXA2. Therefore, the HCV proteins NS3-to-5B (genotype 
1b, pTM NS3-5B_ET) were heterologously expressed in naïve Huh-7 cells harboring 
a T7 RNA polymerase (lunet-T7), and the newly synthesized proteins were 
metabolically labeled with 35S. The advantage of this system was the higher 
expression level of the viral proteins which was caused by a T7 promoter-driven 
expression. The cells were lysed and subjected to an immunoprecipitation assay 
(Fig. 41). However, none of the IPs using antisera against HCV NS proteins showed 
a co-precipitation of ANXA2 (Fig. 41A and B, lanes 8 to 11). On the other hand, 
ANXA2-specific antibodies seemed to precipitate at least a low amount of NS3, but 
this result was not very convincing due to the low efficiency and the high background 
of the anti-ANXA2 antibody (compare lanes 6 and 12). A precipitation of other NS 
proteins with this antiserum was not detectable. In addition, co-precipitation of NS3 
was also observed in the anti-NS4B and anti-NS5A reaction (compare lanes 3 and 9 
as well as lanes 4 and 10). These co-precipitations are regularly observed due to the 
association of the non-structural proteins (V. Lohmann, personal communication). 
Due to this fact, the presence of NS3 in the anti-ANXA2 IP could therefore be caused 
by co-precipitation of another NS protein. Therefore, this experiment indicated an 
interaction of ANXA2 with HCV NS protein but did not unambiguously identify the 
distinct viral partner.  
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Fig. 41. Heterologous expression of HCV non-structural proteins. (A) Co-immunoprecipitation analysis 
of cells heterologously expressing HCV NS proteins. 4 h post transfection, lunet-T7 cells transfected 
with pTM NS3-5B/ET as well as mock transfected cells were subjected to a metabolic 35S-labeling 
followed by an immunoprecipitation analysis using protein A agarose-coupled polyclonal antibodies 
(rabbit) directed against the viral proteins NS3, NS4B, NS5A, NS5B, and protein G sepharose-coupled 
monoclonal antibodies specific for ANXA2, respectively. Protein A agarose was used as control for 
unspecific binding (bead control). Precipitated proteins were separated in a SDS-PAGE and detected 
by autoradiography. Arrows on the right side (top down) indicate the molecular weights of NS3 (70 
kDa), NS5B (68 kDa), NS5A (56/58 kDa), ANXA2 (36 kDa), and NS4B (27 kDa). (B) Enlargement of 
(A). 
 
Therefore, I tried to identify the interaction partner of ANXA2 by co-precipitation 
studies using lunet-T7 cells transfected with DNA coding for single HCV non-
structural proteins. The newly synthesized proteins were metabolically labeled with 
35S and subjected to immunoprecipitation assay using antisera specific for the HCV 
NS proteins or ANXA2. Precipitated proteins were separated by SDS-PAGE and 
detected by autoradiography. However, also in this experiment an interaction of 
ANXA2 with viral NS proteins was not observed. None of the antibodies directed 
against a viral NS protein was able to co-precipitate ANXA2 (Fig. 42; lanes 8, 14, 20, 
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28, and 35). Likewise, the ANXA2-specific antibody did not coprecipitate any HCV 
NS protein (Fig. 42; lanes 12, 18, 24, 30, and 36). 
 
 
Fig. 42. Co-immunoprecipitation analysis of cells heterologously expressing individual HCV NS 
proteins. 4 h post transfection, lunet-T7 cells transfected with pTM constructs encoding different single 
NS proteins as well as mock transfected cells were subjected to a metabolic 35S-labeling followed by 
an immunoprecipitation analysis using protein A agarose-coupled polyclonal antibodies (rabbit) 
directed against the proteins NS3, NS4B, NS5A, NS5B, and ANXA2, respectively. Protein A agarose 
was used as control for unspecific binding (bead control). Precipitated proteins were separated in a 
SDS-PAGE and detected by autoradiography.  
 
Co-precipitation studies of cells harboring subgenomic replicons or heterologously 
expressing the viral NS proteins either individually or as polyprotein did not clearly 
reveal the viral interaction partner of ANXA2. Another widely-used approach to 
investigate the putative interaction between two different proteins is the yeast two-
hybrid (Y2H) assay. Although this experimental system was more prone to artifacts 
than those utilized before, it represented a possible alternative for the identification of 
the viral NS protein interrelated with ANXA2. Therefore, NS3, NS3 helicase, NS5A 
(all genotype 1b), as well as truncated forms of the NS5B polymerase of genotype 1b 
and 2a (NS5BΔC21 Con and NS5BΔC21 JFH, respectively; deletion of the C-
terminal 21 aa) served as bait, whereas ANXA2 was the prey in this Y2H assay. 
ANXA2 showed only a very weak interaction with NS5A and none with any other of 
the tested viral non-structural proteins (data not shown).  
In the co-precipitation studies, it was shown that ANXA2-specific antibodies are able 
to precipitate a small portion of NS3. These interactions with NS3 as well as with 
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NS5A in Y2H assays still had to be verified by other experiments to confirm their 
reliability. 
In HCV-harboring cells, an intracellular redistribution of ANXA2 as well as its 
colocalization with viral NS proteins was always detectable. We were interested 
whether this would also be visible in cells heterologously expressing the HCV 
proteins and in using this assay to address the viral protein retrieving ANXA2. Cells 
were transfected with DNA for the heterologous expression of the viral non-structural 
proteins and analyzed by IFA (Fig. 43). In mock transfected lunet-T7 cells, ANXA2 
showed a homogeneous cytosolic distribution (Fig. 43A). However, upon transient 
exogenous expression of the NS proteins NS3-to-5B (pTM NS3-5B, Fig. 43B), a 
modification in the intracellular distribution of ANXA2 was clearly visible, just as in the 
immunofluorescence studies of HCV replicating cells before (see chapters 3.3.1 to 
3.3.4). ANXA2 was found in dot-like structures and, furthermore, an explicit 
colocalization with HCV NS3 was also observed in this experimental setup (Fig. 
43B). Therefore, this assay was suitable to analyze the redistribution of ANXA2 due 
to the expression of individual NS proteins. The analysis was complicated by the fact 
that the HCV NS proteins in general showed an ER-like arrangement when they were 
expressed individually except for the membranous web inducing NS4B which exhibits 
a clearly punctuated pattern (V. Lohmann, personal communication). Since it was 
possible that ANXA2 is reallocated upon interaction with an HCV non-structural 
protein, lunet-T7 cells expressing a single viral NS protein (genotype 1b) were 
investigated by IFA (Fig. 43C-G). ANXA2 did not specifically colocalize with 
individually expressed NS3, NS3-4A, NS4B, and NS5B, but retained a cytoplasmic 
distribution as in naïve lunet-T7 cells (compare Fig. 43A with Fig. 43 C-E, and G). 
However, as shown in Fig. 43F, ANXA2 clearly colocalized with heterologously 
expressed NS5A which was detected in a spotted pattern probably due to the 
overexpression. Apparently, ANXA2 was also induced by HCV NS5A, since in 
neighboring cells not expressing NS5A the signal for ANXA2 was significantly lower. 
In cells exogenously expressing the NS proteins NS3-to-5B, ANXA2 was 
redistributed and colocalized with the NS proteins. IFAs of cells expressing the 
individual non-structural proteins revealed that NS5A was most likely the viral 
interaction partner of ANXA2 and responsible for the increased ANXA2 levels in 
HCV-harboring cells. 
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Fig. 43. Colocalization studies of ANXA2 and HCV NS proteins heterologously expressed in lunet-T7 
cells. Cells transfected with DNAs coding for either NS3-to-5B (B) or different individual non-structural 
proteins (C-G) were fixed 8 hours post transfection and subjected to IFA using monoclonal antibodies 
specific for ANXA2 (A-G), and polyclonal antisera raised against NS3 (A-D), NS4B (E), NS5A (F), and 
NS5B (G), respectively. Mock transfected cells were used as a negative control (A). Indicated on the 
left are the constructs used for transfection. 
 
In summary, 2D gel analyses of PrK-resistant CRCs of cells harboring subgenomic 
replicons (9-13; genotype 1b) showed that ANXA2 was a potential cellular cofactor of 
the viral replication complex. The subcellular distribution of ANXA2 was rearranged 
upon HCV replication as well as infection and was neither dependent on the HCV 
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genotype nor on a certain host cell line. It was rather specific for HCV, since 
redistribution of ANXA2 was not caused by other positive-strand RNA viruses. 
Overexpression and silencing of ANXA2 had so far no major impact on HCV 
replication, but it seemed that ANXA2 expression was induced upon HCV 
transfection, potentially interfering with efficient silencing. Furthermore, a positive 
correlation between ANXA2 levels and HCV replication was observed. The viral 
interaction partner probably was NS5A, however, the function of ANXA2 in the viral 
life cycle remains to be determined. 
 
3.4 Quantitative analysis of the Hepatitis C Virus replication 
complex 
As mentioned before, the non-structural proteins NS3 to 5B are necessary and 
sufficient for HCV RNA replication. They form a membrane-associated complex 
containing viral proteins and RNA as well as cellular cofactors. Biochemical analyses 
of CRCs prepared from lysates of replicon cells provided deeper insights into the 
organization and structure of the viral replication complex5,8,52,86,125,153,193, however, a 
detailed stoichiometric analysis of the  HCV replication complex has not been carried 
out yet.  
Due to the polyprotein nature of the HCV genome, all viral proteins should be 
produced equimolarly, independent on their function. However, one could assume 
that the structural proteins which are involved in particle morphogenesis are required 
in higher amounts than the non-structural proteins. I determined if there is indeed an 
overproduction of non-structural proteins and which ratio of non-structural proteins to 
RNA is required for HCV RNA replication.  
 
3.4.1 Quantification of the HCV RNA to protein ratio in Huh-7 cells 
The first question addressed in my study was, how the number of HCV positive- and 
negative-strand RNA molecules correlates with the amount of different HCV proteins 
in cells with productive HCV RNA replication. Therefore I transfected a full-length 
HCV genome with cell culture adaptive mutations (Con1/ET, Fig. 44,172) into Huh7-
Lunet cells, a cured replicon cell clone featuring increased permissiveness for HCV 
replication. Cells were seeded in aliquots after electroporation, harvested at different 
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time points, counted and analyzed for the amount of HCV RNA and proteins. Fig. 
44B shows a typical northern blot analysis of such a transient replication assay by 
using known numbers of in vitro transcripts to determine the quantity of positive- and 
negative-strand RNA in cells transfected with Con1/ET. The obvious detectable 
negative-strand RNA signal displays that RNA replication had already started 24 h 
after transfection, reached its maximum at 48 h and 72 h after transfection and 
slightly decreased at 96 h, after the cells had reached confluence (Fig. 44B, top and 
middle panel).  
HCV core and non-structural proteins 4B and 5B were quantified by western blot 
analysis of cell lysates in comparison with well-defined amounts of purified proteins 
from the same HCV isolate141, and by using antibodies raised against these particular 
antigens (Fig. 44C). The number of core, NS4B and NS5B molecules in the 
transfected cells followed the same changes over time as the RNA. The results 
obtained for the quantitative evaluation are summarized in Table 2. 
Earlier studies have shown that transfected RNA of replication-deficient genomes is 
degraded to trace amounts 24 h after transfection and completely absent after  
48 h34,172. On account of this, the quantitative analysis was limited to the data 
obtained at 48-96 h, thereby preventing any impact of transfected input RNA. I found 
on average 40 copies of negative-strand RNA, a fivefold excess of positive-strand 
RNA and approximately one million copies of core, NS4B and NS5B per cell, 
indicating a vast excess of viral proteins to RNA molecules. Within the expected 
range of accuracy the ratio of the non-structural proteins NS4B and NS5B was very 
similar. The 3-6-fold higher relative levels of core might be due to premature 
termination of translation leading to an overrepresentation of the aminoterminal 
portions of the HCV polyprotein. Nevertheless, the data were consistent in showing a 
tremendous surplus of HCV proteins compared to RNA molecules. 
Since we intended to ascertain the stoichiometry of RNA to protein in the HCV 
replication complex, I searched for the most appropriate biochemical equivalent. 
Every active replication complex must bear at least one negative-strand RNA 
molecule, therefore the maximal number of HCV replication complexes per cell can 
be estimated by the amount of negative-strand RNA copies. Based on this 
assumption, I found on average less than forty active replication complexes per cell, 
but each of it was attended by 20,000-40,000 copies of non-structural proteins. 
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Fig. 44. Quantification of HCV RNA and non-structural proteins in Huh-7 cells transfected with a full-
length genome. (A) Structure of the HCV RNAs used in this study. Con1/ET represents a full-length 
HCV genome harboring cell culture adaptive mutations in NS3 and NS4B 172. The monocistronic 
replicon contains only a single open reading frame consisting of nt 342–389 of the core-coding region, 
the hygro gene (encoding the hygromycin phosphotransferase), the ubiquitin-encoding sequence (Ubi) 
and the HCV non-structural proteins NS3–NS5B 66 and was used to select Huh-7 cell clone 11-1, 
which was analyzed in this study (Table 2). The bicistronic replicon is composed of the first 377 
nucleotides of the HCV genome fused to the neo gene (encoding the neomycin phosphotransferase). 
Translation of the HCV non-structural proteins NS3-5B is initiated by the EMCV-IRES. The bicistronic 
replicon was used to generate cell-clone 9-13 140. (B) Time course of HCV positive and negative-
strand synthesis following transfection of Con1/ET RNA into Huh7-Lunet cells. Cells were harvested 
and counted at the time points indicated above the figure (hours pE, post electroporation) and total 
RNA was prepared. 5µg of total RNA corresponding to 2.5, 2.1, 2.1 and 2.3 x105 cells at 24 h, 48 h, 72 
h and 96 h, respectively, was subjected to Northern hybridization using radiolabeled riboprobes 
specific for the detection of HCV positive-strand (top panel),  negative-strand (middle panel) or β-Actin 
(lowest panel). Specific signals are indicated by arrowheads. Signals were quantified by phosphor 
imaging using known amounts of in vitro transcripts of positive or negative polarity corresponding to a 
subgenomic replicon and normalized for different loadings by the β-Actin signal. Total RNA from naïve 
Huh-7 cells was used as negative control (Huh-7). (C) Quantification of HCV core (upper panel) NS4B 
(middle panel) and NS5B (lowest panel) expression following transfection of Con1/ET RNA into Huh7-
Lunet cells. An aliquot of the cells harvested for total RNA preparation at the time points given above 
each panel was lysed in protein sample buffer and subjected to immunoblot analysis using monoclonal 
antibodies (NS5B) or polyclonal antisera (core, NS4B) with the specificities given on the right. 
Samples were quantified by comparison of signal intensities derived from known amounts of the 
respective antigens as indicated above each panel. The amount of loaded proteins correspond to 1.2, 
1.8, 1.6, 2.0 x 105 cells at 24 h, 48 h, 72 h and 96 h, respectively.  
 
Although the analysis of a HCV full-length genome should reflect the properties of 
viral translation and replication most accurately, I wanted to confirm the data in a 
steady-state situation, which resembles a persistent infection. The most efficient and 
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convenient systems to study persistent HCV RNA replication are Huh-7 cell clones 
with subgenomic replicons, keeping constant HCV RNA and protein levels over 
years, even in the absence of selective pressure173. Therefore I analyzed two 
different types of replicon cells to evaluate the data obtained with the full-length 
genome (Fig. 44A): (i) a Huh-7 cell clone designated 11-1, harboring a monocistronic 
replicon resembling closely the translational properties of a full-length genome66 and 
(ii) a Huh-7 cell clone designated 9-13139,140 with a bicistronic replicon representing 
the most efficient and most often used system to investigate persistent HCV 
replication. I seeded cells bearing the respective replicons in aliquots and analyzed 
them in the same way as the full-length genome at different time points after seeding. 
Despite the different architecture of the replicons and the assay format (transient 
replication versus stable replicon cell clones), I obtained very similar results (table 2) 
with more than 10,000 NS4B or NS5B copies per negative-strand RNA molecule. 
This outcome indicated that the synthesis of a massive excess of NS proteins over 
RNA seems to be an elemental property of HCV translation and replication in Huh-7 
cells. Since the half-lives of the NS proteins (11-16h173) were shown to be 
comparable to the half-life of RNA (about 11h166) in replicon cells and HCV RNA and 
proteins are kept on similar steady-state levels over years of continuous passaging, 
HCV RNA and protein synthesis should also be quite constant. Therefore, based on 
the data shown in table 2, each positive-strand RNA template is translated numerous 
times giving rise to one thousand to ten thousand polyprotein copies. Another 
important conclusion was that the stoichiometry of HCV protein to RNA in replicon 
cell clones closely resembles the one found with full-length genomes. Therefore, 
replicon cell clones were an appropriate tool for further analyses. 
 
Table 2: Number of positive-strand RNA, negative-strand RNA, core, NS4B and NS5B molecules per 
Huh-7 cell. 
 
 
data represent mean values and standard deviations of samples harvested at 48 h, 72 h and 96 h 
after seeding 
na not applicable 
* per cell data not normalized for transfection efficiency, which was routinely 50%-80% 
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3.4.2 Isolation of active replication complexes from Huh-7 cell harboring 
subgenomic replicons 
We then asked whether the massive surplus of non-structural proteins indeed is 
directly involved in RNA synthesis or may serve some other function. To distinguish 
between these two possibilities, I isolated crude replication complexes (CRCs) from 
replicon cells and further analyzed them in vitro for their protein and RNA content. 
The method for the preparation of CRCs has been described before (chapter 3.1.1) 
and is again shown schematically in Fig. 45A. To verify for in vitro replicase activity, 
cell lysates were incubated with radiolabeled nucleotides in the presence of 
Actinomycin D and in the absence of exogenous template RNA. Reaction products 
were further analyzed by denaturing agarose gel electrophoresis (Fig. 45B). The 
dominant product of in vitro replication was a single band corresponding in size to the 
full-length replicon RNA (arrowhead). HCV replicase activity was already detectable 
in the total hypotonic lysate of replicon cells but was enriched in CRCs that were 
obtained by pelleting the membranous material in supernatant 1 (S1). The resulting 
supernatant 2 (S2) did not contain any detectable replicase activity. The distribution 
of the non-structural proteins in different fractions of the CRC preparation is shown in 
Fig. 45C. Similar proportions of NS3, NS4B, and NS5B were regained in S1 and 
concentrated in parallel to the replicase activity in the CRC fraction, leaving only 
minor amounts in S2. 
I wanted to exclude that the CRC fraction contained only a minor subpopulation of 
HCV replication complexes which might not be representative, and therefore followed 
the fate of viral positive- and negative-strand RNA during CRC preparation (Fig. 
45D). I found that 35% of the negative- and 25% of the positive-strand RNA existent 
in the replicon cells before lysis were recovered in the CRC fraction. The remainder 
was either associated with the nuclear pellet (40% of negative-strand, 30% of 
positive-strand RNA), or was destroyed during cell lysis (20% of negative-strand, 
30% of positive-strand RNA) or during centrifugation of CRCs (15% of negative-
strand and positive-strand RNA, respectively); only traces of RNA were retained in 
S2. In consequence, about half of the positive-strand RNA and 25% of the negative-
strand RNA were degraded most likely by the action of cellular nucleases liberated 
during cell lysis. This fraction might include damaged replication complexes and 
positive-strand HCV RNAs that were not integrated into the replication complex but 
engaged in some other processes such as RNA translation. A variable amount of NS 
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proteins, HCV RNA and replicase activity always stayed associated with the nuclear 
pellet and could not be recovered even by vigorous douncing, in all probability on 
account of the accumulation of replication complexes in the perinuclear region74 and 
due to the mild extraction excluding the use of detergents.  
 
 
Fig. 45. Preparation and characterization of CRCs from HCV replicon cells. (A) Schematic diagram of 
the CRC preparation protocol. (B) Analysis of in vitro replicase activity in total lysates (TL) and 
different subcellular fractions of replicon cells (left half) and naïve Huh-7 cells (right half). In vitro 
replicase activity was determined in 4 µl of each fraction, reaction products were analyzed by 
denaturing glyoxal-gel electrophoresis followed by autoradiography of the dried gel. A radioactively 
labeled in vitro transcript identical in size to the replicon was loaded as a marker (M). The major 
reaction product of the in vitro replicase assay is indicated by an arrowhead. (C) Detection of NS3, 
NS4B and NS5B in different fractions of the CRC preparation. The volume of the NP fraction was 
adjusted to the volume of S1 and 10 µl of each fraction were analyzed by immunoblot using a 
polyclonal antiserum raised against HCV NS3 (upper panel) or NS4B (middle panel) or monoclonal 
antibodies specific for NS5B (lower panel, 154) and compared to 10 µl of “CRC”-fraction from naïve 
Huh-7 cells (Huh-7). (D) Fate of viral positive and negative-strands during hypotonic lysis and CRC-
preparation. Total RNA was prepared from 50 µl of a replicon cell suspension before lysis (BL) and 
from the same volumes of TL, S1, NP (adjusted to the volume of S1), S2 and CRC and subjected to 
Northern hybridization analysis using the same controls and probes to detect HCV positive (upper 
panel) and negative-strand RNA (lower panel) as in Fig. 44B. To calculate the recovery rate samples 
were analyzed by phosphor imaging and correlated with the value obtained before cell lysis (BL). Data 
of the CRC fraction were corrected for the difference in total volume. For further details refer to the 
text. 
 
Taken together, CRCs most likely depicted a representative fraction of HCV 
replication complexes in replicon cell clones and were therefore appropriate to study 
the stoichiometry of RNA to NS proteins required for RNA replication. I chose the cell 
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clone 9-13, which harbors a bicistronic replicon, for further experiments, since it was 
the most efficient source for the preparation of active replication complexes. 
 
3.4.3 In vitro replicase activity and viral RNA were fully resistant to 
nuclease and protease treatment 
It has been shown previously that in vitro replicase activity is resistant to nuclease 
and protease treatment5,8,52,153. I exploited these results to specify which fraction of 
viral RNA and proteins is resistant to nuclease and protease, respectively, in order to 
determine the stoichiometry of the viral components of the HCV replication complex. 
Therefore, I treated CRCs with high concentrations of proteinase K (0.8 or 8 mg/ml) 
and/or S7 nuclease (200 or 2000 U/ml), stopped the reaction by adding PMSF or 
EGTA, respectively, and analyzed an aliquot of the pretreated CRCs for in vitro 
replicase activity. As shown in Fig. 46, in vitro replicase activity was neither affected 
by pretreatment with S7 nuclease (lanes 4 and 5) nor proteinase K (lanes 8 and 9) 
alone or in combination (lanes 10 and 11). Protease and nuclease resistance was not 
limited to replicase activity contained in the CRC fraction but was also found for 
replicase activity in total cell lysate, the nuclear pellet and supernatant 1 (data not 
shown), indicating that the replication complexes in the CRC fraction were not a 
selected subpopulation with distinct properties. HCV replicase activity was only 
abolished by addition of 1% Triton X-100, in the absence (lane 6) or presence (lane 
7) of additional nuclease, indicating that the resistance of HCV replicase to proteases 
and nucleases is mediated by detergent-sensitive structures. The full protease and 
nuclease resistance of in vitro replicase activity enabled me to investigate which 
portion of viral RNA and proteins were not affected by protease and nuclease and 
therefore were necessary and sufficient for RNA synthesis. To address this question, 
I analyzed aliquots of the protease and/or nuclease treated CRCs by Northern 
hybridization and immunoblot to determine the ratio of HCV RNA and non-structural  
proteins involved in replication. 
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Fig. 46. HCV replicase activity is completely resistant to protease and nuclease treatment. 50 µl of 
CRCs prepared from replicon cell clone 9-13 were incubated for 60 min at 25°C in the presence of 1% 
Triton X-100 and/or 0.8 (+) or 8 (++) mg/ml proteinase K and/or 0.2 (+) or 2 (++) U/µl S7-nuclease, 
respectively as indicated above each lane. After termination of the proteinase K and S7 nuclease 
digest by the addition of 1.4 mM PMSF and/or 2.75 mM EGTA, respectively, equal amounts of each 
sample were analyzed for in vitro replicase activity. Reaction products were separated by denaturing 
glyoxal agarose gel electrophoresis and autoradiography. Lane 1 and 2 represent control reactions 
with CRCs from naïve Huh-7- or replicon cells in the absence of any preincubation. CRCs in lane 3 
were mock incubated for 60 min at 25°C prior to the in vitro replicase assay. 
 
I first focused upon the effect of S7 nuclease treatment on the fate of viral and 
cellular RNA (Fig. 47). Viral positive- and negative-strand RNAs were fully resistant 
to nuclease in CRCs as shown by Northern blot analysis (Fig. 47, top and middle 
panel, compare lane 3 with lanes 4 and 5). The marked reduction of 28S rRNA in the 
S7 nuclease treated samples indicated the efficiency of the digest (Fig. 47, top and 
middle panel, lanes 4, 5, 8 and 9). Protection from nucleases seemed not to be 
mediated by proteins, since further addition of proteinase K had no effect on RNA 
stability (lanes 8 and 9). In contrast, addition of Triton X-100 resulted in complete 
degradation of both viral RNA species, even in the absence of exogenous nuclease 
(lanes 6 and 7). This signified that membranes rather than proteins protected the 
RNA and that the loss of replicase activity upon detergent treatment (Fig. 46) was 
primarily due to the destruction of template RNA by endogenous nucleases and S7 
nuclease. In opposition to the viral RNAs, the cellular mRNA, exemplified by β-Actin,  
was absent in CRCs because it was not attached to membranes or almost 
completely devastated by the action of endogenous nucleases liberated during CRC-
preparation (Fig. 47, lowest panel, lanes 2 and 3) and the remaining traces were fully 
accessible to S7 nuclease (lanes 4 and 5).  
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Fig. 47. Quantification of nuclease-resistant HCV positive- and negative-strand RNA and β-Actin 
mRNA in CRCs. Total RNA equivalent to 5 µl of CRCs treated with 1% Triton X-100, 0.8 (+) or 8 (++) 
mg/ml proteinase K and/or 0.2 (+) or 2 (++) U/µl S7 nuclease for 60 min at 25°C or from mock treated 
CRCs, as indicated on top, was subjected to Northern hybridization analysis using a negative-strand 
riboprobe to detect viral positive-strand RNA (top panel), a positive-strand riboprobe for HCV negative-
strand detection (middle panel) and a riboprobe specific for the detection of cellular β-Actin mRNA. 
The positions of viral positive- and negative-strand RNA and β-Actin are indicated by arrowheads at 
the right. For quantification, in vitro transcribed replicons corresponding to known amounts of viral 
positive- and negative-strand RNA were mixed with 2 µg of total cellular RNA from naïve Huh-7 cells 
and loaded as indicated at the bottom of the figure. 4 µg total RNA from naïve Huh-7 cells were used 
as negative control (Huh-7, lane 1). I quantified the viral RNAs by phosphor imaging and found ca. 
3x106 negative-strands and 3x107 positive-strand RNAs per microliter CRC preparation in this 
particular experiment. 
 
Taken together, my data indicate that the viral positive- and negative-strand RNA in 
the replication complex is completely protected from nucleases and that this 
protection is mediated by detergent-sensitive membrane structures rather than by 
proteins. 
 
3.4.4 Only a minor portion of the HCV NS proteins was resistant to 
protease treatment 
Since in vitro replicase activity was completely resistant to protease and nuclease 
treatment, the ratio of HCV NS proteins to RNA actively involved in RNA synthesis 
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was determined by the number of nuclease-resistant RNA molecules compared to 
protease-resistant protein molecules. To measure the fraction of viral NS proteins 
resistant to protease, aliquots of the differently treated CRC samples were analyzed 
for the impact of proteinase K incubation by Western blot (Fig. 48B). Even with the 
lower protease concentrations I found a massive degradation of almost all cellular 
proteins to nearly undetectable amounts (Fig. 48A, lanes 8-11), whereas detergent 
and nuclease treatment as expected had no significant effect (lanes 4-7).  As an 
example for a cellular protein I chose Calnexin for a closer analysis by Western blot, 
using an antiserum directed against its N-terminal part, which is located in the ER 
lumen and therefore should be protected from proteases in an intact ER structure, 
whereas the carboxyterminus was expected to be protease-sensitive in a cell 
lysate153.  
 
 
Fig. 48. Effect of proteinase K digest on cellular proteins and quantification of protease-resistant HCV 
non-structural proteins in CRCs. Equal amounts of CRCs prepared from replicon cell clone 9-13 were 
incubated for 60 min at 25°C in the presence or absence of 1% Triton X-100 and/or 0.8 (+) or 8 (++) 
mg/ml proteinase K and/or 0.2 (+) or 2 (++) U/µl S7-nuclease, respectively, as indicated above each 
lane. The reaction was stopped by addition of 1.4 mM PMSF and 2.75 mM EGTA, boiled in sample 
buffer and total protein equivalent to 2 µl CRCs was subjected to SDS-10%PAGE. In case of the 5x 
concentrated samples, proteins were TCA-precipitated and the equivalent of 10 µl CRCs was loaded. 
Proteins were either visualized by silver staining (A) or subjected to immunoblot analysis (B) using 
monoclonal antibodies specific for the ER-luminal part of Calnexin (upper panel), a polyclonal 
antiserum raised against HCV NS3 or NS4B (middle two panels) and monoclonal antibodies specific 
for HCV NS5B (bottom panel), as indicated at the right. The concentrated fractions (lane 12) are 
shown from identical expositions of the same blot. A serial dilution of purified NS5B was loaded in 
parallel for quantification as depicted at the bottom of the figure. 
 
As shown in Figure 48B (top panel), no full-length Calnexin was detectable after 
protease treatment and only traces of a C-terminally truncated fragment were visible 
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with the lower amount of protease (lanes 8-11). Only after 5-fold concentration of the 
sample, I was able to obtain a clear signal (lane 12). The absence of full-length 
Calnexin even in the concentrated samples indicated that the used amount of 
proteinase K was sufficient for a complete digest. Since the majority of the ER-
luminal N-terminal Calnexin fragments were also accessible to protease (Fig. 48B top 
panel, signal strength in lanes 1-7 compared with 8-11) it seemed that most of the 
regular ER-structures were not intact after CRC preparation and protease digest. The 
HCV replication complex therefore appears to represent a more rigid structure in 
order to the complete protease and nuclease resistance of in vitro replicase activity. 
However, when I analyzed the viral non-structural proteins 3, 4B and 5B after 
protease digest (Fig. 48B, second, third and lowest panel, respectively, lanes 8-12), I 
found detectable amounts again only after 5x concentration of the samples (lane 12). 
The absence of lower molecular weight products indicated the completeness of 
digestion. Based on densitometric analysis and including the dilution factor, I 
calculated that roughly 2.5% of NS5B was resistant to proteinase K digest, but 
accounted for the full replicase activity (Fig. 46). This result suggested that the 
majority of viral non-structural proteins was not directly involved in RNA synthesis at 
a given time point. The portions of protease-resistant NS3 and NS4B were similar, 
indicating a 1:1 stoichiometry of the NS proteins in the replication complex. A serial 
dilution of purified NS5B applied on the same Western blot allowed us to quantify the 
number of NS5B molecules resistant to protease digest (Fig. 48B lowest panel) and 
we calculated about 5x109 molecules NS5B per microliter CRCs in this experiment. 
Compared to 3x106 negative-strands and 3x107 positive-strands (Fig. 47), the 
surprising result was, that although only 2.5 percent of the NS5B molecules were 
engaged in replicase activity at a given time, I still found a 1,600-fold excess of NS5B 
compared to negative-strand RNA and a more than 100-fold excess compared to 
positive-strand RNA in CRCs. 
 
3.4.5 The HCV replication complex contained multiple copies of the non-
structural proteins 
The data obtained from the experiment shown in Figures 46-48 (experiment 1) and 
from an additional, independent experiment are summarized in Table 3. Both sets of 
data displayed very similar results: In preparations of HCV replication complexes, 
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viral positive- and negative-strand RNA was entirely resistant to nucleases compared 
to less than 3 percent of NS5B being protease-resistant. The ratio of positive- to 
negative-strand RNA was varying and might be dependent on the physiological state 
of the cells at the time of harvest. Negative-strand RNA is the most restricted 
component in HCV RNA replication and therefore the best indicator for the total 
number of active replication complexes.  
 
Table 3. Portions and ratios of nuclease-resistant positive-strand, negative-strand and protease-
resistant NS5B in CRCs 
 
 
 * mean and standard deviation of four nuclease treated samples  
 
Based on the data presented in Table 2 and assuming that each active replication 
complex contains per definition at least one copy of negative-strand RNA, there were 
on the average less than one hundred active replication complexes per replicon cell 
but more than a million polymerase molecules. After biochemical preparation of 
replication complexes and excessive protease digest, I still found more than 1,000 
NS5B molecules per negative-strand RNA (Table 3), and similar amounts of NS4B 
and NS3, indicating that a huge excess of non-structural proteins was required to 
build up the viral replication complex. 
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4. Discussion 
HCV replication is believed to take place in vesicular membrane structures harboring 
the viral RNA and non-structural proteins as well as cellular host factors involved in 
viral RNA amplification. In the present study, we developed a purification strategy for 
the membrane-associated HCV replication complexes based on their proteinase K 
(PrK) insensitivity and showed that their in vitro activity was different from purified 
NS5B polymerase activity. Several host factors associated with the purified viral RC 
were identified by proteomics, and the most reproducible candidate  
- ANXA2 - was investigated in detail. We found a specific recruitment of ANXA2 by 
NS5A; however, its functional role in HCV replication remained to be determined. 
Based on quantitative analysis of nuclease- and protease-resistant RCs, we were 
able to determine the ratio of viral protein to RNA in enzymatically active RCs and 
compared it with the ratio in the cell finding in both settings an excess of viral proteins 
over RNA molecules.  
HCV replication occurs at the membranous web, i.e. at vesicular membrane 
structures harboring the NS proteins and the viral RNA51,74. Isolated CRCs are 
capable of viral RNA amplification, without addition of an exogenous template RNA. 
These vesicles probably have a connection to the cytoplasm, allowing the constant 
supply of nucleotides for RNA synthesis. It is still not entirely clear to which extend 
the isolated CRCs in vitro resemble functions of RCs in vivo. However, the fact that a 
non-nucleosidic RdRp inhibitor as well as an inhibitory antibody directed against 
NS5B154 did not interfere with in vitro replicase activity indicated that not the RdRp 
activity of NS5B alone is responsible for RNA synthesis in the CRC fraction. Then 
again it is possible that the NS5B binding sites for both different inhibitors were 
concealed because NS5B forms a complex with other NS proteins and/or the 
membrane or that the vesicular structure prevents the access of larger molecules like 
the inhibitors to the inside. 
Miyanari and colleagues found that HCV replicase activity in digitonin-permeabilized 
cells was resistant to protease153, and we showed that the in vitro activity of isolated 
HCV replication complexes was not sensitive to proteinase K, too, although the 
majority of all cellular and viral proteins was degraded. In the present study, I 
exploited this for the purification of viral replication complexes and their associated 
cellular factors. However, proteins associated with or localized inside intracellular 
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membrane compartments, e.g. early and late endosomes, mitochondria, ER, Golgi, 
etc., are possibly also protected against PrK and thus can still be found in the CRC 
fraction.  
Alternative purification strategies imply the use of detergents since several groups 
reported that HCV replication occurs on detergent-resistant membranes (DRMs) 
which are stable to Triton X-100 extraction in the cold5,193. Therefore, treating CRCs 
with TX-100 at 4°C should result in the extraction of all proteins not associated with 
lipid rafts. Although this approach worked fine in terms of protein purification in my 
hands, replicase activity was not detectable in the DRM fractions. Most probably the 
replication complexes were disrupted or dissociated in the presence of the remaining 
TX-100 when heated up to the incubation temperature of the in vitro replicase assay. 
On the other hand, it was possible that the RNA of the replication complexes was 
now accessible to cellular nucleases present in these cellular fractions and was 
therefore degraded. Incubation of CRCs in the presence of other detergents resulted 
in most cases also in a loss of in vitro replicase activity. Since the in vitro replicase 
activity was the most important readout for the integrity of the replication complexes, 
we refrained from using detergents for the purification of RCs. However, Mannova 
and coworkers used detergent treatment to isolate lipid rafts and identify protein 
modifications in these rafts resulting from HCV replication148.  
In the present study, cellular factors associated with the HCV RC were identified by 
proteomic analyses of PrK-resistant CRC fractions. In the literature, host cell proteins 
involved in the viral life cycle are identified by diverse methods, e.g. Y2H screens or 
DNA microarrays showing an upregulation of certain genes. These methods are 
often useful, although the possible interaction partners are sometimes found under 
very artificial conditions and not all results can be confirmed in vivo. The advantage 
of the strategy to purify RCs by PrK treatment and sucrose density gradient 
centrifugation was that the integrity of the complexes seemed to be maintained since 
the in vitro replicase activity was not reduced or inhibited. Thereby, the purified RCs 
probably resembled closely the RCs found in an in vivo situation and reflect their 
natural composition.  
There exist also other possibilities to identify cellular factors putatively involved in 
viral replication. Harris and coworkers developed a novel RNA affinity capture system 
in which a biotinylated oligonucleotide was annealed to one end of a run-off transcript 
corresponding to the positive-strand 3’-NTR of HCV. Subsequent immobilization of 
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this partial duplex on paramagnetic streptavidin-coated beads and incubation with 
hepatocyte extracts allowed them to isolate cellular proteins bound to the 3’-NTR 
RNA87. Recently, another interesting strategy was presented: Huang and colleagues 
inserted a Flag epitope-tagged GFP at the cytosolic C-terminus of NS5A. Membrane-
bound NS5A was purified from crude cell lysates by an immuno-isolation technique 
using magnetic beads coated with anti-Flag96. Bound fractions also contained viral 
NS3, NS4B, and NS5B, as well as viral RNA, but were not tested for in vitro replicase 
activity. Major cellular organelles like Golgi, ER, mitochondria or endosomes did not 
bind to the beads indicating that a high level of purification was achieved. 
Interestingly, among the cellular proteins associated with these isolated fractions, 
they also found ANXA2, but did not further investigate the impact of this protein. 
None of the protein spots differentially represented in my comparative 2D gel 
analyses of PrK treated CRC fractions from replicon-harboring and cured Huh-7 cells 
was identified as an HCV NS protein. Adessi and colleagues reported that membrane 
and hydrophobic proteins (like the viral NS proteins) can be poorly represented in the 
second dimension of a 2D gel analysis, which is probably due to protein/gel 
interactions during IEF2. Some larger proteins may also be lost and it has been 
suggested that this is due to size exclusion when the proteins are loaded onto the 
gel. Otherwise, it is possible that the NS protein amount was simply below the 
detection limit, since the majority of proteins had been digested by PrK. By using 
fluorescence-based 2D gel analyses like the DIGE system211,216 which possess a 
higher sensitivity, it may be possible to identify the protein spots representing the 
viral NS proteins. 
 
During the present study, I have also analyzed the stoichiometry of HCV RNA and 
proteins in cells with ongoing HCV replication and found a massive excess of 
structural and non-structural protein molecules over RNA, indicating that each 
positive-strand RNA molecule is excessively translated before a replication complex 
is formed and RNA synthesis is initiated. In agreement with the polyprotein nature of 
the major HCV ORF, all analyzed cleavage products are found in similar amounts. A 
ca. 1,000-10,000-fold excess of viral proteins to positive-strand RNA as observed in 
this study might fit well to the requirements for particle formation, since virions of 
other enveloped positive-strand RNA viruses like alphaviruses, tick-borne 
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encephalitis virus or Dengue virus usually contain several hundred copies of 
structural proteins per particle60,70,122,164. 
I wondered whether a similar excess of non-structural proteins was required for RNA 
replication and addressed this question by studying crude replication complexes 
isolated from cells harboring persistent HCV replicons. It has been shown previously 
that in vitro replicase activity is resistant to protease and nuclease treatment in 
CRCs5,8,52 and that in digitonin-solubilized replicon cells only a minor portion of the 
HCV NS proteins is protease-resistant and therefore seems to be involved in 
replication153. My data are in good agreement with these earlier results, however, 
although I find as well that less than 5 percent of the non-structural proteins in CRCs 
are protease-resistant and account for full replication activity in vitro, this still results 
in a ca. 1,000 : 1 stoichiometry of NS proteins to active replication complexes, 
estimated by the number of negative-strand RNA molecules.  
Based on my data and on previously published EM-studies51,74, we propose a 
tentative model of the HCV replication complex (Fig. 49): Multiple copies of HCV non-
structural protein complexes encompassing NS3 to NS5B build up a vesicular 
membrane structure, which mediates the protection against nucleases and proteases 
and may hide double strand RNA from detection by the host cells innate immune 
system. The existence of HCV non-structural protein complexes rather than 
individual proteins is indicated by similar fractions of NS3, NS4B and NS5B being 
resistant to protease and seems plausible due to numerous interactions within the 
non-structural proteins that have been described yet15,48. Each vesicle should have a 
connection to the cytoplasm allowing the constant supply with nucleotides for RNA 
synthesis, but preventing the access of molecules larger than 16 kDa, e.g. S7 
nuclease and proteinase K. A number of these vesicles accumulate at distinct sites in 
the cytoplasm and form the membranous web, which was shown to be the site of 
RNA replication74. Within every vesicle that contains an active replication complex, I 
find at least one negative-strand RNA, several positive-strand RNAs and up to one 
thousand copies of each of the non-structural proteins. The precise stoichiometry of 
RNA to protein in the replication complex is hard to tell, since a number of replication 
complexes might await initiation of negative-strand synthesis at a given time and 
therefore contain only non-structural proteins and positive-strand RNA. If this variant 
is frequent, ca. 100-200 copies of the non-structural proteins per replication complex 
would be a more realistic estimate. On the other hand, several replication complexes 
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might include more than one molecule of negative-strand RNA and therefore the 
number of non-structural protein molecules per active replication complex could even 
be higher. Finally, I cannot exclude the existence of vesicles without viral RNA, which 
still might render the included NS proteins protease resistant, because the induction 
of membrane alterations is an intrinsic property of NS4B51 and I do not know whether 
the presence of RNA is necessary to induce protease resistance of the non-structural 
proteins.  
 
 
Fig. 49. Schematic model of the HCV replication complex. HCV NS proteins are indicated by orange 
ellipses; blue and green wavy lines represent viral positive and negative-strand RNA, respectively. 
Individual NS proteins and RNA are not drawn to scale. For closer explanations refer to the text.  
 
Our picture of the HCV replication complex is very similar to a model suggested by 
Miyanari et al.153, however, the data presented in this study provide the first 
experimental evidence that each HCV replication complex is composed of multiple 
copies of the viral non-structural proteins. This resembles closely results obtained for 
brome mosaic virus190. It has been shown that 400 copies of protein 1a form a 
spherular structure connected to the cytoplasm and containing viral RNA together 
with a few copies of the viral polymerase 2a. Interestingly, a similar virus-induced 
compartment was lately analyzed by electron microscope tomography. The flock 
house virus (FHV) replicates in spherules that are outer mitochondrial membrane 
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invaginations with interiors connected to the cytoplasm by a necked channel of 
approximately 10-nm diameter117. These spherules contain, on average, three RNA 
replication intermediates and an interior shell of circa 100 membrane-spanning, self-
interacting proteins A, which alone is needed for FHV RNA replication. In case of 
HCV, the majority of protease-resistant non-structural protein complexes might as 
well be required to build up the vesicular structure, whereas only a few complexes 
are required for polymerase activity. This calculation is based on the kinetics of RNA 
and protein synthesis in replicon cells: The intracellular levels of viral RNA and 
proteins remain relatively constant over years of continuous passaging166, 
representing a steady-state situation at any given time point. Since the half-lives of 
viral NS proteins and viral positive-strand RNA in replicon cells have been shown to 
be 11-16 h166,173 the rate of newly synthesized RNA and protein per day should 
roughly be in the range we find in the steady state situation (Table 2). Based on this 
and on my data, I estimate that only about 1,000 positive-strand RNA molecules are 
synthesized per day per cell by ca. 100 replication complexes, but more than 
1,000,000 copies of non-structural proteins. In consequence, each newly synthesized 
positive-strand has to be excessively translated to yield the ascertained surplus of 
proteins, whereas RNA synthesis is a rather rare event, which most likely is achieved 
only by a few non-structural protein complexes. Recently, Dahari and coworkers 
published a mathematical modeling of subgenomic HCV replication42 that was mainly 
based on this data. Given my calculation, less than 0.1 % of all NS5B molecules are 
required to be enzymatically active.  
Many positive-strand RNA viruses have evolved strategies to regulate the amounts of 
active polymerase, either by expression from an independent cistron, like BMV190, by 
the expression of a polyprotein containing rarely suppressed stop codons, like 
alphaviruses129 or by producing stable precursor intermediates lacking polymerase 
activity, like poliovirus 3CD20. In case of HCV, polymerase activity could be regulated 
by different conformations of the non-structural protein complex, depending on its 
function. It has been shown that a carboxyterminal region of NS5B, encompassing 
amino acids 545-562 inhibits polymerase activity1 and that only a small fraction of 
purified NS5B containing this region is enzymatically active35. Crystal structure 
analysis revealed that this carboxyterminal domain protrudes into the RNA binding 
cavity of NS5B and interferes with template binding128. Deletion of this region 
increases polymerase activity as well as RNA binding of NS5B128. Therefore, it is 
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tempting to speculate that the majority of NS5B is inactive after translation by 
refolding of the carboxyterminus into the RNA binding cleft, whereas only those few 
molecules that stay bound to the viral RNA keep the template binding site in an open 
conformation and retain enzymatic activity. The ability to self-inactivate viral 
polymerase not required for RNA synthesis might represent an alternate strategy to 
deal with the stoichiometric constraints of a polyprotein. 
In contrast, the majority of non-structural protein complexes not directly involved in 
RNA synthesis may be required e.g. as a structural component of the membrane 
vesicle. The viral non-structural protein primarily involved in this process is NS4B, 
since it is able to induce vesicular structures even in the absence of other HCV 
proteins51. The different roles of non-structural protein complexes might be regulated 
by the association with individual host cell factors, like hVAP-A, a cellular protein 
which has been shown to interact with NS5A and NS5B56,214. Since this protein is 
involved in intracellular vesicle trafficking, it seems to be a good candidate for a 
cofactor of membrane structure rearrangements and has already been suggested to 
be involved in HCV replication complex formation5,71. In addition, other cellular 
factors might be required for RNA synthesis. A detailed biochemical analysis of the 
protease-resistant non-structural protein fraction might reveal some of the cellular 
proteins that are directly involved in the formation of the replication complex and in 
RNA synthesis. 
The functions of the protease-sensitive portion of the non-structural proteins, 
encompassing more than 95%, remain obscure. Since my analysis presents a 
snapshot at a given time point and I have no precise data on the dynamics of 
replication complex assembly and disassembly, parts of these proteins might be in 
the process of vesicle generation and disintegration. The remainder could simply be 
a byproduct of structural protein synthesis, which might be required in excess 
amounts for virus production. Miyanari and coworkers suggested potential roles of 
the non-structural proteins in virion formation or indirect modulation of viral replication 
by interaction with host cell proteins153. Along the same line, the NS3/4A moiety 
might be required to block the IRF-3 induced pathway of the host cells’ innate 
immune system, which has been shown to play a critical role in HCV replication63.  
In the present study, I have shown that during the replication cycle of HCV a massive 
excess of non-structural proteins is produced due to extensive translation. An 
interesting but yet unanswered question is, how the transition of translation to 
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replication is regulated. A number of proteins have been shown to bind to the HCV 
5’-NTR, which might be involved in this process6,7,82,111,143. Alternatively, the switch 
could rely on concentration-dependent inhibition of translation by an HCV protein. 
Interestingly, I found no significant differences in the ratio of HCV RNA and protein 
between an authentic HCV genome, a monocistronic and a bicistronic replicon (Table 
2), indicating that the nature of the IRES element directing translation of the non-
structural proteins is not important for this stoichiometry. After translation, replication 
complex formation, and RNA synthesis, the progeny RNA has to get back into the 
cytoplasm to enter a new round of translation/replication or packaging into particles. 
We currently do not know if this process includes an active transport, like in the 
replication cycle of dsRNA reoviruses181, or if the progeny RNA accumulates in the 
replication complex and is released by disintegration of the vesicle.  
A limitation of my analysis is that no viral particles are produced by the chosen 
replication systems172. Since I do not know how many positive-strand RNA molecules 
would end up in virions and whether viral genomes undergo translation prior to 
packaging it is very hard to predict the consequences of simultaneous RNA 
replication and particle morphogenesis on the ratio of RNA to proteins in infected 
cells. Shortly after this stoichiometric study, three independent studies demonstrated 
the production of infectious HCV particles in cell culture using the non-structural 
proteins of the JFH-1 HCV isolate133,219,240. It will be interesting to evaluate my 
findings in this system covering the whole life cycle of HCV. However, due to the lack 
of appropriate antibodies, this investigation was not possible within the scope of my 
PhD thesis.  
 
After the successful establishment of an effective purification strategy for the 
membrane-bound HCV replication complexes, I had identified cellular proteins 
associated with the viral RC by proteomic approaches. The most reproducible and 
therefore promising candidate was Annexin II (ANXA2) which belongs to the 
Annexins, a large family of structurally similar proteins that bind to negatively charged 
phospholipids and have versatile functions. They are involved in many membrane-
related events, such as the regulated organization of membrane domains and/or 
membrane-cytoskeleton linkages, certain exocytic and endocytic transport steps and 
the regulation of ion fluxes across membranes.  
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Annexins are Ca2+/lipid-binding proteins that differ from most other Ca2+-binding 
proteins in their Ca2+-binding sites. They have a unique architecture that allows them 
to dock onto membranes in a peripheral and reversible manner. The conserved Ca2+- 
and membrane-binding module is the Annexin core domain, which consists of four 
so-called Annexin repeats, each of which is 70 residues in length. It is highly α-helical 
and forms a compact, slightly curved disc that has a convex surface harboring the 
Ca2+- and membrane-binding sites and a concave side that points away from the 
membrane and is thereby available for other types of interaction/regulation (Fig. 50). 
The N-terminal region precedes the core domain and is diverse in sequence and 
length for each single Annexin. It mediates regulatory interactions with protein 
ligands and regulates the Annexin-membrane association. 
 
 
Fig. 50. Annexin structure. (A) Schematic drawing of an Annexin that is peripherally attached to a 
membrane surface through bound Ca2+ ions (blue). (B) Structural model of an Annexin core. Each 
Annexin repeat (colored differently) contains five α-helices that are connected by short loops or turns. 
The N and C termini are colored black. Red spheres within stick-representation residues highlight 
atomic oxygens that are involved in forming the type-II Ca2+-binding sites, whereas blue spheres 
denote nitrogen atoms of highly conserved basic residues. Adapted from Gerke et al., Nature 
Reviews, 200573. 
 
ANXA2 is found intra- and extracellularly serving different functions. In the 
extracellular compartment, it is involved in fibrinolysis109. Intracellularly, ANXA2 
serves as membrane scaffold, plays a role in membrane organization and traffic, 
transport events, endocytosis as well as exocytosis, and exhibits ion channel activity. 
Annexin II is found in living cells as a monomer, heterodimer and heterotetramer. 
Monomeric Annexin II is mainly located in the cytosol; however, upon a stimulus like 
increase in Ca2+-levels or posttranslational modification, it binds to cellular 
membranes, in particular the cytosolic leaflets of the plasma membrane and various 
organelle membranes. The heterodimer is composed of two Annexin II monomers 
and 3-phosphoglycerat-kinase and is located in the nucleus. The most dominant form 
in most cells is, however, the heterotetrameric complex (A2-p11)2, composed of two 
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Annexin II monomers and a dimer of the S100A10 protein (also called p11) which is 
its major ligand. This heterotetramer is important for numerous functions of ANXA2 
and is primarily found at the cytosolic leaflet of the plasma membrane but also 
extracellularly (reviewed in 73). In addition, ANXA2 has been reported to bind certain 
species of RNA61,218, which indicates a possible role of ANXA2 in RNA transport or 
export from the nucleus. For HIV, ANXA2 was also shown to be essential for the 
proper assembly of new virions in monocyte-derived macrophages183. 
In the present study, ANXA2 was associated with the PrK-resistant fraction of CRCs. 
Its cytoplasmic distribution was rearranged in HCV-harboring cells resulting in a 
perfect colocalization with the NS protein components of the viral replication 
complex. This colocalization did not depend on a certain cell type or HCV genotype. 
Furthermore, it was detected in cells infected or transiently transfected with HCV as 
well as in cells stably replicating the viral RNA. A colocalization of NS proteins with 
other Annexins was not observed and neither a colocalization of ANXA2 with other 
positive-stranded RNA viruses. This indicated a specific interaction of HCV with 
ANXA2. 
It is known that HCV replication takes place in vesicular structures, designated as 
membranous web, which are probably derived from the Endoplasmic Reticulum 
(ER)51,74, although a specific colocalization of the ER marker Calnexin and NS 
proteins was not visible in this study. ANXA2 interacts with membranes of varying 
cellular organelles45,47,55,79, however, a binding of ANXA2 to ER membranes was so 
far not reported.  
Naïve HepG2 cells possess only minor amounts of endogenous ANXA2175 that were 
not detectable in our immunofluorescence studies. In contrast, ANXA2 was clearly 
seen in HepG2 cells stably replicating HCV RNA, indicating an induction, stabilization 
or simply concentration of this cellular protein by HCV. However, the increased 
ANXA2 levels in these cells may be attributed to a selection advantage of cells 
possessing higher endogenous ANXA2 amounts thereby supporting the viral 
replication more efficiently. Nevertheless, overexpression of ANXA2 in naïve HepG2 
cells did not result in an enhanced replication of transiently transfected HCV RNA. 
On the other hand, silencing of ANXA2 in HepG2 cells persistently harboring 
subgenomic HCV replicons did also not have any impact on the HCV RNA level 
suggesting that ANXA2 is not limiting HCV replication in these cells. 
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Likewise, stable as well as transient silencing of ANXA2 in Huh-7 cells did not 
influence viral replication levels but indicated a positive correlation of the ANXA2 
protein amount and HCV replication. This was corroborated by FACS analyses 
showing that the HCV levels were slightly decreased in ANXA2-silenced cells 
compared to control-silenced cells. FACS analyses proved evidence for the increase 
of ANXA2 levels upon HCV replication, too; however, the mechanism by which HCV 
induced ANXA2 was not clear. The increased ANXA2 levels in cells transiently 
transfected with HCV and in presence of siRNA directed against ANXA2 compared to 
control cells could be explained by either enhanced gene transcription, boosted 
mRNA translation, decreased mRNA degradation or stabilization of the protein. Our 
FACS analyses demonstrated a slight but reproducible induction of ANXA2 levels by 
HCV; however, this could so far not be clearly confirmed by immunoblot assay or RT-
PCR. 
In addition to the induction of ANXA2 by HCV, it is also possible that the ANXA2 
protein is further stabilized by interaction with HCV. It has been reported that 
downregulation of ANXA2 in HeLa cells by RNA interference (RNAi) efficiently 
depletes the intracellular ANXA2 pool, however, some ANXA2 remains in the cortex 
underneath the plasma membrane, presumably because of a significantly longer half-
life243. In this study of Zobiack et al., the RNAi had no effects on plasma-membrane-
related events. In the colocalization studies of my RNAi experiments, I obtained 
comparable results. It was also observed that the cytosolic ANXA2 was no longer 
detectable upon ANXA2 silencing, but the colocalization with HCV NS proteins 
remained. Therefore, it can be assumed that the association of ANXA2 with the HCV 
replication complex in the membranous web stabilized ANXA2 thereby prolonging its 
half-life. Strong silencing of ANXA2 only had a moderate impact on HCV replication. 
A possible explanation was that the functions of ANXA2 were taken over by other 
Annexins since they possess a high structural similarity or that ANXA2 involved in 
HCV replication was recruited from stable pools as observed by Zobiack and 
colleagues. Annexin-knockout models often exhibit no obvious phenotype related to 
a primary defect in e.g. vesicle docking and/or fusion events32,88,136. This indicates 
that the Annexins targeted in these mice do not serve as essential factors in vesicle 
docking and/or fusion or that such functions are redundant or taken over by another 
member of the family during mouse development. Given the sequence and structural 
homology among the Annexins and their overlapping tissue distributions, such 
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compensatory mechanisms have to be considered. On the other hand, it was 
observed that HCV induces ANXA2 which of course might interfere with the ANXA2-
silencing. It is not known in which amounts ANXA2 is necessary for HCV replication, 
and the induction of ANXA2 by HCV is putatively sufficient to counteract the silencing 
effects. 
HCV NS5A was identified as the viral interaction partner of ANXA2 by heterologous 
expression of the single NS proteins. The expression of NS5A led to the induction 
and rearrangement of ANXA2 in these cells. NS5A is a versatile protein which has 
already been shown to interact with many different cellular proteins that influence the 
viral RNA replication, e.g. Vap-A214,239, FBL2221 and amphiphysin II238. The precise 
function of NS5A has not been defined yet, but it has been suggested that it 
regulates the switch between replication and packaging: cell culture adaptive 
mutations increasing the RNA replication impede infectivity in chimpanzees34. NS5A 
is a hot spot of cell culture adaptive mutations most of which reduce 
hyperphosphorylation and seem to interfere with particle production. In addition, 
hyperphosphorylation of NS5A interferes with efficient RNA replication56,160 indicating 
that the transition from replication to virus assembly might be triggered by NS5A 
phosphorylation. Therefore, the ANXA2-NS5A interaction might play a role in the 
regulation of replication and packaging. 
ANXA2 acts in membrane aggregation by linking two different membranes126, but 
does not act as a fusogen. Therefore, a possible function of this protein is the 
formation of a neck of the vesicle harboring the HCV replication complexes which 
builds the junction between the vesicle and the cytoplasm (Fig. 51C). In general, the 
(ANXA2-p11)2 heterotetramer is involved in such membrane aggregations; however, 
colocalization of p11 with the HCV RC was not observed indicating that it is not 
involved in HCV replication. Nevertheless, it is possible that either the p11 amounts 
in the RCs were below detection limit or p11 is replaced by another protein taking 
over its function. Furthermore, the functions of ANXA2 are controlled by 
phosphorylation. Membrane aggregation by ANXA2 is strongly inhibited when it is 
phosphorylated by protein kinase C (PKC)103. Interestingly, it was shown that HCV 
NS3 interferes with the phosphorylation activity of PKC30 indicating that the inhibition 
of PKC by HCV NS3 could possibly lead to a stabilization of the membranous web by 
abrogating phosphorylation of ANXA2. Furthermore, ANXA2 was identified as a 
substrate of casein kinase I (CKI)72 which is also responsible for the 
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hyperphosphorylation of NS5A178. It is imaginable that the phosphorylation of ANXA2 
by CKI interferes with the membrane aggregation activity of ANXA2, too. 
Hyperphosphorylation of NS5A by CKI putatively leads to the switch from viral RNA 
replication to virion assembly. Opening of the membranous vesicles harboring the 
HCV replication complexes might be necessary to release the viral progeny RNA 
strands for packaging and could be triggered by CKI-mediated phosphorylation of 
ANXA2. Furthermore, ANXA2 is a RNA-binding protein like it has been shown for 
NS5A61,97 and therefore both proteins could be involved in an interaction with the viral 
RNA. 
Besides the possible neck formation of the RC-harboring vesicle and according to the 
reported functions of ANXA2, there are other scenarios for its role in the viral RNA 
replication. Several studies showed that HCV replication occurs on detergent-
resistant membranes also referred to as lipid rafts5,193. ANXA2 binds to the lipid raft 
component PtdIns(4,5)P289,182 and is involved in cholesteryl-ester transport from 
caveolae to internal membranes215 as well as in the organization of cholesterol-rich 
lipid microdomains10-12. By engaging in homophilic lateral interactions, Annexin II 
could then induce and/or stabilize raft clustering and thereby may provide the 
platform of viral RNA amplification (Fig 51A). On the one hand, it is plausible that 
ANXA2 sequesters cholesterol from the plasma membrane to intracellular 
compartments to form the replication complex. On the other hand, it is possible that 
ANXA2 is only associated with the replication complex because it simply follows the 
formation of lipid microdomains through its specific binding to certain head-groups, 
e.g. PtdIns(4,5)P2. Assuming that ANXA2 is not only a bystander, the recruitment of 
the HCV RCs to lipid rafts by ANXA2 could occur by its interaction with NS5A or, 
since ANXA2 has also a RNA-binding activity61,218, with the viral RNA. This could 
then lead to the binding of the other RC components and assembly of the RC (Fig. 
51A and B). 
Although the precise role of ANXA2 in the viral replication remains to be determined, 
it is likely that this protein is involved in the assembly of the HCV RC. Further studies 
should be performed to confirm that NS5A is the viral interaction partner and to 
precisely map the interaction sites. In addition, the mechanism of the ANXA2 
induction by HCV has to be analyzed. Despite these open questions, this study 
greatly helped in understanding the biogenesis and composition of the HCV 
replication complex. 
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Fig. 51. Hypothetical functions of ANXA2 in HCV replication. (A) Recruitment of lipid microdomains 
components from the plasma membrane and transport to internal membranes by ANXA2 to provide a 
platform for HCV RC assembly. ANXA2 sequesters cholesterol or other lipid raft components from the 
plasma membrane to intracellular compartments. Upon interaction of ANXA2 with HCV NS5A or the 
viral RNA the missing RC components are recruited to the lipid microdomains and form the RC. 
Vesicle formation is then induced by NS4B. (B) ANXA2 helps maintaining the vesicular structure by 
interaction with lipid microdomains and the RC. (C) ANXA2 is involved in formation of a neck of the 
vesicle which builds the junction between the vesicle and the cytoplasm. It is possible that other 
factors are involved in this process. Detergent-sensitive membranes are represented by yellow-orange 
striped structures, lipid rafts by yellow structures. HCV NS proteins are indicated by orange ellipses; 
blue and green wavy lines represent viral positive and negative-strand RNA, respectively. Violet 
ellipses indicate ANXA2, red ellipses unknown proteins potentially playing a role in viral replication. 
Individual proteins and RNA are not drawn to scale. 
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7. Abbreviations 
2D: two-dimensional 
aa: amino acid 
ab: antibody 
ANXA2: Annexin II 
ARF: alternative reading frame 
ATP: adenosine triphosphate 
bp: base pairs 
BrdU: 5-bromo-2-deoxyuridine 
CFP: cyan fluorescent protein 
CMC: critical micellar concentration 
Con: consensus 
CRC: crude replicase complex 
CyPB: Cyclophilin B 
DM: dodecyl maltoside 
DMEM: Dulbecco's Modified Eagle Medium 
DMSO: dimethyl sulfoxide 
DNA: desoxyribonucleic acid 
dNTP: desoxynucleotide triphosphate 
DOC: (sodium) desoxycholate 
DRM: detergent-resistant membrane 
dsRNA: double strand RNA 
DTT: dithiothreitol 
DV: Dengue virus 
EGTA: ethylene glycol tetraacetic acid 
EI: Encephalomyocarditis virus IRES 
EMCV: Encephalomyocarditis virus 
emGFP: emerald green fluorescent protein 
ER: Endoplasmic Reticulum 
FACS: fluorescence activated cell sorting 
FBL2: F-box and leucine rich protein 2 
FCS: fetal calf serum 
Fig.: figure 
GFP: green fluorescent protein 
HCV: Hepatitis C Virus 
HCVpp: HCV pseudoparticles 
IEF: isoelectric focusing 
IF(A): immunofluorescence (assay) 
IFN: Interferon 
Ig: immunoglobulin 
IP: immunoprecipitation 
IRES: internal ribosome entry site 
JFH: Japanese fulminant hepatitis 
kb: kilobases 
kDa: kilo-Dalton 
LDL: low density lipoprotein 
luc: luciferase 
MALDI-TOF MS: matrix-assisted laser 
desorption/ionization -time-of-flight-mass 
spectrometry 
MW: molecular weight 
NaAc: sodium acetate 
NB: Northern blot 
neo: neomycin phosphotransferase 
NP: nuclear pellet 
NP40: Nonidet P40 
NS: non-structural 
nts: nucleotides 
NTP: nucleotide triphosphate 
NTR: non-translated region 
OG: octyl glucoside 
ORF: open reading frame 
p.i.: post infection 
p.tr.: post transfection 
PBS: phosphate buffered saline 
PCR: polymerase chain reaction 
PFA: paraformaldehyde 
pI: isoelectric point 
PI: Poliovirus IRES 
PMSF: phenyl methyl sulfonyl fluoride 
PrK: proteinase K 
PTB: polypyrimidine tract binding 
RC: replication complex 
RdRp: RNA-dependent RNA polymerase 
RFP: red fluorescent protein 
RNA: ribonucleic acid 
RNAi: RNA interference 
rpm: rounds per minute 
RT-PCR: reverse transcriptase PCR 
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S1: supernatant 1 
SDS: sodium dodecyl sulphate 
SDS-PAGE: SDS polyacrylamide gel 
electrophoresis 
SFV: Semliki Forest virus 
shRNA: short hairpin RNA 
siRNA: small interfering RNA 
SL: stem loop 
SRBI: scavenger receptor class B type I 
ssRNA: single stranded RNA 
TCA: trichloroacetic acid 
TL: total lysate 
tSNARE: target membrane-associated soluble 
N-ethylmaleimide-sensitive factor-attachment 
protein receptor 
TX-100: Triton X-100 
U: units 
Vap-A: vesicle-associated-membrane-protein 
associated protein A 
vol: volume/volumina 
WB: Western blot 
wt: wild type 
Y2H: yeast two-hybrid 
α: anti (antibodies) or alpha 
β-ME: β-mercapto-ethanol 
 
